Nurses Revision

Pharmacology

Anti-Parkinsonian Medicines: Complete Pharmacology and Nursing Care

Anti-Parkinsonian medicines are medicines used to improve motor and selected non-motor symptoms of Parkinson disease, or—using different choices—to manage drug-induced parkinsonism and other extrapyramidal symptoms. They improve symptoms but do not cure Parkinson disease or reliably stop its progression.

Critical distinction: idiopathic Parkinson disease results mainly from degeneration of dopaminergic neurons and is commonly treated by increasing or imitating dopamine. Antipsychotic-induced parkinsonism results from dopamine D2 receptor blockade; management begins with review of the causative medicine, and short-term anticholinergic treatment may be used when appropriate. Levodopa and dopamine agonists can worsen psychosis and are generally not routine treatments for antipsychotic-induced parkinsonism.

Relevant Pharmacology and Therapeutic Goals

Loss of dopamine in the nigrostriatal pathway creates a relative excess of cholinergic activity within the basal ganglia. This produces bradykinesia, rigidity, resting tremor and postural impairment. Treatment therefore aims to:

  • Replace dopamine precursor with levodopa.
  • Directly stimulate dopamine receptors with dopamine agonists.
  • Reduce dopamine breakdown using MAO-B or COMT inhibitors.
  • Increase dopamine release/reduce glutamatergic activity with amantadine.
  • Reduce relative cholinergic excess with central antimuscarinics, especially for tremor or selected drug-induced extrapyramidal symptoms.

Choice is individualised according to symptom impact, age, cognition, falls, psychosis, comorbidities, pregnancy, occupation, medicine availability, patient preference and cost. If motor symptoms affect quality of life, NICE recommends offering levodopa.

Classification

ClassExamplesMain place in therapy
Dopamine precursor + peripheral decarboxylase inhibitorLevodopa/carbidopa; levodopa/benserazideMost effective symptomatic treatment for bradykinesia and rigidity; also improves tremor.
Non-ergot dopamine agonistsPramipexole, ropinirole, rotigotine; apomorphine for advanced “off” episodesMonotherapy in selected early disease or adjunct to levodopa.
Ergot dopamine agonistsBromocriptine, cabergolineRarely preferred because of fibrotic and valvular risks; specialist monitoring required.
MAO-B inhibitorsSelegiline, rasagiline, safinamideEarly mild symptoms or adjunct for wearing-off.
COMT inhibitorsEntacapone, opicapone, tolcaponeAdjunct to levodopa for end-of-dose wearing-off; no useful effect without levodopa.
Dopaminergic/NMDA antagonistAmantadineModest motor benefit; often considered for levodopa-induced dyskinesia.
Central antimuscarinicsTrihexyphenidyl (benzhexol), benztropine, biperiden, procyclidineTremor in selected younger patients; acute dystonia and drug-induced parkinsonism. Avoid routine use in older/cognitively impaired patients.

Levodopa with Carbidopa or Benserazide

Mechanism and pharmacodynamics

Levodopa crosses the blood–brain barrier and is converted to dopamine by aromatic L-amino-acid decarboxylase. Carbidopa or benserazide acts mainly outside the brain, reducing peripheral conversion. This increases levodopa reaching the brain and reduces peripheral nausea, vomiting, tachycardia and hypotension. The combination particularly improves bradykinesia and rigidity.

Pharmacokinetics

  • Absorbed mainly from the proximal small intestine; gastric delay and constipation make response unpredictable.
  • Levodopa competes with large neutral amino acids from high-protein meals for intestinal absorption and transport into the brain.
  • Plasma half-life is short—approximately 1–2 hours—so repeated dosing is usually required.
  • Peripheral decarboxylase inhibitors do not significantly cross the blood–brain barrier.

Indications and representative adult dosing

Used for symptomatic Parkinson disease and parkinsonism where a specialist considers dopaminergic replacement appropriate. A commonly used immediate-release starting regimen is carbidopa/levodopa 25/100 mg orally three times daily, titrated gradually to response and tolerability. Formulations and ratios vary; the prescribed product must be followed exactly. Dose changes are individualised and not made independently by the nurse.

Adverse effects

  • Early/peripheral: nausea, vomiting, anorexia, postural hypotension, dizziness and cardiac rhythm disturbance.
  • Neuropsychiatric: confusion, vivid dreams, hallucinations, agitation, delusions and impulse-control problems.
  • Motor complications: dyskinesia; end-of-dose wearing-off; delayed “on”; unpredictable on–off fluctuations; painful dystonia.
  • Harmless changes: saliva, sweat or urine may become dark; explain this while checking that discoloration is not haematuria or another illness.

Contraindications, precautions and interactions

  • Use specialist caution in active psychosis, severe cardiovascular disease, glaucoma, melanoma history/suspicious skin lesion and peptic ulcer history.
  • Non-selective monoamine oxidase inhibitors can cause dangerous hypertension and require an appropriate washout; verify the medicine list.
  • Dopamine-blocking antipsychotics and metoclopramide may reduce benefit and worsen parkinsonism. Antipsychotic selection in Parkinson disease needs specialist input.
  • Antihypertensives increase postural hypotension; iron salts may reduce levodopa absorption—separate when prescribed.
  • High-protein meals may reduce or delay effect in some patients; never restrict protein dangerously—dietary timing should be individualised with dietetic/clinical advice.
Never stop levodopa suddenly. Abrupt withdrawal or major dose reduction may produce severe rigidity, fever, altered consciousness and autonomic instability resembling neuroleptic malignant syndrome. Treat as an emergency and seek urgent medical review.

Dopamine Agonists

These medicines directly stimulate dopamine receptors and do not require conversion to dopamine. Non-ergot agents are generally preferred to ergot derivatives.

MedicinePharmacokinetics and representative doseImportant adverse effects/monitoring
PramipexoleRenally eliminated largely unchanged; immediate-release is often started at 0.125 mg three times daily and titrated slowly. Reduce in renal impairment.Nausea, oedema, hypotension, hallucinations, sudden sleep, impulse-control disorder and withdrawal syndrome.
RopiniroleHepatic CYP1A2 metabolism; immediate-release often starts at 0.25 mg three times daily with weekly titration. Smoking changes may alter exposure.Somnolence, sudden sleep attacks, dizziness, hypotension, hallucinations, dyskinesia and compulsive behaviours.
Rotigotine patchContinuous transdermal delivery; dose varies by stage. Apply once daily to a different site.Skin reactions plus class effects; document patch removal to prevent accidental duplication.
ApomorphineRapid subcutaneous rescue/intermittent injection or infusion for advanced disease; initiated and titrated by a specialist.Profound nausea, hypotension, somnolence, nodules, hallucinations and QT concerns. Concomitant 5-HT3 antagonists such as ondansetron are contraindicated because of severe hypotension/loss of consciousness.
Bromocriptine/cabergolineLonger-acting ergot derivatives; specialist-only selection.Cardiac valvular, pulmonary/retroperitoneal fibrosis; baseline and ongoing cardiac/fibrotic monitoring is required.

Impulse-control disorders

Dopamine agonists may cause gambling, hypersexuality, compulsive shopping, binge eating, punding or excessive medication use. Risk may not be volunteered. Educate the patient and family/carer before treatment, ask privately and repeatedly, document impact, and refer promptly for prescriber review. Do not shame the patient or simply stop the medicine abruptly.

Withdrawal

Sudden reduction can produce anxiety, panic, depression, pain, fatigue, sweating and drug craving. Taper only according to the prescriber's plan.

Monoamine Oxidase-B Inhibitors

DrugAction and doseAdverse effects and interactions
SelegilineIrreversibly inhibits MAO-B, reducing dopamine breakdown. Common oral total is 5–10 mg/day; give earlier in the day because amphetamine-like metabolites may cause insomnia.Nausea, dizziness, hypotension, insomnia, hallucinations and dyskinesia when combined with levodopa.
RasagilineIrreversible MAO-B inhibitor; commonly 1 mg once daily.Headache, influenza-like symptoms, hypotension, hallucinations and increased levodopa adverse effects.
SafinamideReversible MAO-B inhibition plus modulation of glutamate release; adjunct for fluctuations, commonly 50 mg daily then 100 mg if prescribed.Dyskinesia, insomnia, dizziness and interaction precautions similar to other MAO-B inhibitors.
  • Avoid combining with other MAO inhibitors, sympathomimetics or certain serotonergic medicines unless specialist guidance confirms safety.
  • Opioids with serotonergic properties—especially pethidine/meperidine, tramadol or methadone—may cause severe reactions; verify interaction resources.
  • Watch for serotonin syndrome: agitation, sweating, diarrhoea, fever, tremor, clonus and hyperreflexia. Stop suspected agents according to emergency protocol and obtain urgent medical care.

COMT Inhibitors

Entacapone, opicapone and tolcapone inhibit catechol-O-methyl transferase and prolong levodopa action. They are adjuncts for wearing-off, not effective standalone dopamine replacement.

MedicineRepresentative administrationKey risks
EntacaponeUsually 200 mg with each levodopa/dopa-decarboxylase-inhibitor dose, within product maximum.Increased dyskinesia, diarrhoea, nausea, hypotension and harmless orange-brown urine.
OpicaponeLong-acting, commonly 50 mg once nightly, separated from food according to product directions.Dyskinesia, constipation, dry mouth, hypotension and hallucinations.
TolcaponePotent central/peripheral action; restricted specialist use.Potentially fatal hepatotoxicity; requires strict liver monitoring and is avoided where safer alternatives work.

When a COMT inhibitor is added, levodopa may need reduction because dopaminergic adverse effects intensify. Nurses report new dyskinesia, confusion or hypotension rather than withholding doses without an order.

Amantadine

Pharmacology

Amantadine increases dopamine release, reduces reuptake and antagonises N-methyl-D-aspartate (NMDA) receptors. It may provide modest benefit for motor symptoms and is particularly used to reduce dyskinesia.

  • Typical adult dosing: commonly 100 mg once daily initially, increasing to 100 mg twice daily when tolerated; specialist regimens vary.
  • Elimination: mainly renal; reduce dose in renal impairment and older adults to prevent accumulation.
  • Common effects: ankle oedema, nausea, dizziness, insomnia, dry mouth and mottled lace-like skin discoloration (livedo reticularis).
  • Serious effects: confusion, hallucinations, agitation, falls and toxicity with renal impairment.
  • Interactions: other anticholinergic or stimulating medicines may increase confusion; medicines that affect QT or renal clearance require review.
  • Withdrawal: avoid abrupt cessation after regular use because severe deterioration, delirium or a malignant-like syndrome can occur.

Central Antimuscarinic Medicines

Trihexyphenidyl (benzhexol), benztropine, biperiden and procyclidine reduce cholinergic activity in the basal ganglia. They improve tremor and rigidity more than bradykinesia. Because cognitive and peripheral adverse effects are substantial, they are mainly reserved for selected younger patients and antipsychotic-induced extrapyramidal symptoms.

MedicineRepresentative adult doseImportant points
Trihexyphenidyl/benzhexolOften start 1 mg/day and titrate gradually; usual divided total 5–15 mg/day depending on indication and response.Common in psychiatric practice for drug-induced parkinsonism; not prophylaxis for every antipsychotic patient.
BenztropineOral commonly 0.5–2 mg once or twice daily; IM/IV may be used for acute dystonia according to protocol.Rapid relief may occur in acute dystonia; observe recurrence after the dose wears off.
BiperidenOral commonly 2 mg one to four times daily; parenteral dosing for acute dystonia follows local protocol/product information.WHO essential-medicine discussions include it among anti-Parkinson medicines; strong anticholinergic precautions apply.
ProcyclidineCommonly 2.5 mg three times daily, titrated; usual total 10–30 mg/day.Used for antipsychotic-induced parkinsonism and acute dystonia in some settings.

Contraindications and adverse effects

  • Peripheral anticholinergic effects: dry mouth, blurred vision, constipation, urinary retention, tachycardia, reduced sweating and heat intolerance.
  • Central effects: impaired memory, confusion, agitation, hallucinations, delirium and misuse/euphoria.
  • Avoid or use extreme caution in narrow-angle glaucoma, prostatic obstruction/urinary retention, paralytic ileus, severe constipation, tachyarrhythmia, myasthenia gravis and older people with cognitive impairment.
  • Additive toxicity occurs with tricyclic antidepressants, sedating antihistamines, antipsychotics with antimuscarinic activity and other anticholinergics.
Tardive dyskinesia warning: anticholinergics do not treat tardive dyskinesia and may worsen it. Differentiate rhythmic oro-facial/choreoathetoid tardive movements from acute dystonia or drug-induced parkinsonism, notify the prescriber and follow a specific tardive-dyskinesia plan.

Antipsychotic-Induced Extrapyramidal Symptoms

Syndrome and timingClinical featuresManagement principles
Acute dystonia: hours–daysPainful neck twisting, jaw spasm, tongue protrusion, oculogyric crisis; laryngeal dystonia may threaten airway.ABCDE; urgent parenteral anticholinergic/antihistamine per protocol; airway help for stridor; continue short oral cover if prescribed; review antipsychotic.
Akathisia: days–weeksInner restlessness, pacing, inability to sit; may be mistaken for agitation/anxiety and is associated with severe distress.Review dose/switch; propranolol or other targeted treatment may be prescribed. Anticholinergics are usually less effective unless parkinsonism coexists.
Drug-induced parkinsonism: weeks–monthsBradykinesia, rigidity, masked face, shuffling gait, often bilateral tremor.Reduce/switch causative medicine when safe; short-term antimuscarinic or amantadine may be prescribed. Review regularly and withdraw when no longer needed.
Tardive dyskinesia: months–yearsChewing, tongue, facial, trunk or limb movements that may persist.Do not add routine anticholinergic; specialist antipsychotic review and targeted therapy.
Neuroleptic malignant syndromeFever, severe rigidity, altered consciousness and autonomic instability; raised creatine kinase may occur.Medical emergency: stop dopamine blocker under emergency protocol, urgent hospital care, cooling, fluids, monitoring and specialist treatment.

Safe Medicine Administration

No.Nursing actionRationale
1Complete medication reconciliation including exact formulation, strength and usual times; ask patient/caregiver and check containers/records.Parkinson medicines are time-critical; substitution or delay can cause profound immobility and aspiration risk.
2Administer at the patient's individual scheduled time—not merely the ward drug-round time.Maintains mobility, swallowing and predictable “on” periods.
3Assess swallowing before oral administration and involve speech/swallow specialists when unsafe.Parkinson disease increases dysphagia and aspiration; crushing modified-release products may be dangerous.
4Measure lying/sitting and standing blood pressure when indicated; institute fall precautions.Dopaminergic medicines commonly cause orthostatic hypotension.
5Observe “on/off” timing, tremor, rigidity, gait, freezing and dyskinesia relative to each dose.A precise diary guides rational adjustment better than “medicine not working.”
6Ask about hallucinations, sleep attacks, gambling, sexual behaviour, shopping and eating changes sensitively and privately.Neuropsychiatric effects may be hidden through shame or lack of insight.
7Monitor bowel, bladder, mouth, vision, cognition and temperature tolerance with anticholinergics.Detects urinary retention, ileus, glaucoma symptoms and delirium early.
8Do not omit or abruptly stop dopaminergic therapy; urgently contact the prescriber if nil by mouth, vomiting or surgery prevents dosing.Alternative routes/timing may be required to prevent severe withdrawal deterioration.
9Document response, adverse effects, falls, missed/late doses and escalation clearly during handover.Maintains continuity and prevents repeated medication error.

Baseline and Ongoing Monitoring

  • Motor symptoms and function: walking, transfers, speech, swallowing, self-care, falls and patient-defined goals.
  • Blood pressure, pulse, weight and oedema; ECG when cardiac risk/product guidance indicates.
  • Cognition, delirium, mood, psychosis, sleepiness and impulse-control behaviours.
  • Renal function for pramipexole/amantadine; liver function where product/medicine such as tolcapone requires it.
  • Skin and eye review according to clinical risk; review suspicious pigmented lesions.
  • For ergot agonists: specialist cardiac valve and fibrotic surveillance.
  • Medication timing, adherence, food relationship, duration of “on,” wearing-off and dyskinesia diary.

Patient and Family Education

  • Take each dose at the exact agreed time and keep an updated medicine list.
  • Do not stop treatment suddenly or double a missed dose unless specifically instructed.
  • Rise slowly, hydrate appropriately and request review after fainting or repeated falls.
  • Do not drive or operate machinery if suddenly sleepy; report sleep attacks immediately.
  • Report hallucinations, marked confusion, new compulsive behaviour, severe vomiting, palpitations or uncontrolled movements.
  • Use a timing/symptom diary and bring it to appointments.
  • Maintain balanced nutrition; discuss protein redistribution only with the clinical/dietetic team.
  • Exercise, physiotherapy, occupational therapy and speech/swallow therapy remain essential; medicines alone do not address all disability.

Special Populations

  • Older adults: start low and titrate slowly; hallucinations, hypotension, falls and anticholinergic delirium are more likely.
  • Renal impairment: pramipexole and amantadine commonly require dose reduction.
  • Hepatic impairment: check medicines with significant hepatic metabolism or hepatotoxicity; tolcapone is especially restricted.
  • Pregnancy/breastfeeding: evidence is limited and drug-specific; specialist assessment is required. Dopamine agonists may suppress lactation.
  • Psychosis/dementia: balance motor benefit against hallucinations/confusion; changes require Parkinson/mental-health specialist coordination.

Common Examination Traps

  • Carbidopa does not treat symptoms alone; it prevents peripheral levodopa breakdown.
  • Entacapone has no useful anti-Parkinson effect without levodopa.
  • Levodopa is not routine treatment for antipsychotic-induced parkinsonism and may worsen psychosis.
  • Anticholinergics may treat acute dystonia or drug-induced parkinsonism but may worsen tardive dyskinesia.
  • Akathisia is subjective inner restlessness, not simply aggressive behaviour.
  • Parkinson medicines are time-critical; late doses may cause immobility and unsafe swallowing.
  • Abrupt withdrawal of levodopa, dopamine agonists or amantadine can be dangerous.
DOPAMINE safety: Doses on time; On/off diary; Postural BP and psychosis; Avoid abrupt stopping; Monitor movements; Impulse-control enquiry; Nutrition/interactions; Educate and escalate.

References

Anti-Parkinsonian Medicines: Complete Pharmacology and Nursing Care Read More »

Hematological Medicines: Classes, Uses, Safety and Nursing Care

Hematological Medicines: Pharmacology, Dosage, Safety and Nursing Care

Hematological medicines prevent or treat disorders of blood formation, haemostasis, coagulation and thrombosis. They include haematinics, growth factors, medicines for haemoglobin disorders, anticoagulants, antiplatelets, thrombolytics, haemostatics and blood products. Incorrect selection, dosing or monitoring can cause catastrophic bleeding, thrombosis, marrow suppression, haemolysis or death.

Dosage note: Doses below are common educational adult examples, not a substitute for a prescription. Always confirm the exact indication, age, current weight, pregnancy status, renal and liver function, laboratory results, product strength and the latest Uganda Clinical Guidelines or facility protocol. Paediatric doses are usually weight-based and should never be extrapolated from adult doses.

Learning Objectives

  • Relate normal haemopoiesis and haemostasis to drug action.
  • Classify hematological medicines and explain pharmacodynamics and pharmacokinetics.
  • State common indications, dosage principles, contraindications, interactions, side effects, serious adverse effects and monitoring.
  • Administer iron, anticoagulants, haemostatics and blood components safely.
  • Recognise major bleeding, thrombosis, heparin-induced thrombocytopenia and transfusion reactions.
  • Develop patient-centred nursing care plans and discharge education.

Foundations of Blood Pharmacology

Haematopoietic stem cells in bone marrow produce erythrocytes, leucocytes and platelets. Erythropoietin from the kidney stimulates red-cell formation. Iron forms haem; folate and vitamin B12 support DNA synthesis. Platelets create the primary plug, coagulation factors stabilise it with fibrin, and plasmin later removes fibrin.

TargetNormal functionDrug effectClinical implication
Red-cell productionRequires iron, folate, B12, erythropoietin and functioning marrow.Haematinics replace deficiencies; erythropoiesis-stimulating agents promote production.Anaemia must be classified; haemoglobin alone does not identify the cause.
PlateletsAdhere, activate and aggregate at vascular injury.Aspirin and P2Y12 inhibitors reduce aggregation.Useful mainly for arterial thrombosis but increase mucosal and intracranial bleeding.
Coagulation cascadeProduces thrombin and cross-linked fibrin.Heparins, warfarin and direct oral anticoagulants inhibit selected steps.Prevent clot propagation; they do not instantly dissolve an existing thrombus.
FibrinolysisPlasmin breaks down fibrin.Thrombolytics accelerate breakdown; tranexamic acid inhibits it.Drug selection depends on whether a clot must be lysed or preserved.

Baseline Assessment Before Any Hematological Medicine

  • Confirm the indication: anaemia, thrombosis, prophylaxis, acute coronary syndrome, stroke, bleeding disorder or replacement of a defined component.
  • Assess bleeding: haematemesis, melaena, haematuria, epistaxis, heavy menses, bruising, recent surgery, trauma, falls, ulcer disease and neurological symptoms.
  • Assess thrombosis: unilateral limb pain/swelling, sudden dyspnoea, chest pain, haemoptysis, focal deficit or catheter failure.
  • Review tests: full blood count, reticulocytes, ferritin/iron studies when indicated, renal/liver function, PT/INR, aPTT, fibrinogen or anti-Xa according to the medicine.
  • Reconcile medicines: NSAIDs, antiplatelets, anticoagulants, antimicrobials, anticonvulsants, antiretrovirals, alcohol and herbal products.
  • Check procedures: surgery, lumbar puncture, neuraxial anaesthesia or invasive procedures require coordinated interruption and restart plans.

Haematinics and Blood-Cell Stimulating Medicines

Comprehensive Haematinic Drug Table

MedicinePharmacodynamics and pharmacokineticsIndications and common dosage guidanceContraindications and precautionsInteractionsSide effects and serious adverse effectsMonitoring and nursing responsibilities
Oral ferrous salts
Ferrous sulfate, fumarate, gluconate
PD: supply elemental iron for haemoglobin, myoglobin and enzymes. PK: absorption occurs mainly in duodenum/proximal jejunum and increases when stores are depleted. Food, phytates, calcium and antacids reduce absorption. Iron is stored as ferritin/haemosiderin; the body has no regulated excretory pathway.Confirmed iron-deficiency anaemia and policy-based prevention. Adult treatment commonly provides about 100–200 mg elemental iron daily, though once-daily or alternate-day regimens may improve tolerance and absorption. Pregnancy regimens must follow current national/WHO guidance. Continue after haemoglobin normalises as prescribed to replenish stores.Iron overload, haemochromatosis, anaemia not caused by iron deficiency. Use caution with active peptic disease, inflammatory bowel disease and repeated transfusions. Do not give blindly in unexplained anaemia.Antacids, calcium, tea/coffee and some foods reduce absorption. Iron reduces absorption of tetracyclines, quinolones, levothyroxine and bisphosphonates; separate administration according to pharmacy guidance. Vitamin C may increase absorption.Common: nausea, epigastric pain, constipation/diarrhoea and dark stool. Liquid stains teeth. Serious: overdose causes corrosive GI injury, shock, metabolic acidosis, hepatic failure and death.Confirm elemental iron content, not tablet mass. Teach expected stool change and adherence. Give on an empty stomach if tolerated; use food if needed for adherence. Use a straw for liquid. Store locked away from children. Recheck Hb response and investigate non-response.
Intravenous iron
Iron sucrose, ferric carboxymaltose and locally available products
PD: iron-carbohydrate complex is taken up by macrophages and releases iron to transferrin for erythropoiesis. PK: bypasses intestinal absorption; product stability, maximum dose and half-life differ markedly.Confirmed deficiency when oral therapy is ineffective, not tolerated, poorly absorbed or too slow; selected CKD and ongoing loss. Dose is calculated from iron deficit and product limits. Iron sucrose is often given in smaller repeated doses; ferric carboxymaltose may permit larger single doses. Never interchange protocols.Known hypersensitivity to product, anaemia without iron deficiency, iron overload. Defer during active systemic infection when clinically appropriate. Caution in asthma/atopy and liver disease.Do not start oral iron simultaneously unless directed; it adds little during immediate IV replacement and may increase GI effects. Avoid mixing with unapproved drugs/solutions.Common: metallic taste, headache, nausea, flushing, infusion-site pain. Serious: hypersensitivity/anaphylaxis, hypotension, bronchospasm; extravasation causes persistent skin staining. Some formulations cause hypophosphataemia.Verify calculated total need, exact preparation, dilution and rate. Ensure patent IV access and resuscitation readiness. Observe during and after. Stop for chest/back pain, wheeze, facial swelling, hypotension or collapse. Never use another product’s instructions.
Folic acidPD: converted to tetrahydrofolate coenzymes required for DNA synthesis. PK: absorbed in proximal small bowel, stored mainly in liver and excreted renally.Folate-deficiency megaloblastic anaemia; prevention in pregnancy and high-risk situations. A common adult therapeutic dose is 5 mg orally daily for about 4 months, longer if the cause persists. Prevention doses differ and must follow national policy.Untreated vitamin B12 deficiency unless B12 is also corrected. Hypersensitivity is rare.Antifolate medicines such as methotrexate, trimethoprim and some anticonvulsants have clinically important interactions; folate may alter anticonvulsant concentrations.Usually well tolerated. Rare rash, bronchospasm or anaphylaxis. Main danger is masking haematological signs of B12 deficiency while neurological injury progresses.Establish cause of macrocytosis. Check B12 before folate alone where feasible. Monitor Hb, MCV and clinical response. Teach duration and dietary sources without implying diet alone treats severe deficiency.
Vitamin B12
Hydroxocobalamin or cyanocobalamin
PD: cofactor for DNA synthesis, myelin maintenance and methylmalonate metabolism. PK: dietary B12 requires intrinsic factor and terminal ileum; IM treatment bypasses absorption. Large hepatic stores mean deficiency develops slowly.Confirmed deficiency due to pernicious anaemia, gastric/ileal disease, malabsorption or poor intake. Common IM regimens use 1 mg doses frequently during loading then maintenance every 2–3 months for irreversible causes; exact preparation and neurological involvement determine schedule.Hypersensitivity to cobalamin/cobalt. Use clinical caution in severe anaemia because rapid marrow response may change potassium.Chloramphenicol may blunt haematological response. Metformin and prolonged acid suppression can contribute to deficiency.Injection pain, rash, itching. Rare anaphylaxis. Hypokalaemia can occur during brisk correction of severe deficiency.Assess paraesthesia, gait, cognition, glossitis and diet. Obtain diagnostic bloods before treatment where feasible, but do not delay urgent treatment for neurological disease. Monitor Hb/reticulocyte response and neurological recovery. Lifelong treatment may be needed.
Epoetin alfa and related ESAsPD: activate erythropoietin receptors on marrow progenitors, increasing RBC production. PK: given IV or SC; response takes days to weeks, so it is not emergency correction.Selected CKD anaemia and chemotherapy-associated anaemia. Dosing is indication- and product-specific, often weight-based or fixed at intervals. Titrate to the lowest dose that reduces transfusion need; do not chase a normal Hb.Uncontrolled hypertension; pure red-cell aplasia due to anti-EPO antibodies. Caution with malignancy, seizure disorder and thrombosis risk.No dominant CYP interactions, but ineffective without adequate iron; combined prothrombotic risks matter clinically.Hypertension, headache, influenza-like symptoms, vascular-access thrombosis. Serious: stroke, myocardial infarction, venous thrombosis, seizures and rare pure red-cell aplasia.Correct iron/folate/B12 deficiency first. Check BP, Hb trend, rate of rise and iron status. Withhold/adjust only by protocol. Teach that benefit is delayed and thrombosis symptoms require urgent care.
FilgrastimPD: recombinant G-CSF stimulates neutrophil precursors. PK: SC/IV; clearance rises as neutrophils recover.Selected chemotherapy-associated neutropenia, stem-cell mobilisation and severe chronic neutropenia. A common starting regimen is 5 micrograms/kg/day SC or IV, adjusted to indication and counts.Hypersensitivity to product. Caution in sickle cell disease, myeloid malignancy and splenic disease.Lithium can increase neutrophil release. Timing close to cytotoxic chemotherapy is protocol-dependent.Bone/muscle pain, fever, headache. Serious: splenic rupture, acute respiratory distress, capillary-leak syndrome and sickle crisis.Monitor CBC and ANC. Assess fever and infection despite treatment. Report left upper-quadrant/shoulder pain, respiratory distress or sudden hypotension urgently.
HydroxyureaPD: inhibits ribonucleotide reductase; in sickle cell disease raises fetal haemoglobin, reduces sickling and improves red-cell hydration. PK: well absorbed orally, widely distributed, partly metabolised and renally eliminated.Disease modification in sickle cell disease; specialist malignant indications. Sickle cell therapy often starts around 15 mg/kg once daily in adults, with lower starting doses in renal impairment and gradual titration to tolerated response under protocol.Severe marrow suppression. Avoid or use only specialist guidance in pregnancy/breastfeeding; counsel about reproductive risk. Caution in renal/hepatic impairment.Other marrow suppressants increase cytopenia. Some antiretroviral combinations increase toxicity; coordinate HIV care.Nausea, skin/nail pigmentation, mouth ulcers. Serious: neutropenia, thrombocytopenia, severe anaemia, leg ulcers and infection.Baseline and regular CBC with differential/reticulocytes, renal/liver tests and pregnancy assessment. Teach daily adherence, handling precautions, contraception discussion and prompt reporting of fever or bleeding.

Anticoagulants

Anticoagulants prevent formation and extension of fibrin-rich clots. They are high-alert medicines. Choice depends on indication, pregnancy, kidney/liver function, bleeding risk, monitoring access, cost, adherence and availability of reversal.

MedicinePharmacodynamics and pharmacokineticsIndications and common adult dosage examplesContraindications and precautionsInteractionsSide effects and serious adverse effectsMonitoring and nursing care
Unfractionated heparinPD: binds antithrombin, rapidly inactivating thrombin IIa and factor Xa. PK: IV effect is immediate; SC slower. Short, dose-dependent half-life; cleared by cellular and renal mechanisms.VTE treatment, ACS, procedures and prophylaxis. A common VTE regimen is 80 units/kg IV bolus then 18 units/kg/hour, adjusted by aPTT/anti-Xa protocol. Prophylaxis is often 5,000 units SC every 8–12 hours. Protocols vary.Active major bleeding, previous immune HIT, severe thrombocytopenia, recent high-risk CNS/eye surgery. Caution with neuraxial procedures, uncontrolled hypertension and ulcers.Antiplatelets, NSAIDs, thrombolytics and other anticoagulants increase bleeding. IV nitroglycerin may reduce heparin effect in some cases.Bleeding, bruising, injection reaction. Serious: HIT with thrombosis, anaphylaxis, hyperkalaemia and osteoporosis with prolonged use.Use independent double-check for infusion. Monitor aPTT/anti-Xa per protocol, CBC, platelets, bleeding and infusion pump. Protamine reverses much of effect. Avoid IM injections and document exact stop time.
Enoxaparin
LMWH
PD: enhances antithrombin inhibition of factor Xa more than IIa. PK: predictable SC bioavailability, peak about 3–5 hours, mainly renal clearance.VTE prophylaxis often 40 mg SC once daily; treatment often 1 mg/kg SC every 12 hours or indication-specific alternative. Reduce/modify in severe renal impairment and special populations.Active major bleeding, immune HIT history, severe thrombocytopenia. Caution with renal impairment, extreme weight and neuraxial anaesthesia.Additive bleeding with NSAIDs, antiplatelets and other anticoagulants.Bleeding, injection-site bruising, thrombocytopenia. Serious: HIT, spinal/epidural haematoma and hyperkalaemia.Check weight, creatinine/CrCl, CBC and platelets. Routine aPTT is not useful. Inject into rotated abdominal sites; do not massage or expel the prefilled syringe air bubble unless instructed. Protamine reversal is incomplete.
WarfarinPD: inhibits vitamin K epoxide reductase, reducing synthesis of II, VII, IX, X and proteins C/S. PK: oral, highly protein-bound, hepatic CYP metabolism; delayed onset/offset because circulating factors must turn over.Mechanical heart valves and selected AF/VTE indications. Start dose varies, commonly 2–5 mg once daily, then adjust strictly to INR target. Acute VTE usually requires overlap with a rapid anticoagulant until therapeutic criteria are met.Pregnancy except rare specialist circumstances, active major bleeding, inability to monitor, recent high-risk surgery. Caution in liver disease, malnutrition, falls and poor adherence.Numerous: many antibiotics/antifungals, amiodarone and alcohol may increase INR; enzyme inducers may reduce it. NSAIDs/antiplatelets increase bleeding. Major changes in vitamin K intake alter effect.Bleeding and bruising. Serious: intracranial haemorrhage, skin necrosis, purple-toe syndrome and fetal harm.Monitor INR, CBC, bleeding, diet/illness/medicine changes. Give at same time; verify tablet strength. Vitamin K reverses slowly; major bleeding may require PCC or plasma per protocol. Carry anticoagulant card.
ApixabanPD: directly inhibits factor Xa. PK: rapid oral absorption; hepatic CYP3A4/P-gp handling plus renal/fecal clearance; half-life about 12 hours.AF stroke prevention often 5 mg twice daily with reduction only when criteria are met. Acute VTE often 10 mg twice daily for 7 days, then 5 mg twice daily. Confirm indication and current label.Active major bleeding, significant hepatic coagulopathy. Caution in severe renal impairment, pregnancy and neuraxial procedures.Strong combined CYP3A4/P-gp inhibitors increase levels; inducers reduce effect. NSAIDs/antiplatelets increase bleeding.Bleeding, nausea, anaemia. Serious: intracranial/GI bleeding and spinal haematoma.No routine INR. Monitor CBC, renal/liver function, bleeding and adherence. Short half-life makes missed doses important. Specific reversal availability varies.
RivaroxabanPD: direct factor Xa inhibitor. PK: oral, partly CYP3A4/P-gp and renal clearance; higher treatment doses require food for reliable absorption.Acute VTE commonly 15 mg twice daily with food for 21 days, then 20 mg once daily with food; prophylaxis and AF doses differ and require renal review.Active major bleeding, significant hepatic coagulopathy. Caution/avoidance thresholds vary with renal function and indication.Strong CYP3A4/P-gp inhibitors/inducers alter exposure; additive bleeding with NSAIDs/antiplatelets.Bleeding, anaemia, GI symptoms. Serious: major bleeding and spinal/epidural haematoma.Confirm phase of VTE therapy to prevent 15 mg/20 mg error. Give specified doses with food. Monitor CBC, renal/liver function and adherence; INR is not a monitoring test.
DabigatranPD: direct thrombin inhibitor. PK: prodrug absorbed orally, P-gp substrate, predominantly renal elimination.Selected AF and VTE. A common adult regimen is 150 mg twice daily; for VTE it follows 5–10 days of parenteral anticoagulation. Age, renal function and bleeding risk may require a different dose.Active major bleeding, mechanical heart valve, severe renal impairment. Caution with oesophageal/GI disease and neuraxial procedures.P-gp inhibitors raise and inducers lower levels. Other antithrombotics increase bleeding.Dyspepsia, abdominal discomfort, bleeding. Serious: major haemorrhage and spinal haematoma.Check renal function. Swallow capsules whole and store exactly as directed because moisture affects stability. Do not use INR to quantify effect. Idarucizumab may reverse effect where available.

Safe Subcutaneous LMWH Administration

  1. Verify product, strength, indication, weight, renal function, platelet count and last dose.
  2. Inspect for active bleeding and excessive bruising; coordinate timing with procedures.
  3. Select and rotate an abdominal site away from umbilicus, scars, wounds and bruises.
  4. Clean and dry skin; pinch a fold. Insert at the angle recommended for the patient/device.
  5. Do not expel the air bubble from a prefilled syringe unless manufacturer instructions say so.
  6. Inject slowly; withdraw and apply gentle pressure if needed. Do not rub.
  7. Document drug, dose, time, site and assessment.

Heparin-Induced Thrombocytopenia

Immune HIT causes a substantial platelet fall and paradoxical venous or arterial thrombosis, commonly 5–10 days after exposure or sooner after recent exposure. New thrombosis, skin necrosis or systemic reaction after a bolus are warning signs. Stop all heparin sources including flushes, notify urgently, assess clinical probability and prepare a protocol-selected non-heparin anticoagulant. Do not substitute LMWH or start warfarin alone during acute HIT.

Anticoagulant Reversal

AgentReversal/management principleCritical nursing responsibilities
UFHStop infusion; protamine dose is based on recent heparin exposure.Record last hours of dosing; monitor for hypotension, bradycardia and anaphylactoid reaction during slow protamine administration.
LMWHWithhold; protamine gives incomplete reversal; specialist advice.Record last dose, renal function, weight and bleeding severity; routine aPTT may be misleading.
WarfarinVitamin K restores synthesis slowly; major bleeding often requires 4-factor PCC or plasma where PCC unavailable.Check INR/bleeding, prepare product, repeat INR, monitor volume overload with plasma and thrombosis after reversal.
DabigatranIdarucizumab where available; supportive/source control and specialist guidance.Confirm last dose and renal function; collect directed tests without delaying life-saving action.
Factor Xa inhibitorsAndexanet alfa where available or PCC-based protocol; supportive/source control.INR is unreliable; report exact medicine, last dose, renal/liver function and interacting drugs.

Antiplatelets and Thrombolytics

MedicinePD/PKIndications and dosage examplesContraindications/interactionsSide effects/adverse effectsNursing monitoring
AspirinIrreversibly inhibits platelet COX-1 and thromboxane A2 for platelet lifespan. Rapid oral absorption; hepatic metabolism and renal excretion.ACS loading commonly 150–300 mg chewed, then maintenance often 75–100 mg daily. Stroke protocols vary. Not for routine primary prevention without individual assessment.Active bleeding, aspirin allergy, some asthma, severe ulcer disease. NSAIDs, anticoagulants, steroids and alcohol increase bleeding. Ibuprofen timing may interfere with antiplatelet action.Dyspepsia, bruising, bronchospasm. Serious: GI/intracranial bleeding, anaphylaxis, renal injury and salicylate toxicity. Avoid in children with viral illness except specialist use.Confirm indication and dose; assess bleeding, allergy/asthma and GI history. In ACS, chewing speeds absorption. Teach not to self-add NSAIDs.
ClopidogrelProdrug irreversibly blocks platelet P2Y12 ADP receptor; requires hepatic CYP activation. Effect lasts platelet lifespan.ACS/PCI loading commonly 300–600 mg, then 75 mg daily; stroke and peripheral arterial indications vary.Active bleeding. CYP2C19 inhibitors may reduce activation; other antithrombotics/NSAIDs increase bleeding.Bleeding, bruising, diarrhoea, rash. Rare serious thrombotic thrombocytopenic purpura and severe neutropenia.Do not stop after coronary stenting without cardiology instruction. Monitor bleeding and CBC when indicated. Fever, neurological change and thrombocytopenia require urgent review.
AlteplaseRecombinant tissue plasminogen activator converts fibrin-bound plasminogen to plasmin. Very short plasma half-life; systemic fibrinolytic effect persists.Selected acute ischaemic stroke: 0.9 mg/kg IV, maximum 90 mg; 10% bolus then remainder over 60 minutes. STEMI/PE regimens differ and are protocol-specific.Active bleeding, previous intracranial haemorrhage and other condition-specific exclusions; recent surgery/trauma, anticoagulation and uncontrolled BP require strict screening. Antithrombotics increase bleeding.Bleeding, orolingual angioedema. Serious: intracranial haemorrhage, systemic haemorrhage and reperfusion arrhythmia in MI.Confirm last-known-well, imaging and exact weight. Independent dose check. Frequent neurological/BP/bleeding observations. Avoid unnecessary punctures. Stop/escalate for headache, vomiting, acute hypertension or deficit.
TenecteplaseModified tPA with greater fibrin specificity and longer half-life, allowing a single IV bolus.Weight-tiered STEMI dosing; selected stroke protocols use 0.25 mg/kg IV bolus, maximum 25 mg. Indication and regulatory/local guidance must be verified.Same major bleeding exclusions as thrombolysis; medication errors arise because MI and stroke doses differ.Major/intracranial bleeding, angioedema, reperfusion arrhythmias.Verify indication-specific dose and vial concentration with an independent checker; monitor as for thrombolysis.

Haemostatic Medicines and Blood Products

MedicinePD/PKIndications and dosage examplesContraindications/interactionsSide/adverse effectsNursing responsibilities
Tranexamic acidCompetitive lysine analogue blocks plasminogen binding and reduces fibrin breakdown. Oral/IV; mainly renal elimination.PPH: 1 g IV over 10 minutes within 3 hours of birth, repeat 1 g after 30 minutes if bleeding continues or within 24 hours if it restarts. Trauma: commonly 1 g IV over 10 minutes then 1 g over 8 hours within 3 hours of injury. Other uses vary.Active intravascular clotting; caution in renal impairment, seizures and selected urinary-tract bleeding. Other prothrombotic therapy requires assessment.Nausea, diarrhoea. Rapid IV causes hypotension. Serious: seizures, visual disturbance and thrombosis.Give early only for correct indication; adjust renal dose, infuse at correct rate and continue definitive haemorrhage control/resuscitation.
Vitamin K
Phytomenadione
Supports hepatic gamma-carboxylation of factors II, VII, IX, X and proteins C/S. Effect requires new factor synthesis and is not immediate.Deficiency, neonatal prophylaxis and warfarin reversal. Dose and route vary widely—from low oral/IV doses for excessive INR without bleeding to higher IV doses with factor replacement for major bleeding.Hypersensitivity. IV route requires caution; avoid unnecessary large doses when rapid re-anticoagulation is needed.Antagonises warfarin. Broad-spectrum antibiotics and cholestasis may contribute to deficiency.Injection reaction, flushing, taste change. Rare severe anaphylactoid reaction with IV use.Verify route and urgency; administer IV slowly as product directs. Monitor INR response; remember it does not replace factors immediately.
DesmopressinV2-receptor agonist releases endothelial von Willebrand factor and factor VIII; also produces antidiuresis. Renal elimination.Selected type 1 von Willebrand disease, mild haemophilia A and uraemic platelet dysfunction. Common haemostatic dose 0.3 micrograms/kg IV diluted and infused over 15–30 minutes; intranasal products differ.Hyponatraemia, significant polydipsia; caution in young children, cardiac/renal disease and repeated dosing.Other hyponatraemia-causing drugs increase risk.Headache, flushing, tachycardia. Serious: water intoxication, hyponatraemia, seizures and thrombosis.Restrict fluid as prescribed; monitor sodium, fluid balance, weight and neurological state. Tachyphylaxis limits repeated dosing.

Blood Components and Their Use

ComponentContent/actionIndication and dose principleContraindications/cautionsAdverse effectsNursing responsibilities
Red-cell concentrateRaises oxygen-carrying capacity; does not replace platelets or clotting factors.Clinically significant symptomatic anaemia or acute blood loss. Adults often receive one unit then reassessment when not massively bleeding; paediatric volume is weight-based.Avoid using solely as volume expansion. Caution heart/renal failure and chronic transfusion.Haemolysis, allergy, fever, overload, lung injury, infection and iron overload.Compatibility and bedside ID; baseline/interval observations; assess Hb and symptoms; use slower rate/diuretic plan when ordered for overload risk.
PlateletsProvides functional platelets.Selected thrombocytopenia or platelet dysfunction with bleeding, high risk or procedure. Dose depends on adult therapeutic unit or paediatric weight.Not routine in immune HIT/TTP without severe bleeding or specialist indication.Fever, allergy, bacterial sepsis, alloimmunisation, lung injury.Check indication/count; transfuse promptly; monitor reaction and post-count when ordered.
Fresh frozen plasmaMultiple coagulation factors.Bleeding with multiple-factor deficiency or selected urgent reversal. Common dose around 10–15 mL/kg, guided by protocol and response.Not a routine volume expander or nutrition source.Allergy/anaphylaxis, overload and lung injury.ABO compatibility, thawing/transport time, volume assessment and coagulation response.
CryoprecipitateConcentrated fibrinogen, VIII, XIII and von Willebrand factor.Bleeding with low fibrinogen; dose based on fibrinogen level, weight and protocol.Do not use when a safer specific factor concentrate is indicated/available.Allergy, fever, infection and thrombosis.Check fibrinogen before/after and monitor bleeding/reaction.
Factor concentrates/PCCReplace one or several factors rapidly.Haemophilia, von Willebrand disease or urgent warfarin reversal; units are indication and weight-based.Thrombosis risk; product-specific hypersensitivity.Thrombosis, inhibitor formation and rare allergy.Verify exact product, factor units, reconstitution, lot, rate and response.

Safe Blood Transfusion Procedure

No.ActionRationale
1Confirm prescription, component, indication, consent, compatibility sample and patent IV access.Ensures the product corrects a defined need and that the patient is prepared.
2Label the pre-transfusion sample at the bedside after positive identification.Prevents wrong-blood-in-tube errors.
3Inspect the component for identity, integrity, unusual colour, clots, expiry and transport conditions.Damaged or contaminated products must not be infused.
4Two authorised trained staff perform the final bedside match of patient, wristband, prescription, group, compatibility label, component number and expiry.The bedside check is the last defence against fatal ABO mismatch.
5Record baseline temperature, pulse, respiration, BP, oxygen saturation and relevant examination.Provides comparison for early reaction detection.
6Use an approved blood set and only compatible fluid. Begin at prescribed rate and observe closely in the early phase.Severe reactions often begin soon after exposure.
7Repeat observations at policy intervals and whenever symptoms develop; complete within the permitted time.Early recognition and stopping reduce harm.
8Document product/number, volume, times, observations, response and any reaction.Ensures traceability, handover and haemovigilance.

Transfusion Reactions and Emergency Response

ReactionRecognitionImmediate management
Acute haemolyticFever, chills, anxiety, chest/back pain, dyspnoea, hypotension, dark urine, bleeding or shock.Stop transfusion; new tubing with compatible fluid; ABC support; call clinician/blood bank; recheck identity; send bag/samples; monitor urine/shock.
Febrile non-haemolyticTemperature rise and chills without haemolysis.Stop and assess; exclude haemolysis and bacterial contamination before labelling benign.
Allergy/anaphylaxisItching/urticaria or wheeze, angioedema, hypotension and collapse.Stop; emergency anaphylaxis protocol and airway/circulation support.
Bacterial sepsisHigh fever, rigors, vomiting, severe hypotension and shock.Stop; cultures, sepsis resuscitation and prescribed antibiotics urgently; send component for investigation.
TACODyspnoea, hypertension, crackles, raised JVP, pulmonary oedema.Stop/slow as directed, sit upright, oxygen, urgent review and prescribed diuretic; monitor balance.
TRALIAcute hypoxaemia and bilateral infiltrates without circulatory overload.Stop, urgent respiratory support and blood-bank notification; diuretics are not automatic.
Universal response: Stop the transfusion immediately, keep IV access with compatible fluid through new tubing, assess and support ABC, call for help, recheck identity, notify the blood bank and follow the reaction protocol. Never restart without authorised direction.

Comprehensive Nursing Care Plan

Nursing problemExpected outcomeInterventions with rationaleEvaluation
Risk for bleedingNo major bleeding; stable haemodynamics/Hb.Inspect skin, gums, urine, stool, wounds and neurological state; trend labs; avoid unnecessary punctures/IM injections; prevent falls; apply prolonged pressure; maintain reversal plan.No new bleeding, stable trends, patient names warning signs.
Ineffective tissue perfusion related to anaemia/blood lossImproved alertness, perfusion and activity tolerance.Monitor ABC, pallor, capillary refill, chest pain, dyspnoea, consciousness and urine output; control bleeding; give prescribed haematinic/component; reassess response.Symptoms and observations improve; laboratory response appropriate.
Risk for thrombosisNo DVT, PE, stroke or device thrombosis.Assess limbs, respiratory and neurological state; verify doses; mobilise/hydrate as prescribed; use mechanical prophylaxis correctly; never massage suspected DVT.No thrombotic signs; prevention delivered consistently.
Activity intoleranceSafe graded activity with manageable fatigue.Cluster care, allow rest, assist mobilisation, monitor exertional symptoms and treat cause.Increasing activity without syncope, severe dyspnoea or chest pain.
Knowledge deficitPatient explains purpose, dose, monitoring, interactions and emergencies.Teach-back; written plan; demonstrate injection if relevant; specific missed-dose advice; review OTC/herbal products and follow-up.Accurate return demonstration and explanation.

Special Populations and Medication Errors

  • Pregnancy: LMWH is preferred for many indications because it does not cross placenta; warfarin causes fetal harm except rare specialist circumstances. Plan delivery timing.
  • Renal impairment: LMWH, dabigatran, several Xa inhibitors and tranexamic acid accumulate. Use calculated renal function, not serum creatinine alone.
  • Liver disease: both bleeding and thrombosis occur; INR alone does not describe whole haemostasis.
  • Common errors: confusing treatment and prophylaxis doses, wrong heparin concentration, using INR for DOACs, omitting renal review, wrong thrombolytic dose, treating every anaemia with iron and bypassing transfusion identity checks.

Patient Education

  • Know generic name, purpose, dose, time and duration; keep an updated medicine list and anticoagulant card.
  • Never double a missed dose unless the specific product instructions say so.
  • Tell clinicians, dentists and pharmacists before procedures or new medicines.
  • Avoid non-prescribed aspirin, ibuprofen, diclofenac and herbal remedies that may increase bleeding.
  • Seek urgent care for haematemesis, melaena, red urine, uncontrolled bleeding, severe headache, weakness, collapse, major trauma or head injury.
  • Seek urgent care for sudden dyspnoea, chest pain, haemoptysis, unilateral swollen leg or focal neurological deficit.
  • Attend all laboratory and follow-up visits even when feeling well.

Uganda-Relevant Practice

  • Investigate malaria, hookworm, nutritional deficiency, obstetric/menstrual loss, sickle cell disease, chronic infection and kidney disease as clinically relevant.
  • Use current Uganda Clinical Guidelines and Essential Medicines and Health Supplies List for dose, level-of-care restriction and referral.
  • Apply patient blood management: treat anaemia, minimise avoidable blood loss and use blood components for evidence-based indications.
  • Refer early when coagulation monitoring, imaging, reversal agents, blood products or specialist/critical care are unavailable.

Revision Summary

  • Confirm the cause before treating anaemia.
  • Understand PD/PK to predict onset, clearance, interactions and reversal.
  • Every hematological drug needs a specific indication, dose, contraindication screen and monitoring plan.
  • HIT is thrombocytopenia with thrombosis: stop all heparin and obtain urgent specialist care.
  • For a suspected transfusion reaction, stop the transfusion first and assess ABC.

Authoritative References

Educational material; apply patient-specific prescriptions, current local protocols and specialist guidance.

Hematological Medicines: Classes, Uses, Safety and Nursing Care Read More »

Dermatological Medicines: Classes, Uses, Safety and Nursing Care

Dermatological Medicines: Classes, Uses, Safety and Nursing Care

Dermatological medicines are topical, intralesional or systemic agents used to prevent, diagnose and treat disorders of the skin, hair, nails and mucous membranes. Their success depends on five linked decisions: the correct diagnosis, active medicine, strength, vehicle and duration. A medicine that is appropriate for a dry plaque on the trunk may be harmful on the eyelid, infected skin, a large body surface or an infant.

The skin is not merely a covering. It controls fluid and heat loss, provides immune and mechanical protection, permits sensation and contributes to vitamin D synthesis. Disease and topical medicines can alter all these functions. Nurses therefore assess the whole patient, not only the visible lesion.

Emergency principle: Skin pain, blistering, mucosal erosion, rapid detachment, widespread redness, fever, hypotension, breathing difficulty, facial swelling or rapidly advancing soft-tissue infection may indicate life-threatening disease. Stop suspected culprit medicines where authorised, stabilise airway/breathing/circulation and escalate urgently.

Learning Objectives

  • Explain factors that affect percutaneous absorption and selection of topical vehicles.
  • Classify dermatological medicines and explain their mechanisms, indications, adverse effects, contraindications and monitoring.
  • Use topical corticosteroids, emollients, antimicrobial, antiparasitic and acne medicines safely.
  • Calculate and teach practical application quantities using fingertip units where appropriate.
  • Recognise severe cutaneous adverse reactions and dermatological emergencies.
  • Plan individualised nursing care, patient education, follow-up and prevention.

Principles of Topical Pharmacology

Factors Affecting Skin Absorption

  • Body site: Eyelids, face, genital skin and flexures absorb more than thick skin on palms and soles. Potency must be reduced on thin or occluded sites.
  • Age: Infants have a larger surface-area-to-body-mass ratio and can absorb proportionally more medicine. Older skin is thinner and more fragile.
  • Skin integrity: Inflamed, eroded or diseased skin permits greater penetration than intact skin.
  • Hydration and occlusion: Moisture and airtight dressings increase penetration, sometimes many-fold. Occlusion should be prescribed, not improvised.
  • Area and duration: Applying potent medicine over a large area or for a long period increases local and systemic toxicity.
  • Vehicle: Ointments are more occlusive; creams are less greasy; lotions/solutions spread over hairy or large areas; gels dry quickly but may sting.

Choosing a Vehicle

VehicleSuitable UsesLimitations
OintmentDry, thick, scaly or lichenified lesions; strong moisturising/occlusive effect.Greasy, heat-retaining and unsuitable for many weeping lesions or very hairy sites.
CreamMoist, flexural or cosmetically sensitive areas; easier daytime use.Contains water and preservatives; may sting or cause contact allergy and is less occlusive.
Lotion/solutionScalp, hairy skin, large areas or wet lesions.Alcohol-based products may sting and dry inflamed skin.
Gel/foamOily or hairy sites and acne.May irritate, dry the skin or be flammable depending on formulation.
PasteLocal protection and absorption of exudate.Thick and difficult to spread/remove.

Fingertip Units and Quantity

One adult fingertip unit (FTU) is the amount expressed from a standard 5-mm nozzle along the fingertip from the distal crease to the tip. It is approximately enough for two adult hand-sized areas. FTU charts differ by age and body site. The nurse should demonstrate the amount rather than merely saying “apply thinly,” which often causes under-treatment or excessive use.

Emollients, Moisturisers and Barrier Preparations

Examples: Petrolatum, emulsifying ointment, paraffin-containing products, glycerol, urea-containing moisturisers and zinc oxide barriers.

  • Mechanism: Occlusives reduce transepidermal water loss; humectants attract water into the stratum corneum; lipid-containing products fill cracks and restore flexibility.
  • Indications: Atopic eczema, xerosis, ichthyosis, irritant dermatitis, fragile skin and prevention of moisture-associated skin damage.
  • Use: Apply generously and repeatedly, including when inflammation has improved. Smooth in the direction of hair growth rather than vigorous rubbing. Use soap substitutes where prescribed.
  • Adverse effects: Folliculitis, slipping hazards, contact sensitivity, stinging from urea on fissured skin and occlusion-related heat rash.
  • Fire hazard: Paraffin or oil residue on clothing, bedding and dressings can ignite and burn rapidly. Keep away from cigarettes, flames and heaters; washing reduces but may not remove residue.
  • Infection prevention: Use a pump dispenser or clean spatula rather than repeatedly putting fingers into a communal jar.

Topical Corticosteroids

Examples by increasing potency: Hydrocortisone (mild); clobetasone butyrate or similar moderate agents; betamethasone valerate (potent depending on strength/formulation); clobetasol propionate (very potent). Potency classification varies by country and product.

  • Mechanism: Bind intracellular glucocorticoid receptors and reduce inflammatory cytokines, vasodilation, oedema, immune-cell activity and itch.
  • Indications: Eczema/dermatitis, selected inflammatory dermatoses and psoriasis according to site and specialist plan. They do not cure infection.
  • Selection: Match potency to diagnosis, severity, site and age. Face, eyelids, flexures, genital skin and infants generally require mild preparations and short courses; thick plaques on palms/soles may need stronger treatment under supervision.
  • Local adverse effects: Skin atrophy, striae, telangiectasia, easy bruising, hypopigmentation, acneiform eruption, periorificial dermatitis, rosacea worsening, delayed healing and infection masking.
  • Systemic adverse effects: Hypothalamic–pituitary–adrenal suppression, Cushingoid effects, hyperglycaemia, growth effects and ocular complications are more likely with very potent agents, large areas, prolonged use, occlusion or young age.
  • Safe practice: Use the least potent effective preparation for the planned duration, continue emollients and review non-response. Do not abruptly stop prolonged extensive potent therapy without a taper/review plan.
  • Dangerous misuse: Steroid–antibiotic–antifungal “triple creams” can temporarily suppress redness while worsening tinea, causing tinea incognito, atrophy and antimicrobial resistance.

Topical Calcineurin Inhibitors

Tacrolimus ointment and pimecrolimus cream inhibit calcineurin-dependent T-cell activation. They are steroid-sparing options for selected atopic eczema, particularly sensitive sites, under guideline criteria. Transient burning is common. Counsel on sun protection and specialist review; they are not treatments for active bacterial, viral or fungal infection.

Dermatological Anti-infective Medicines

Topical Antibacterials and Antiseptics

  • Examples: Mupirocin or fusidic acid where locally recommended; chlorhexidine, povidone-iodine and other approved antiseptics.
  • Mechanism: Antibiotics inhibit specific bacterial targets; antiseptics act more broadly on microorganisms.
  • Indications: Limited impetigo, selected infected wounds or decolonisation protocols. Widespread cellulitis, fever, lymphangitis or systemic illness requires systemic assessment.
  • Risks: Contact dermatitis, delayed healing from harsh antiseptics, altered flora and resistance from prolonged/repeated topical antibiotics.
  • Stewardship: Do not automatically prescribe antibiotics for every weeping eczema flare. Optimise emollients and anti-inflammatory treatment; culture recurrent or unresponsive infection when indicated.

Topical Antifungals

Class/ExamplesMechanism and UsesNursing Points
Azoles
Clotrimazole, miconazole, ketoconazole
Inhibit ergosterol synthesis; used for dermatophytes, candidiasis and selected Malassezia disease.Apply beyond the visible margin and for the prescribed duration. Miconazole can interact with warfarin even when topical in some situations.
Allylamines
Terbinafine
Inhibits squalene epoxidase; strong activity against dermatophytes.Often requires a shorter topical course than azoles; not every Candida infection responds equally.
Other agents
Nystatin
Binds fungal membrane sterols; active against Candida but not dermatophytes.Do not use nystatin for ordinary ringworm/tinea.

Systemic antifungals such as terbinafine, fluconazole, itraconazole or griseofulvin are used for selected extensive disease, scalp/hair infection or onychomycosis. Confirm diagnosis where possible; review pregnancy, liver disease, cardiac disease and interactions. Monitor liver function when indicated. Tinea capitis generally requires systemic treatment because topical agents do not penetrate the infected hair shaft sufficiently.

Antiviral Medicines

Topical or systemic aciclovir/related agents inhibit viral DNA replication in herpes simplex or varicella-zoster disease. Systemic therapy is more important for extensive herpes zoster, immunosuppression, eczema herpeticum or ocular involvement. Begin early when indicated and adjust systemic doses in renal impairment. Painful clustered vesicles with fever in a patient with eczema may be eczema herpeticum and require urgent care.

Antiparasitic Medicines

Scabies

Scabies is caused by Sarcoptes scabiei. Medicine failure commonly results from incomplete application, untreated contacts, failure to repeat treatment, reinfestation or misdiagnosis—not necessarily drug resistance.

MedicineUse and MechanismPrecautions
Permethrin 5% creamDisrupts parasite sodium channels. Apply to all required skin according to age/product instructions and repeat at the recommended interval.Avoid eyes/mucosa. Follow infant and pregnancy guidance. Burning/itch may occur.
Benzyl benzoate 10–25%Topical scabicide widely used where available; concentration/application schedule depends on age and national protocol.Can be very irritant, especially on excoriated skin and in children; correct dilution/product is essential.
Precipitated sulfur 5–10%Alternative topical scabicide in selected groups.Messy, odorous and requires repeated application, but may be useful when alternatives are unsuitable.
Oral ivermectinBinds parasite chloride channels. Used for selected ordinary, crusted or outbreak-associated scabies; often repeated because it does not reliably kill eggs.Avoid or use specialist guidance in pregnancy and small children according to national protocol; calculate by weight and review interactions.

Complete Scabies Nursing Plan

  1. Confirm the pattern: Nocturnal itch, burrows and typical distribution; examine contacts. Consider crusted scabies in immunosuppressed patients.
  2. Prepare the patient: Trim nails, bathe if instructed and dry/cool the skin before topical treatment.
  3. Cover all required sites: Apply to the whole prescribed surface, including finger/toe webs, under nails, wrists, axillae, groin, buttocks and soles; scalp/face instructions vary with age and product.
  4. Treat contacts together: Household and close physical contacts require simultaneous management even if asymptomatic, according to guidance.
  5. Manage textiles: Wash and hot-dry or iron recently used clothes/linen where feasible; seal non-washable items away from skin contact as directed.
  6. Repeat correctly: Repeat after the product-specific interval to kill newly hatched mites.
  7. Explain post-scabetic itch: Itch can persist for weeks after eradication. New burrows or new typical lesions suggest failure/reinfestation and require reassessment.

Pediculosis (Lice)

Permethrin or other locally approved pediculicides may be used with wet-combing and environmental measures. Apply exactly as labelled, repeat when required to address newly hatched lice, examine close contacts and avoid toxic insecticides or flammable home remedies. Resistance patterns and approved products vary.

Medicines for Acne

Medicine/ClassMechanism and RoleAdverse Effects and Teaching
Benzoyl peroxideOxidising antibacterial and mildly comedolytic; reduces Cutibacterium acnes without bacterial resistance and helps protect antibiotic stewardship.Dryness, irritation and bleaching of hair/fabric. Start gradually; use moisturiser and sun protection.
Topical retinoids
Adapalene, tretinoin
Normalise follicular keratinisation, prevent comedones and reduce inflammation.Irritation and photosensitivity; introduce gradually. Avoid in pregnancy according to product/guideline.
Azelaic acidComedolytic, antimicrobial and anti-inflammatory; may help post-inflammatory pigmentation.Stinging and irritation; benefit develops over weeks.
Topical antibiotics
Clindamycin
Reduce acne bacteria and inflammation.Do not use as monotherapy; combine with benzoyl peroxide/other non-antibiotic therapy to reduce resistance and limit duration.
Oral tetracyclines
Doxycycline or locally recommended alternative
Antibacterial and anti-inflammatory treatment for moderate–severe inflammatory acne combined with topical therapy.Photosensitivity, gastrointestinal/oesophageal irritation; pregnancy and age restrictions. Take with adequate water and avoid unnecessary prolonged courses.
Hormonal therapySelected combined oral contraceptives or anti-androgen strategies reduce androgen-driven sebum.Requires individual assessment for thrombotic and other contraindications; not suitable for every patient.
Oral isotretinoinStrongly reduces sebum, follicular blockage and inflammation; reserved for severe/scarring or refractory acne under specialist supervision.Highly teratogenic. Requires strict pregnancy-prevention procedures, mental-health/sexual-function review per current safety guidance, laboratory monitoring as indicated, and counselling about dryness, sun sensitivity and no blood donation.

Assess acne severity, scarring, pigmentation and psychological effects. Visible improvement commonly takes 6–8 weeks or longer. Avoid picking lesions. Refer nodulocystic acne, scarring, diagnostic uncertainty, severe distress or treatment failure.

Other Important Dermatological Medicines

Keratolytics and Wart Treatments

Salicylic acid softens keratin and is used for selected warts, corns and thick scale. Protect normal skin, avoid large/broken surfaces and use extra caution in children, diabetes or impaired circulation. Urea is moisturising at lower concentrations and keratolytic at higher concentrations. Do not apply strong wart preparations to face/genitals unless specifically formulated and prescribed.

Psoriasis Medicines

  • Vitamin D analogues: Calcipotriol regulates keratinocyte proliferation; avoid excessive quantity because of calcium disturbance risk.
  • Topical corticosteroids: Reduce inflammation but require potency/site limits and planned breaks or combination regimens.
  • Coal tar/keratolytics: Reduce scale and inflammation but may irritate, stain and be cosmetically difficult.
  • Systemic methotrexate: Folate antagonist/immunomodulator for severe disease; weekly—not daily—dosing is a critical safety point. Monitor full blood count, liver and renal function; prevent pregnancy and review interactions.
  • Ciclosporin: Rapid immunosuppression for selected severe disease; monitor blood pressure, renal function, infection and interactions.
  • Biologic medicines: Target specific cytokines; require specialist screening for tuberculosis/hepatitis and monitoring for infection.

Antipruritic Medicines

Emollients, cooling preparations and treating the cause are central. Oral antihistamines help histamine-mediated urticaria; sedating agents may aid short-term night-time sleep but can cause falls, impaired driving, confusion and anticholinergic effects. They do not treat every form of itch.

Sunscreens and Photoprotection

Broad-spectrum sunscreen protects against ultraviolet A and B radiation. Apply adequate quantity before exposure, reapply after sweating/washing and combine with shade, clothing and hats. Sunscreen is an adjunct, not permission for prolonged exposure. Photoprotection is important with retinoids, tetracyclines, photosensitive disease and pigment disorders.

Procedure: Applying a Topical Medicine

No.ActionRationale
1Verify patient, prescription, diagnosis, medicine, concentration, vehicle, site, area, frequency, duration, allergy and expiry date.Prevents wrong-strength/site errors and confirms that treatment fits the lesion.
2Assess and document lesion type, distribution, size, pain, exudate, surrounding skin and systemic signs.Provides a baseline and identifies infection or emergency disease before it is masked by treatment.
3Explain, provide privacy, perform hand hygiene and wear gloves when exposure or transmission is possible.Protects dignity and prevents contamination or medicine absorption by the caregiver.
4Clean only as prescribed and pat dry. Use a clean spatula/applicator rather than dipping contaminated fingers into a jar.Protects tissue and prevents contaminating the bulk preparation.
5Measure the appropriate amount using FTU or prescribed quantity; apply gently in the direction of hair growth.Achieves even dosing and reduces folliculitis from vigorous rubbing against hairs.
6Avoid eyes, mucosa and healthy surrounding skin unless instructed; apply dressings/occlusion only when prescribed.Prevents toxicity and unintended increased absorption.
7Remove gloves, wash hands, store the medicine safely and document application and response.Completes infection prevention and ensures continuity/evaluation.

Dermatological Emergencies and Severe Reactions

  • Anaphylaxis: Skin/mucosal changes with airway, breathing or circulation compromise require immediate intramuscular adrenaline according to emergency protocol, oxygen/support and urgent transfer.
  • Stevens–Johnson syndrome/toxic epidermal necrolysis: Fever, skin pain, target-like lesions, blistering, detachment and mucosal erosions after a medicine. Stop suspected non-essential culprit medicines under emergency direction, support ABC, fluids, temperature, eyes and wounds, and refer urgently.
  • Drug reaction with eosinophilia and systemic symptoms: Rash with fever, facial oedema, lymphadenopathy and organ injury weeks after a medicine requires urgent laboratory assessment and specialist care.
  • Necrotising soft-tissue infection: Pain out of proportion, rapid progression, crepitus, bullae, anaesthesia, toxicity or shock needs immediate surgical review, resuscitation and IV antibiotics.
  • Staphylococcal scalded-skin syndrome or extensive blistering: Requires urgent paediatric/specialist care.
  • Erythroderma/generalised pustular psoriasis: Widespread redness or pustules can cause heat/fluid loss, electrolyte disturbance and infection; avoid abrupt systemic steroid changes and admit/refer.
  • Eczema herpeticum: Rapid painful monomorphic vesicles/erosions with fever in eczema requires urgent systemic antiviral treatment.

Nursing Care Plan

Assessment

  • History of onset, progression, itch/pain, triggers, occupation, contacts, travel, sexual exposure where relevant, new medicines, allergies, traditional remedies and previous treatment.
  • Describe primary lesion, colour, border, surface, distribution, symmetry, mucosal/nail/hair involvement and signs of secondary infection.
  • Assess temperature, hydration, nutrition, sleep, mobility, self-image, stigma, school/work and risk of self-harm in severe visible disease.
  • Review microscopy/culture, full blood count, renal/liver tests, pregnancy testing and therapeutic monitoring relevant to prescribed systemic agents.

Priority Problems, Interventions and Rationales

No.InterventionRationale and Desired Outcome
1Assess itch/pain regularly; protect excoriated skin, keep nails short and use prescribed antipruritic/analgesic therapy.Reduces scratching, sleep loss, infection and distress; patient reports tolerable symptoms.
2Maintain skin hydration with correctly selected emollient and gentle washing; avoid known irritants.Restores barrier function and reduces flares/fissuring.
3Administer topical treatment using measured quantity, correct site and ordered sequence; use emollient and active drug separately as directed.Achieves therapeutic exposure while preventing dilution, spread and toxicity.
4Monitor spreading erythema, fever, pus, lymphangitis, severe pain and vital-sign change.Detects secondary infection or systemic deterioration early.
5Use contact precautions/isolation when indicated for scabies, crusted scabies or transmissible infection; manage linen safely.Prevents institutional and household transmission.
6Monitor systemic therapy using medicine-specific observations and laboratory tests; check pregnancy risk where teratogenic medicines are used.Detects marrow, liver, renal, blood-pressure, infection or fetal risk before serious harm.
7Teach with demonstration and teach-back; provide a written schedule for multiple products.Improves adherence and distinguishes maintenance emollient from short-course active medicine.
8Support privacy, body image and coping; address stigma and refer severe psychological distress.Visible disease affects relationships, school/work and mental health as well as skin.

Patient Education and Prevention

  • Use only labelled medicines for the diagnosed condition; avoid sharing or unlabelled “mixed creams.”
  • Apply the demonstrated quantity and complete the planned course; more is not necessarily better.
  • Do not scratch, squeeze acne lesions or cut warts/corns with blades.
  • Keep infected areas, personal towels, clothing and razors separate when transmission is possible.
  • Use sun protection with photosensitising medicines.
  • Return for fever, rapid spread, blistering, mucosal lesions, facial swelling, breathing difficulty or severe pain.

Uganda-Relevant Practice

  • Follow current Uganda Clinical Guidelines and the Essential Medicines and Health Supplies List; availability and approved strengths vary.
  • Consider HIV-associated dermatoses, scabies, tinea capitis, bacterial infection, medicine reactions, leprosy and other skin-related neglected tropical diseases where clinically relevant.
  • Counsel respectfully about harmful bleaching products, potent steroid mixtures and non-sterile traditional applications without dismissing the patient’s beliefs.
  • Refer early when microscopy, culture, biopsy, dermatology review, burn care or monitoring for systemic therapy is unavailable.
Before topical treatment remember “S-K-I-N”:
S — Site, surface area and severity.
K — Know the diagnosis, strength and vehicle.
I — Infection, interactions and integrity of the barrier.
N — Nursing monitoring, quantity and next review.

Revision Summary

  • Correct diagnosis, potency, vehicle, quantity and duration determine safety.
  • Emollients are active barrier treatment and should be used generously.
  • Topical steroids reduce inflammation but can cause atrophy, infection masking and systemic effects.
  • Antibiotics should not be used routinely or alone for acne.
  • Scabies care fails when the whole skin surface, repeat dose, contacts or linen are ignored.
  • Isotretinoin, methotrexate, ciclosporin and biologics require specialist safeguards and monitoring.
  • Blistering, mucosal disease, severe skin pain, rapid spread or systemic illness requires urgent escalation.

Authoritative References

This educational article does not replace patient-specific diagnosis, an authorised prescription, local protocol or specialist care.

Dermatological Medicines: Classes, Uses, Safety and Nursing Care Read More »

Eye, Ear, Nose and Throat Medicines: Classes, Uses and Nursing Care

Eye, Ear, Nose and Throat Medicines: Classes, Uses and Nursing Care

Medicines acting on the eye, ear, nose and throat include local and systemic preparations used to prevent, diagnose or treat disorders of these specialised organs. Local preparations—drops, ointments, gels, sprays, irrigations, gargles and lozenges—can deliver a high medicine concentration at the affected site with less systemic exposure. However, they can still be absorbed, cause serious adverse effects, interact with other medicines or damage delicate tissues when used incorrectly.

The nurse must therefore understand not only which medicine is used, but also its mechanism, indication, correct anatomical site, preparation strength, administration technique, contraindications, adverse effects, monitoring requirements and referral limits. A red eye, discharging ear, blocked nose or sore throat is a symptom rather than a diagnosis; medicine should follow appropriate assessment.

Core safety principle: Never treat loss of vision, severe ocular pain, penetrating injury, sudden hearing loss, mastoid swelling, stridor, drooling or rapidly progressive facial/neck swelling as an ordinary minor complaint. Stabilise urgent threats, avoid harmful instillation and arrange prompt specialist or emergency referral.

Learning Objectives

By the end of this lesson, the learner should be able to:

  • Classify ophthalmic, otic, nasal and oropharyngeal medicines according to their therapeutic action.
  • Explain the mechanisms, indications, administration, contraindications, adverse effects and important interactions of the major classes.
  • Assess the patient and distinguish uncomplicated presentations from conditions requiring urgent referral.
  • Administer eye drops, eye ointment, ear drops and nasal preparations safely using infection-prevention principles.
  • Monitor therapeutic response, recognise medicine-related harm and educate patients for safe self-administration.
  • Develop a practical nursing care plan with measurable outcomes, interventions and rationales.
  • Apply antimicrobial stewardship and Uganda-relevant prescribing and referral principles.

Anatomical and Pharmacological Foundations

Why Local Medicines Behave Differently

  • Small treatment surface: A single drop usually exceeds the capacity of the conjunctival sac. Extra drops mainly overflow or drain through the nasolacrimal duct; they do not necessarily improve effect.
  • Rapid drainage: Blinking, tears and nasal clearance shorten contact time. Ointments remain longer but blur vision.
  • Systemic absorption: Eye drops can enter the nasal mucosa through the nasolacrimal duct; nasal and throat preparations can be swallowed; inflamed ear or nasal mucosa can absorb more medicine. Topical beta-blockers, sympathomimetics and corticosteroids may therefore cause systemic effects.
  • Barrier penetration: The intact cornea, tympanic membrane and skin protect deeper structures. Trauma, ulceration or perforation changes both penetration and toxicity.
  • Vehicle matters: Solutions act quickly, suspensions require shaking, gels and ointments prolong contact, and preservative-free products reduce exposure to sensitising preservatives when use is frequent.

General Assessment Before Administration

  1. Confirm the complaint and urgency: Ask about onset, pain, discharge, itch, trauma, foreign body, fever, visual or hearing change, breathing and swallowing.
  2. Verify the prescription: Apply the rights of medicine administration, including the correct organ and side—right eye, left eye, both eyes, right ear or left ear.
  3. Check patient factors: Age, pregnancy, breastfeeding, allergies, contact-lens use, glaucoma, asthma, heart block, hypertension, diabetes, renal/liver disease, immunosuppression and recent surgery.
  4. Review other products: Include prescribed medicines, over-the-counter preparations, herbal remedies and previous partially used drops. Multiple products may duplicate ingredients or interact.
  5. Inspect the product: Check name, concentration, expiry date, seal, appearance, storage and date opened. Do not use a cloudy solution unless it is formulated as a suspension.

Medicines Acting on the Eye

Ophthalmic Dosage Forms

FormAdvantagesLimitations and Nursing Implications
SolutionRapid action, easy instillation and little blurring.Short contact time. More frequent dosing may be needed. One correctly placed drop is generally sufficient unless the prescription states otherwise.
SuspensionPermits delivery of poorly soluble medicines.Must be shaken well to redistribute particles; otherwise early doses may be weak and later doses too concentrated.
OintmentLong contact time; useful at night and in children who cannot cooperate with frequent drops.Temporarily blurs vision and may interfere with daytime activity. Apply after drops when both are prescribed.
Gel or insertProlonged effect and sometimes less frequent dosing.May cause transient blurring, foreign-body sensation or difficulty with correct placement.

1. Ocular Lubricants and Tear Substitutes

Examples: Hypromellose, carmellose, polyvinyl alcohol, hyaluronic-acid preparations, lubricating gels and petrolatum/mineral-oil ointments.

  • Mechanism: Supplement the tear film, reduce friction between the eyelid and ocular surface, retain moisture and protect damaged epithelium.
  • Indications: Dry-eye symptoms, exposure-related dryness, minor irritation, reduced blinking, some postoperative states and lubrication during impaired eyelid closure.
  • Administration: Drops are useful during the day; thicker gels or ointments are often used at bedtime. Preservative-free preparations are preferable when dosing is frequent or the ocular surface is sensitive.
  • Adverse effects: Brief stinging, sticky lids, temporary blurred vision and sensitivity to preservatives.
  • Nursing point: Persistent unilateral redness, significant pain, photophobia, purulent discharge or reduced vision is not simple dry eye and requires assessment.

2. Ocular Antibacterial Medicines

Examples: Chloramphenicol, tetracycline eye ointment, gentamicin, tobramycin, ciprofloxacin, ofloxacin and other locally approved preparations.

  • Mechanism: Chloramphenicol and tetracyclines inhibit bacterial protein synthesis; aminoglycosides interfere with the 30S ribosomal subunit; fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase.
  • Indications: Selected bacterial conjunctivitis, blepharitis, corneal bacterial infection under appropriate supervision, neonatal prophylaxis/treatment according to national protocol, and perioperative prophylaxis where prescribed.
  • Selection: Depends on likely organism, severity, corneal involvement, contact-lens use, age, allergy and local resistance. Severe keratitis requires corneal sampling and intensive specialist therapy.
  • Adverse effects: Burning, allergy, eyelid swelling, contact dermatitis, surface toxicity and selection of resistant organisms. Aminoglycosides may be epitheliotoxic with prolonged use.
  • Stewardship: Many adult infectious conjunctivitis cases are viral and self-limited; antibiotics neither treat viruses nor prevent every complication. Avoid leftover or shared drops and review failure rather than extending treatment blindly.
  • Urgent groups: Neonates with eye discharge, contact-lens wearers with a painful red eye, patients with corneal opacity/ulcer, gonococcal-like copious discharge or reduced vision need urgent evaluation.

3. Ocular Antiviral and Antifungal Medicines

  • Antivirals: Aciclovir eye ointment, ganciclovir gel and systemic aciclovir/valaciclovir are used for selected herpes simplex or varicella-zoster ocular disease. They inhibit viral DNA replication. Adverse effects include local irritation and superficial corneal toxicity.
  • Antifungals: Natamycin and specialist-selected azoles or compounded agents may be used for fungal keratitis. Risk is greater after plant/soil trauma, prolonged topical steroid use or immunosuppression.
  • Critical precaution: Ocular herpes and fungal keratitis can resemble other red-eye conditions. Unsupervised corticosteroid drops may accelerate infection, thin the cornea and threaten sight.

4. Ocular Corticosteroids and Non-steroidal Anti-inflammatory Drugs

Corticosteroid examples: Prednisolone acetate, dexamethasone, betamethasone and fluorometholone. Non-steroidal anti-inflammatory drug (NSAID) examples: Ketorolac, diclofenac and nepafenac.

  • Corticosteroid mechanism: Suppress inflammatory gene expression, capillary permeability and leukocyte activity. They are used for selected uveitis, severe non-infectious inflammation and postoperative inflammation under ophthalmic supervision.
  • Corticosteroid hazards: Raised intraocular pressure, steroid-induced glaucoma, posterior subcapsular cataract, delayed epithelial healing, corneal thinning and worsening of bacterial, fungal or herpetic infection.
  • Monitoring: Confirm indication, duration and taper plan. Prolonged therapy requires review of intraocular pressure, lens and cornea. Do not stop prolonged intensive therapy abruptly unless directed.
  • NSAID mechanism and use: Cyclo-oxygenase inhibition reduces prostaglandins, pain and postoperative inflammation. Risks include stinging, delayed healing and rare corneal complications, especially in compromised ocular surfaces.

5. Anti-allergy Eye Medicines

  • Mast-cell stabilisers: Sodium cromoglicate reduces release of inflammatory mediators and works best with regular preventive use rather than as immediate rescue.
  • Antihistamine/mast-cell stabiliser combinations: Olopatadine or ketotifen reduce histamine-mediated itch, redness and watering and also reduce mediator release.
  • Supportive measures: Cold compresses, allergen avoidance, tear substitutes and avoidance of eye rubbing.
  • Precaution: Vasoconstrictor “redness-relief” drops may cause rebound redness and do not treat the underlying allergy. Persistent unilateral disease, pain or visual loss suggests another diagnosis.

6. Mydriatics, Cycloplegics and Miotics

ClassAction and UsesAdverse Effects and Precautions
Antimuscarinic mydriatics/cycloplegics
Atropine, cyclopentolate, tropicamide
Block muscarinic activity, dilating the pupil; stronger agents also paralyse accommodation. Used for refraction, examination and selected uveitis to relieve ciliary spasm and prevent adhesions.Photophobia, blurred near vision, raised intraocular pressure in susceptible narrow angles and systemic anticholinergic effects—dry mouth, flushing, fever, tachycardia, confusion—especially in children.
Sympathomimetic mydriatic
Phenylephrine
Stimulates alpha receptors in the iris dilator muscle, producing mydriasis without marked cycloplegia; used diagnostically and perioperatively.Can raise blood pressure and cause palpitations; use cautiously in cardiovascular disease, hyperthyroidism and small infants.
Miotic
Pilocarpine
Muscarinic agonist that constricts the pupil and increases trabecular aqueous outflow; used in selected glaucoma situations.Brow ache, headache, blurred/dim vision, induced myopia and rare retinal complications. It is not a substitute for complete emergency management of acute angle closure.

7. Local Anaesthetics and Diagnostic Agents

  • Local anaesthetics: Tetracaine or proxymetacaine blocks corneal nerve conduction for examination, tonometry, foreign-body removal or minor procedures. Repeated self-use is dangerous because it masks deterioration, delays epithelial healing and can cause corneal ulceration.
  • Fluorescein: A diagnostic dye that reveals epithelial defects and assists tear-film or contact-lens assessment. It is not a treatment. Examine with the appropriate blue light and document staining pattern.
  • Nursing responsibility: Protect the anaesthetised cornea until sensation returns; instruct the patient not to rub the eye.

8. Medicines for Glaucoma

Glaucoma treatment lowers intraocular pressure to protect the optic nerve. The patient may feel no immediate benefit, so adherence and follow-up are essential. Choice depends on glaucoma type, target pressure, comorbidity, pregnancy, cost, availability and response.

Class and ExamplesMechanism and RoleImportant Adverse Effects, Contraindications and Nursing Care
Prostaglandin analogues
Latanoprost, travoprost, bimatoprost
Increase mainly uveoscleral outflow. Long duration and strong pressure reduction make them common first-line agents for chronic open-angle disease.Conjunctival redness, iris/periocular pigmentation, eyelash growth and periorbital fat changes. Usually given once daily. Avoid contaminating the tip; monitor response and adherence.
Beta-blockers
Timolol, betaxolol
Reduce aqueous-humour production.Bradycardia, hypotension, fatigue, heart block and bronchospasm. Timolol is particularly concerning in asthma, severe chronic obstructive pulmonary disease and conduction disease. Check pulse/history and use punctal occlusion to reduce systemic absorption.
Alpha-2 agonists
Brimonidine
Reduce aqueous production and may increase outflow.Dry mouth, fatigue, hypotension and allergic conjunctivitis. Can cause severe central nervous system depression in young children; observe age restrictions.
Topical carbonic anhydrase inhibitors
Dorzolamide, brinzolamide
Reduce bicarbonate formation and aqueous secretion.Stinging, bitter taste and local allergy. Review sulfonamide hypersensitivity history and corneal/endothelial disease.
Systemic carbonic anhydrase inhibitor
Acetazolamide
Rapidly reduces aqueous production; used in selected acute or refractory situations.Paraesthesia, diuresis, metabolic acidosis, potassium disturbance, renal stones and sulfonamide reactions. Review renal function, electrolytes and contraindications.
Hyperosmotic agents
Intravenous mannitol
Create an osmotic gradient that reduces ocular volume in selected emergencies.Fluid shifts, pulmonary oedema, electrolyte disturbance and renal risk. Requires prescribed emergency monitoring and careful assessment of cardiac/renal status.
Acute angle-closure warning: Severe eye pain, headache, halos, nausea/vomiting, a red eye, cloudy cornea and a fixed or poorly reactive mid-dilated pupil require immediate ophthalmic emergency care. Pressure-lowering medicines are temporising measures; definitive treatment is usually procedural.

9. Anti-vascular Endothelial Growth Factor Medicines

Intravitreal bevacizumab, ranibizumab or aflibercept inhibits vascular endothelial growth factor and is used by specialists for conditions such as neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion. Nursing care includes consent support, aseptic preparation, post-injection education and urgent recognition of endophthalmitis—worsening pain, redness, photophobia or visual loss.

Procedure: Instilling Eye Drops and Ointment

No.ActionRationale
1Check the prescription, patient, medicine, concentration, expiry date and correct eye; assess allergies, vision, pain and appearance.Prevents wrong-patient, wrong-eye and wrong-strength errors and establishes a baseline for evaluating response or deterioration.
2Explain the procedure, provide privacy, perform hand hygiene and position the patient sitting or supine with the head supported.Promotes cooperation, reduces sudden movement and prevents transfer of organisms.
3If discharge is present, clean from inner to outer canthus using a fresh swab for each stroke and separate materials for each eye.Removes material that may obstruct the medicine and limits cross-infection.
4Shake suspensions. Ask the patient to look upward; gently pull the lower lid down to expose the conjunctival sac.Redistributes suspended medicine and creates a safe pocket away from the cornea.
5Hold the dropper about 1–2 cm above the sac and instil the prescribed drop without touching lashes, lid or eye.Prevents injury and contamination. Direct corneal instillation is uncomfortable and triggers blinking.
6Ask the patient to close the eye gently; apply light pressure over the nasolacrimal duct for about 1–2 minutes when appropriate.Prolongs ocular contact and reduces systemic absorption through the nasal mucosa.
7When several drops are prescribed, separate different preparations by the recommended interval; apply drops before ointment. For ointment, place a thin ribbon from inner to outer lower sac without touching the tip.Prevents one medicine washing out another. Ointment forms a barrier and would reduce penetration of drops applied afterward.
8Replace the cap immediately, clean excess medicine, reassess comfort/vision and document medicine, dose, eye, time, response and teaching.Maintains product sterility and creates an accurate record for evaluation and handover.

Eye Red Flags and Immediate Actions

  • Chemical exposure: Begin immediate copious irrigation with clean water or normal saline; do not delay for history, referral or a preferred fluid. Remove contact lenses if easily possible and continue irrigation while arranging urgent assessment.
  • Penetrating injury or embedded object: Do not remove the object or apply pressure/drops. Protect with a rigid shield, keep the patient nil by mouth if surgery is possible and refer urgently.
  • Sudden visual loss: Treat as time-critical even without pain.
  • Painful red eye with photophobia or corneal opacity: Consider keratitis, uveitis or acute glaucoma rather than simple conjunctivitis.
  • Contact-lens-related painful red eye: Remove lenses, avoid re-use and arrange urgent corneal assessment.
  • Neonatal discharge: Urgent evaluation is required because gonococcal, chlamydial or other infection may damage the cornea or indicate systemic infection.

Medicines Acting on the Ear

Assessment Before Ear Medicines

  • Differentiate external-ear canal disease from middle-ear disease. Ask about pain on moving the pinna/tragus, swimming, discharge, fever, hearing loss, trauma, foreign body and previous surgery.
  • Inspect the canal and tympanic membrane when trained and equipment is available. Do not assume the membrane is intact when discharge is present.
  • Ask about diabetes and immunosuppression because severe otitis externa can progress to invasive disease.
  • Review concurrent ototoxic medicines and baseline hearing or balance problems.

1. Antibacterial Ear Drops

Examples: Ciprofloxacin or ofloxacin; aminoglycosides such as neomycin or gentamicin in selected preparations.

  • Mechanism: Fluoroquinolones inhibit bacterial DNA enzymes; aminoglycosides inhibit the 30S ribosome.
  • Indications: Bacterial otitis externa and selected discharging ears based on examination and local protocol. Aural toilet and keeping the canal dry are important.
  • Tympanic membrane caution: When perforation, grommet or open middle ear is possible, use only a preparation considered non-ototoxic and approved for that situation. Aminoglycoside exposure to the middle/inner ear may damage hearing or balance, particularly with prolonged/repeated use.
  • Adverse effects: Burning, irritation and allergic contact dermatitis; neomycin is a recognised sensitiser.

2. Antibiotic–Corticosteroid Combinations

Preparations combining an antibacterial with hydrocortisone or dexamethasone treat infection plus marked canal inflammation. The steroid reduces swelling and itch, improving medicine penetration when the canal is inflamed. Use only for a diagnosed indication and prescribed duration; combination products can mask fungal infection, sensitise skin and promote resistance when used indiscriminately.

3. Antifungal Ear Medicines

Clotrimazole or another locally approved antifungal may be used for otomycosis. Typical clues include intense itch, fullness, characteristic debris and failure of antibacterial therapy. Effective care combines gentle professional cleaning, dryness, correction of risk factors and the appropriate antifungal. Persistent pain, granulation, cranial-nerve signs or systemic illness requires referral.

4. Cerumenolytics

Approved wax-softening preparations may contain sodium bicarbonate, oil-based agents or other cerumenolytics. They soften impacted wax before natural expulsion or removal. Do not instil them when perforation, grommet, recent ear surgery, foreign body, infection, severe pain or discharge is suspected unless a qualified clinician has assessed the ear.

5. Analgesics and Medicines for Middle-ear Disease

  • Paracetamol or ibuprofen: Provide pain and fever relief when appropriate. Calculate paediatric doses by weight, check maximum daily dose and avoid duplicating combination products.
  • Acute otitis media: This is behind the tympanic membrane; ordinary antibiotic ear drops do not automatically treat it. Many uncomplicated cases improve with analgesia and observation, while selected children or severely unwell patients require systemic antibiotics under guideline criteria.
  • Otitis media with effusion: Antibiotics, antihistamines, decongestants and oral/nasal corticosteroids do not routinely restore hearing from uncomplicated effusion; hearing assessment and follow-up are more important.

Ototoxic Medicines

Aminoglycosides, loop diuretics, platinum chemotherapy and some other systemic medicines can damage cochlear or vestibular function. Risk rises with high exposure, renal impairment, combinations and pre-existing disease. Ask about tinnitus, new hearing loss, imbalance, oscillopsia or vertigo; review renal function and medicine levels where required and escalate early.

Procedure: Instilling Ear Drops

No.ActionRationale
1Verify the prescription, affected ear, allergy history, expiry date and tympanic-membrane status.Prevents wrong-ear errors and avoids potentially ototoxic drops when the middle ear is exposed.
2Perform hand hygiene and warm the closed bottle in the hands; do not heat directly.Cold fluid can stimulate the vestibular apparatus and cause vertigo or nausea.
3Position the affected ear upward. Gently pull the pinna up and back in adults/older children and down and back in young children.Straightens the external auditory canal for effective delivery.
4Instil the prescribed drops along the canal wall without touching the tip. Gently press the tragus if appropriate.Reduces contamination and helps move drops through the canal without creating painful pressure.
5Keep the patient in position for several minutes. Insert a wick only when prescribed and within competence.Provides adequate contact time; an ear wick may carry medicine past severe canal swelling.
6Reassess pain, dizziness and hearing; document administration and any discharge or reaction.Detects immediate intolerance and tracks response.

Ear Red Flags

  • Post-auricular tenderness/swelling, protruding pinna or suspected mastoiditis.
  • Sudden sensorineural hearing loss, facial weakness, severe vertigo or neurological deficit.
  • Button battery or penetrating foreign body; do not irrigate a battery.
  • Clear fluid after head trauma, significant bleeding or suspected basal skull injury.
  • Severe night pain or granulation in a patient with diabetes/immunosuppression.
  • Persistent foul discharge, cholesteatoma suspicion or failure of correctly used therapy.

Medicines Acting on the Nose

1. Saline Drops, Sprays and Irrigation

Isotonic or hypertonic saline moisturises mucosa, loosens thick secretions and assists mechanical clearance in rhinitis and sinus symptoms. It has no antimicrobial resistance risk. Use sterile commercially prepared saline or water prepared safely according to local infection-prevention advice for irrigation devices. Clean the device and avoid sharing.

2. Intranasal Corticosteroids

Examples: Beclometasone, budesonide, fluticasone and mometasone.

  • Mechanism: Suppress local inflammatory cells, cytokines, mucosal oedema and secretion.
  • Indications: Persistent allergic rhinitis, nasal polyps and selected inflammatory sinus disease.
  • Use: Benefit is greatest with regular correct use and may take several days. Clear the nose first, aim away from the septum and avoid hard sniffing.
  • Adverse effects: Dryness, irritation, sore throat and epistaxis. Septal injury is uncommon but more likely with repeated spraying directly onto the septum. Systemic steroid effects are uncommon at recommended doses but become more relevant with high doses, prolonged use and multiple steroid routes.
  • Monitoring: Review technique, adherence, nasal bleeding, growth in children receiving prolonged high exposure and total corticosteroid burden.

3. Antihistamines

  • Oral agents: Cetirizine and loratadine reduce sneezing, itch and watery rhinorrhoea. Older agents such as chlorphenamine cause more sedation, blurred vision, dry mouth and urinary retention.
  • Intranasal agents: Azelastine has faster local onset and can help allergic rhinitis, but may cause bitter taste and drowsiness.
  • Nursing care: Warn about driving, alcohol and other sedatives with sedating antihistamines; use caution in older adults, glaucoma and prostatic urinary retention.

4. Nasal Decongestants

Examples: Topical xylometazoline or oxymetazoline; systemic pseudoephedrine where authorised.

  • Mechanism: Alpha-adrenergic vasoconstriction reduces mucosal swelling and rapidly opens the nasal airway.
  • Limitation: Topical products should generally be limited to a few days. Longer use can cause rhinitis medicamentosa—rebound congestion that encourages repeated dosing.
  • Adverse effects: Dryness, irritation, palpitations, tremor, insomnia and increased blood pressure. Accidental ingestion can be dangerous in children.
  • Contraindications/cautions: Uncontrolled hypertension, significant heart disease, hyperthyroidism, narrow-angle glaucoma, urinary retention and interacting monoamine oxidase inhibitors. Follow age restrictions.

5. Other Nasal Medicines

  • Ipratropium nasal spray: Antimuscarinic that reduces watery rhinorrhoea but has little effect on congestion; may cause dryness and epistaxis.
  • Leukotriene-receptor antagonists: Montelukast may help selected patients with asthma plus allergic rhinitis but is not a routine replacement for intranasal corticosteroids; counsel about possible neuropsychiatric effects.
  • Antibiotics: Most acute sinusitis is viral. Consider antibacterial treatment only when clinical pattern and guideline criteria support bacterial disease or complications. Avoid automatic antibiotics for coloured mucus alone.

Procedure: Using a Nasal Spray

  1. Prepare: Verify the product, shake/prime as directed and ask the patient to blow the nose gently.
  2. Position: Keep the head upright or slightly forward; close the opposite nostril.
  3. Direct correctly: Use the opposite hand where helpful and aim the nozzle outward toward the ear, away from the septum.
  4. Administer: Spray during a gentle inward breath; do not sniff forcefully because medicine will run into the throat.
  5. Finish: Wipe the nozzle, replace the cap, avoid sharing and record response. Review technique whenever treatment appears ineffective.

Epistaxis Medicines and First Aid

For uncomplicated anterior nosebleed, sit the patient forward, ask them to spit blood out and compress the soft part of the nose continuously for 10–15 minutes. A topical vasoconstrictor may be used by a trained clinician when appropriate. Persistent bleeding may require cautery, packing, tranexamic-acid-based protocols or specialist intervention. Heavy bleeding, airway compromise, haemodynamic instability, anticoagulant use or a posterior source requires urgent escalation.

Nasal and Sinus Red Flags

  • Button battery or paired magnets in the nose—urgent removal; do not delay because tissue necrosis can occur.
  • Unilateral foul discharge in a child suggesting a foreign body.
  • Periorbital swelling, painful eye movement, reduced vision, severe frontal headache, altered consciousness or neurological signs suggesting orbital/intracranial complication.
  • Recurrent unilateral bleeding, mass or persistent obstruction requiring investigation.

Medicines Acting on the Throat and Oropharynx

1. Analgesics and Antipyretics

Paracetamol or ibuprofen, when not contraindicated, reduces pain and fever in pharyngitis/tonsillitis. Verify the patient’s weight in children, calculate accurately, check maximum daily dose and look for duplicate ingredients in cold-and-flu products. Ibuprofen requires caution with dehydration, renal disease, peptic ulcer, bleeding risk and some asthma histories.

2. Lozenges, Gargles, Local Anaesthetics and Antiseptics

  • Warm saline gargles and soothing fluids may reduce discomfort.
  • Lozenges increase salivation and may contain mild antiseptic, anti-inflammatory or local anaesthetic agents.
  • Benzocaine, lidocaine or benzydamine preparations can reduce pain temporarily but excessive local anaesthesia may impair protective swallowing and conceal deterioration.
  • Do not give lozenges to a child who cannot safely manage them because of choking risk. Follow product age limits and avoid swallowing mouthwash.

3. Antibiotics for Bacterial Pharyngitis/Tonsillitis

Most acute sore throats are viral. Use clinical assessment and local testing/guidelines to identify patients likely to benefit from antibiotics. When prescribed, select the recommended narrow-spectrum agent, verify allergy, give the correct weight-based paediatric dose and complete the course. Unnecessary broad-spectrum therapy causes adverse effects and resistance.

4. Antifungals for Oropharyngeal Candidiasis

Nystatin suspension, clotrimazole preparations or systemic fluconazole may be used depending on age, severity and immune status. Teach adequate contact time before swallowing where relevant. Review inhaled-corticosteroid technique, denture hygiene, diabetes, antibiotics and immunosuppression. Persistent or oesophageal symptoms require evaluation.

Throat and Airway Red Flags

  • Stridor, drooling, cyanosis, severe respiratory distress or inability to swallow secretions—manage as an airway emergency; do not force throat examination in a distressed child with suspected epiglottitis.
  • Trismus, muffled “hot-potato” voice, unilateral swelling or uvular deviation—possible peritonsillar/deep-neck abscess.
  • Neck swelling, toxic appearance, rapidly progressive pain or crepitus.
  • Persistent hoarseness, unexplained weight loss, neck mass, haemoptysis or progressive dysphagia—refer for malignancy assessment.

Special Populations and High-risk Situations

  • Children: Use weight-based systemic doses, age-appropriate formulations and careful drop counts. Avoid adult decongestant products unless specifically authorised. Small children are more vulnerable to systemic effects of ophthalmic anticholinergics, alpha agonists and nasal sympathomimetics.
  • Pregnancy and breastfeeding: Confirm necessity and select preparations with established safety. Reduce systemic absorption of eye drops with punctal occlusion. Avoid assuming that every topical product is safe.
  • Older adults: Review polypharmacy, cognition, dexterity and vision. Sedating antihistamines and anticholinergic medicines increase falls, confusion, constipation and urinary retention.
  • Renal/hepatic impairment: Local drugs may still be absorbed; systemic antivirals, antibiotics, acetazolamide and other agents may require dose adjustment or avoidance.
  • Contact-lens users: Remove lenses for active infection or as the product directs. Preservatives may bind to soft lenses. Replace contaminated lenses/cases and resume only after recovery and professional advice.

Important Interactions and Avoidable Errors

  • Ophthalmic timolol plus systemic beta-blocker: Additive bradycardia, hypotension or bronchospasm.
  • Several anticholinergic products: Increased dry mouth, blurred vision, constipation, confusion and urinary retention.
  • Decongestants plus stimulants or monoamine oxidase inhibitors: Risk of severe hypertension and cardiovascular effects.
  • Multiple corticosteroid routes: Greater cumulative systemic exposure; record eye, nasal, inhaled, oral and injected steroids.
  • Wrong bottle/wrong route: Ear and eye labels can look similar. Eye preparations require ophthalmic sterility; never put a product in the eye unless labelled/prescribed for ophthalmic use.
  • Touching the tip: Contaminates the container and can transmit infection. Never share bottles between patients.
  • Ignoring opening date: Multidose containers have a limited usable period after opening. Label and discard according to the manufacturer/facility policy.

Nursing Care and Responsibilities

Comprehensive Nursing Assessment

  • Subjective data: Onset, duration, pain severity/character, itch, discharge, visual/hearing change, nasal obstruction, swallowing, fever, trauma, exposure, allergies, previous episodes, medicine use and effect on sleep/eating/work.
  • Objective data: Vital signs; general appearance; visual acuity before eye treatment where possible; pupil response; eye/ear/nose/throat appearance; airway sounds; hydration; lymph nodes; facial/orbital swelling; neurological findings and response to initial treatment.
  • Laboratory/diagnostic review: Culture, staining, hearing tests, intraocular pressure, slit-lamp or imaging findings where ordered. Confirm that specimens are obtained correctly without delaying emergency treatment.

Priority Nursing Problems and Expected Outcomes

  1. Acute pain related to inflammation or infection: Patient reports reduced pain to an agreed level and rests without new danger signs.
  2. Disturbed sensory perception related to visual or auditory dysfunction: Patient remains safe, communicates needs and shows no deterioration.
  3. Risk for spread of infection: Patient demonstrates hand hygiene and avoids sharing contaminated items; no cross-infection occurs.
  4. Deficient knowledge/ineffective self-management: Patient correctly demonstrates administration, states timing/duration and identifies warning signs.
  5. Risk for injury related to blurred vision, vertigo or sedation: Patient avoids falls, driving or hazardous activity until effects resolve.

Nursing Interventions with Rationales

No.Nursing InterventionRationale and Evaluation
1Measure baseline pain, visual acuity/hearing function where appropriate, vital signs and appearance before the first dose.Creates a comparison point and prevents medicine administration from delaying recognition of deterioration.
2Check the medicine, concentration, side/site, allergies, contraindications and last dose at every administration.ENT and eye preparations have similar containers and multiple strengths; systematic checks prevent high-impact errors.
3Use aseptic non-touch technique and separate equipment for infected eyes/ears.Prevents contaminating the product, worsening infection or transferring organisms to another site/person.
4Administer in the correct order and interval; document omitted/refused doses and the reason.Maintains therapeutic concentration and prevents one topical product reducing another’s absorption.
5Monitor local and systemic adverse effects—rash, swelling, wheeze, bradycardia, severe dizziness, hypertension, worsening pain or sensory loss.Topical medicines can produce systemic toxicity and severe allergy; early recognition limits harm.
6Provide pain relief, cold/warm compresses only when appropriate, quiet/dim environment for photophobia and falls assistance for vertigo/blurred vision.Promotes comfort and prevents secondary injury while the underlying condition is treated.
7Teach the patient to demonstrate the technique using their own container; correct hand position, tip contamination and dose timing.Teach-back identifies practical errors that verbal instruction alone may miss.
8Reassess at the expected review time and escalate no improvement, recurrence or danger signs.Treatment failure may indicate wrong diagnosis, resistance, obstruction, poor technique, non-adherence or a complication.
9Document assessment, exact preparation/strength, side, administration, patient response, education, referral and handover.Ensures continuity, pharmacovigilance and legal accountability.

Patient and Family Education

  • Wash hands before and after treatment; never touch the nozzle/dropper tip.
  • Do not share drops, towels, cosmetics, hearing devices or nasal equipment.
  • Complete the prescribed duration; do not save leftovers for another illness.
  • Keep an administration schedule when several preparations are prescribed.
  • Store exactly as labelled and keep all medicines away from children.
  • Do not drive when vision is blurred, vertigo is present or an antihistamine causes drowsiness.
  • Return urgently for worsening pain, visual/hearing loss, severe headache, facial swelling, breathing/swallowing difficulty, rash or collapse.
Remember “S-I-T-E” before every local medicine:
S — Side and site: confirm the correct eye, ear, nostril or throat preparation.
I — Indication and integrity: confirm the diagnosis and check cornea, tympanic membrane or mucosa where relevant.
T — Tip and technique: maintain non-touch technique and use the correct position/order.
E — Evaluate: reassess effect, adverse reactions, adherence and emergency signs.

Uganda and Resource-limited Setting Considerations

  • Use the current Uganda Clinical Guidelines, Essential Medicines and Health Supplies List, authorised prescriber’s order and facility protocol.
  • Choose affordable effective essential medicines while avoiding unlabelled mixtures, counterfeit products and harmful traditional substances placed in the eye or ear.
  • Refer early when slit-lamp examination, intraocular-pressure measurement, audiology, microscopy, imaging or specialist surgery is unavailable.
  • For chemical eye injury, irrigation comes before transfer and should not wait for a particular commercial fluid.
  • Promote vaccination, facial cleanliness, safe water, eye protection, hearing conservation and avoidance of cotton buds/matchsticks as preventive care.

Revision Summary

  • Local medicines can still cause systemic harm; dose, site, technique and monitoring matter.
  • Pain, photophobia or visual loss is not ordinary conjunctivitis.
  • Unsupervised ocular corticosteroids and repeated local anaesthetics may destroy the cornea.
  • With possible tympanic-membrane perforation, use only an ear preparation known to be safe for the middle ear.
  • Intranasal corticosteroids require regular correct technique; topical decongestants are short-term medicines.
  • Most uncomplicated sore throats and many conjunctivitis/sinusitis presentations are viral; use antimicrobials selectively.
  • Teaching by demonstration, infection prevention and timely escalation are central nursing responsibilities.

Authoritative References

This educational article supports nursing learning and does not replace patient-specific assessment, an authorised prescription, local protocols or specialist care.

Eye, Ear, Nose and Throat Medicines: Classes, Uses and Nursing Care Read More »

Pharmacology of Antimalarial Agents

Pharmacology of Antimalarial Agents

Pharmacology of Antimalarial Agents

Antimalarial Pharmacology

I. Foundational Concepts: Understanding the Enemy

Before memorizing any drug, you must understand what malaria is. Malaria is not caused by a bacterium or a virus; it is caused by a single-celled protozoan parasite of the genus Plasmodium. Because it is a eukaryotic organism (like human cells), creating drugs that are toxic to the parasite but safe for the human host is pharmacologically challenging.

Crucial Physiology: The "Heme" Toxicity Mechanism

To survive inside a human Red Blood Cell (RBC), the malaria parasite must eat. It consumes human Hemoglobin. However, digesting hemoglobin releases free Heme (ferriprotoporphyrin IX), which is highly toxic to the parasite's own cell membranes.

To prevent poisoning itself, the parasite uses an enzyme called Heme Polymerase to convert the toxic free heme into a harmless, crystallized, dark pigment called Hemozoin.

Pharmacology Rule: A massive chunk of antimalarial drugs (like Chloroquine, Quinine, Mefloquine) work by accumulating in the parasite's acidic food vacuole and blocking this heme polymerization process. The parasite is subsequently killed by its own toxic metabolic waste (free heme)!

1. Global and Local Burden (The Epidemiology)

Malaria remains a devastating global health crisis, heavily dictated by climate, vectors, and drug resistance.

  • Global Burden: In 2023, an estimated 263 million cases and ~597,000 deaths occurred worldwide (WHO World Malaria Report 2024).
  • African Burden: The African Region carries an overwhelming ~94% of all global cases and ~95% of all deaths.
  • Ugandan Country Profile: Uganda remains highly endemic, with nearly the entire population at risk.
    • It accounts for 478 cases per 1,000 population per year (as of May 2023).
    • It accounts for up to 40% of all outpatient visits and 25% of hospital admissions.
    • It causes between 70,000 and 100,000 deaths annually in Uganda. It is a major public health concern, especially for highly vulnerable populations: children under five and pregnant women.
  • Drivers of Surging Cases: Case counts rose sharply after 2019 due to COVID-19 disruptions, and surged again in 2022–2023. This is driven by insecticide and drug resistance, climate-related events, health system disruptions, and severe humanitarian crises/funding gaps.

2. The Causative Organisms

There are five species of Plasmodium that infect humans. Knowing which one you are treating dictates the drug choice:

  • Plasmodium falciparum: The most virulent and deadly. It causes the most mortality, is the most common in sub-Saharan Africa, and is notorious for severe drug resistance.
  • Plasmodium vivax: The most common species outside of Africa. It causes relapsing disease because it can hide dormant in the liver (as hypnozoites).
  • Plasmodium ovale: Similar to P. vivax, it has two subspecies and also forms liver hypnozoites, causing relapsing disease.
  • Plasmodium malariae: Causes "quartan" fevers (fever every 72 hours). It causes a chronic, low-grade infection.
  • Plasmodium knowlesi: A zoonotic species (transferred from macaque monkeys) found primarily in SE Asia. It can cause rapidly severe and fatal disease.

II. The Plasmodium Life Cycle & Clinical Relevance

Antimalarial drugs are classified entirely based on where in the life cycle they strike the parasite. If you know the cycle, you know the drug class.

  1. Inoculation: A female Anopheles mosquito bites a human and injects Sporozoites into the bloodstream.
  2. Exo-erythrocytic (Hepatic) Phase: The sporozoites quickly travel to the liver and invade hepatocytes. Here, they multiply massively and develop into Tissue Schizonts.
    • Dormant Phase: In P. vivax and P. ovale, some parasites don't develop immediately. They go to sleep in the liver as Hypnozoites. These can wake up months or years later, causing a relapse.
  3. Erythrocytic (Blood) Phase: The liver cells burst, releasing thousands of Merozoites into the blood. They invade Red Blood Cells (RBCs). Inside the RBC, they grow from ring forms → trophozoites → blood schizonts. The RBC eventually ruptures, releasing more merozoites and toxins. This mass rupture is what causes the classic cyclic malaria fevers and clinical illness!
  4. Sexual Phase (Transmission): Some blood parasites develop into male and female Gametocytes. When another mosquito bites the human, it ingests these gametocytes, allowing the cycle to continue.
1. Tissue Schizonticides

Drugs that kill the parasite in the liver before it enters the blood. This prevents the initial clinical infection (Causal Prophylaxis).
Examples: Primaquine, Atovaquone-proguanil, Pyrimethamine, some Tetracyclines.

2. Hypnozoiticides (Radical Cure)

Drugs that specifically hunt down and kill the dormant hypnozoites in the liver, preventing future relapses of P. vivax and P. ovale.
Examples: Primaquine, Tafenoquine.

3. Blood Schizonticides (Clinical Cure)

Drugs that kill the actively dividing parasites inside the RBCs. This cures the acute clinical symptoms and stops the fever.
Fast-acting: Artemisinins, Chloroquine, Quinine, Mefloquine.
Slow-acting: Doxycycline, Sulfonamides, Pyrimethamine.

4. Gametocides / Sporontocides

Drugs that kill the sexual gametocytes in the blood, blocking transmission to the mosquito.
Examples: Primaquine (for P. falciparum), Artemisinins. Quinine (for vivax/malariae/ovale).


III. Clinical Presentation & Diagnostic Terminology

1. Symptoms and Disease Progression

  • Early (Non-specific) Symptoms: Fever, severe headache, malaise, myalgia (muscle aches), and nausea.
  • The Classic Paroxysm: When the RBCs rupture synchronously, the patient experiences a severe 3-stage attack:
    1. Cold Stage: Intense shivering and rigors.
    2. Hot Stage: Extremely high fever.
    3. Sweating Stage: Massive diaphoresis (defervescence) as the fever drops.
  • Periodicity: The paroxysms happen every 48 hours (Tertian) for P. vivax and P. ovale, and every 72 hours (Quartan) for P. malariae. P. falciparum is often continuous or irregular.
Severe Malaria (Medical Emergency)

P. falciparum causes infected RBCs to become "sticky," clogging tiny capillaries in vital organs. This requires urgent parenteral (IV) therapy and supportive care. Signs include:

  • Cerebral Malaria: Impaired consciousness, seizures, or coma.
  • Severe Anemia: Hb < 5–7 g/dL due to massive RBC destruction.
  • Metabolic Collapse: Severe hypoglycemia and metabolic acidosis.
  • Organ Failure: Renal failure, Pulmonary Edema, Jaundice, Shock.
  • Blackwater Fever: Massive intravascular hemolysis causing dark, hemoglobin-filled urine.
  • Hyperparasitemia: Huge percentage of RBCs infected.

2. Defining Recurrence

A returning fever is not always the same mechanism:

  • Relapse: Reappearance of the disease from dormant liver hypnozoites (exclusive to vivax/ovale). Requires a Radical Cure (Primaquine/Tafenoquine) to fix.
  • Recrudescence: Reappearance of the disease because the initial blood treatment failed (due to inadequate therapy or drug resistance). Surviving blood parasites multiply again.
  • Reinfection: The patient was completely cured but was bitten by a new infective mosquito.
  • Advertisements

3. Diagnostic Methods (Clinical + Lab)

Always pair testing with clinical assessment. If microscopy is unavailable, treat severe cases empirically!

  • Microscopy (Thick & Thin Smears): The Gold Standard when skilled personnel are available. Thick smears detect the presence of parasites (density); thin smears identify the exact species.
  • Rapid Diagnostic Tests (RDTs): Fast lateral-flow tests that detect parasite antigens (HRP2 or pLDH). Pros: Fast and require no electricity. Cons: Some P. falciparum strains have mutated and deleted the HRP2 gene, causing dangerous false negatives.
  • PCR: Extremely high sensitivity; used mainly for research and complex confirmations.

IV. Pharmacological Classification & The 4-Aminoquinolines

1. Chloroquine

Chloroquine is a 4-aminoquinoline (a weak base). Historically, it was the "wonder drug" and absolute first-line treatment for malaria. Today, its use is heavily restricted due to massive global resistance.

  • Mechanism of Action (MOA): Because it is a weak base, it naturally concentrates inside the highly acidic food vacuole of the parasite. There, it violently inhibits Heme Polymerase. The parasite can no longer convert toxic free heme into safe hemozoin. The toxic heme-chloroquine complex builds up, destroying the parasite's membranes and killing it.
  • Indications: Rapid clinical cure (blood schizonticide). Currently only used for P. vivax, P. ovale, and P. malariae where they remain susceptible. It is NO LONGER recommended for P. falciparum in most countries.
  • Pharmacokinetics (PK): Very good oral absorption. It is famous for its massive Volume of Distribution (Vd). It binds heavily to tissues (liver, spleen, lung, skin, retina). Because it is sequestered in tissues, its terminal elimination half-life takes weeks to months! (Early plasma t½ is a few days, but tissue retention leads to prolonged post-treatment levels). Metabolized in the liver; excreted partly in urine.
Dosing, AEs, and Cautions for Chloroquine
Typical Dosing: Note that salts matter! (250 mg chloroquine phosphate = 150 mg active base). The typical WHO total adult dose for acute sensitive infection is 10 to 25 mg base/kg given over 3 days.
Adverse Effects (AEs): GI upset, intense pruritus (itching - extremely common in African populations), headache, dizziness. Rare but severe: QT prolongation, can precipitate seizures, exacerbates psoriasis. Long-term use (when used in rheumatology for Lupus/RA) causes severe Retinopathy (bull's-eye maculopathy).
Cautions & Pregnancy: Contraindicated in pre-existing retinal disease, severe seizure disorders, and porphyria. It is totally SAFE in pregnancy and breast-feeding for sensitive infections.
Mechanism of Resistance: P. falciparum developed mutations in the pfcrt (chloroquine resistance transporter) and pfmdr1 genes. This literally creates an efflux pump that spits the chloroquine out of the food vacuole before it can work.

2. Amodiaquine

A structural 4-aminoquinoline analogue of chloroquine.

  • MOA & PK: Exact same mechanism as chloroquine (inhibits heme detoxification). It is converted in the liver to an active metabolite called des-ethylamodiaquine, which has a much longer half-life.
  • Clinical Role: Historically used for chloroquine-resistant falciparum. Today, it is primarily used as a highly effective, cheap partner drug in ACTs (e.g., Artesunate-Amodiaquine [AS-AQ]).
  • Severe Toxicities: Prolonged use causes rare but fatal Agranulocytosis (destruction of white blood cells) and severe Hepatotoxicity. Therefore, it is strictly used for short-term treatment and never for long-term prophylaxis!

V. The Cinchona Alkaloids (Quinine & Quinidine)

Derived from the bark of the Cinchona tree, Quinine is one of the oldest and most important antimalarials in existence. It is a powerful, fast-acting blood schizonticide.

  • Indications: Historically the first-line treatment for Severe Malaria. Today, it is the second-line for Severe Malaria (used when IV Artesunate is unavailable). It is also used as a primary drug for treating uncomplicated malaria during the 1st Trimester of Pregnancy (where ACTs are often avoided). Always used in combination with an antibiotic (Doxycycline or Clindamycin) for resistant infections.
  • MOA: Like chloroquine, it accumulates in the food vacuole and interferes with heme detoxification, causing the parasite to die from its own toxic waste.
  • Pharmacokinetics (PK): Rapid oral absorption. For severe disease, IV formulations are used.
WHO Guidelines: Dosing Quinine for Severe Malaria
  • Loading Dose (IV): Required to rapidly reach therapeutic levels and save the patient's life. 20 mg salt/kg (up to a max of 1,400 mg) by IV infusion slowly over 4 hours. Alternative: 7 mg salt/kg IV over 30 minutes, followed instantly by maintenance.
    CRITICAL RULE: Do NOT give a loading dose if the patient has received quinine, quinidine, or mefloquine in the previous 12-24 hours (massive risk of fatal cardiac toxicity).
  • Maintenance Dose (IV): 8 hours after the start of the loading dose, give 10 mg salt/kg by IV infusion over 4 hours. Repeat this every 8 hours.
  • Switch to Oral: As soon as the patient is conscious and can swallow, switch to a full course of an oral ACT, or complete 7 days of oral quinine (600 mg every 8 hours) + Clindamycin/Doxycycline.
Severe Quinine Toxicity & Adverse Effects

Quinine has a very Narrow Therapeutic Index, meaning the effective dose is dangerously close to the toxic dose. You must continuously monitor cardiac rhythm and blood glucose!

  • Cinchonism: A classic syndrome of poor tolerability characterized by severe Tinnitus (ringing in the ears), high-frequency hearing loss, dizziness, visual disturbances, nausea, and vomiting.
  • Severe Hypoglycemia: Quinine forces the human pancreas to secrete massive amounts of insulin. This is especially dangerous in pregnant women and children. Frequent blood glucose monitoring and dextrose infusions are mandatory.
  • Cardiotoxicity: Causes massive QT prolongation. Rapid IV infusion will cause severe hypotension and deadly cardiac arrhythmias. Must never be mixed with other QT-prolonging drugs.
  • Hemolysis: Can trigger massive RBC destruction in patients with G6PD deficiency.
  • Complex Dosing: The required 7-day, 3-times-a-day (TID) oral regimen leads to incredibly poor patient adherence.

VI. Quinoline Methanols & Bis-quinolines


1. Mefloquine

A quinoline methanol structurally related to quinine.

  • Indications: Highly effective for both the treatment and prophylaxis of chloroquine-resistant P. falciparum. Used as a partner drug in some ACTs (Artesunate-Mefloquine).
  • MOA: Disrupts parasite heme detoxification (similar to chloroquine).
  • PK & Dosing: It has a phenomenally long half-life (~2 to 4 weeks) with good oral bioavailability. For prophylaxis: 250 mg taken once weekly for adults (start 1–2 weeks before travel, continue for 4 weeks after returning home).
  • Severe Adverse Effects (The "Black Box" Warning): Mefloquine easily crosses the blood-brain barrier. It is notorious for causing profound Neuropsychiatric effects including severe anxiety, vivid/nightmarish dreams, severe depression, dizziness, and frank psychosis.
    Absolute Contraindication: Must NEVER be given to patients with a recent psychiatric history, active depression, or any seizure disorder. Can also cause cardiac QT prolongation.
  • Advertisements

2. Piperaquine

A long-acting bis-quinoline.

  • Clinical Role: It is almost exclusively used as a highly effective partner drug to Dihydroartemisinin (DHA) in the ACT combination DHA-Piperaquine (DHA-PPQ).
  • The Synergy: The Artemisinin (DHA) kills the bulk of the parasites instantly but clears from the body in hours. Piperaquine supplies the long half-life needed to kill any remaining parasites over the next few weeks, preventing recrudescence.
  • AEs: Primary risk is QT prolongation. Must be heavily monitored if combined with other QT-prolonging agents.

VII. Artemisinins & Artemisinin-Based Combination Therapies (ACTs)

Artemisinins are derived from the sweet wormwood plant (Artemisia annua). They revolutionized malaria treatment and are currently the absolute first-line therapy for uncomplicated P. falciparum malaria worldwide.

The class includes the prodrugs Artesunate (water-soluble, used IV/IM/Oral), Artemether (lipid-soluble, used Oral/IM), and Arteether. Inside the body, they are rapidly metabolized into the primary active metabolite: Dihydroartemisinin (DHA).

Mechanism of Action: The "Endoperoxide Bomb"

Artemisinins are incredibly potent, extremely rapid blood schizonticides. They kill all blood stages, including ring forms and early schizonts, faster than any other drug.

  1. The chemical structure of artemisinins contains a unique Endoperoxide Bridge.
  2. When the drug enters the parasite's food vacuole, the iron (Fe 2+) from the parasite's digested heme cleaves this endoperoxide bridge.
  3. This cleavage acts like a bomb, generating a massive burst of highly reactive free radicals.
  4. These radicals indiscriminately alkylate and destroy the parasite's proteins and cell membranes. (It is also believed to inhibit PfATP6, a calcium SERCA pump in the parasite).

1. The Rationale for ACTs (Why we never use Artemisinins alone)

Artemisinins have a critical flaw: a phenomenally short elimination half-life (DHA is cleared in ~1 to 3 hours). If given alone, the drug disappears before all parasites are killed, leading to a guaranteed recrudescence (relapse of the blood infection) and rapid drug resistance.

To solve this, the WHO mandates Artemisinin-Based Combination Therapies (ACTs). You combine the ultra-fast, short-acting Artemisinin (to rapidly clear the parasite biomass and fever) with a slow-acting, long half-life partner drug (to "mop up" any surviving parasites over the next few weeks).

2. Common ACT Partner Combinations

  • Artemether-Lumefantrine (AL / Coartem): The most widely used ACT globally. Lumefantrine provides the long-half life clearing action. Crucial PK Note: Lumefantrine absorption is highly fat-dependent; it must be taken with food or milk. It also carries a risk of QT prolongation.
  • Artesunate-Amodiaquine (AS-AQ): Very common in Africa; cheap and effective.
  • Dihydroartemisinin-Piperaquine (DHA-PPQ): Highly efficacious because piperaquine has an exceptionally long half-life, providing prolonged post-treatment prophylaxis against new bites.
  • Artesunate-Mefloquine & Artesunate-Pyronaridine: Alternative ACTs used based on regional resistance policies.
Artemisinin Safety, Toxicity & Resistance
  • Adverse Effects: Generally extremely well-tolerated. Can cause transient GI upset, headache, and dizziness. IM preparations can cause injection site pain.
  • Delayed Hemolysis: A specific, serious complication seen in survivors of severe malaria treated with IV Artesunate. The drug damages the infected RBCs, and the spleen aggressively destroys them weeks later. You must monitor the patient's Hemoglobin (Hb) weekly for 4 weeks post-treatment!
  • Emerging Resistance: A terrifying "delayed clearance phenotype" has emerged in Southeast Asia and is now appearing in Africa. This resistance is genetically linked to mutations in the kelch13 (K13) gene. Strict adherence to ACTs and molecular surveillance is critical to stop this spread.

VIII. The Antifolates & Atovaquone Combinations

1. Sulfadoxine-Pyrimethamine (SP)

Just like bacteria, the malaria parasite must synthesize its own folic acid to make DNA. It cannot absorb folic acid from the human host. SP works by destroying this synthetic pathway.

  • Mechanism of Action (Sequential Blockade):
    • Sulfadoxine: A sulfonamide that competitively inhibits Dihydropteroate Synthase (DHPS).
    • Pyrimethamine: A diaminopyrimidine that competitively inhibits Dihydrofolate Reductase (DHFR).
    • Together, they synergistically block nucleotide synthesis. They are slow-onset blood schizonticides.
  • Clinical Use: Due to widespread DHFR and DHPS gene mutations, SP is essentially useless for the treatment of acute P. falciparum. Today, its incredibly long half-life makes it the primary drug for Intermittent Preventive Therapy in Pregnancy (IPTp) and in infants (IPTi) to prevent maternal malaria and low birth weight.
  • Severe Toxicities: Contraindicated in patients with sulfa allergies. Can cause bone marrow suppression, megaloblastic anemia (prolonged use), and rare but fatal skin shedding syndromes: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

2. Atovaquone-Proguanil (Malarone)

A highly synergistic, powerful, but expensive combination drug used for both treatment of uncomplicated falciparum and causal prophylaxis in travelers.

  • Mechanism of Action:
    • Atovaquone: Directly inhibits the parasite's mitochondrial electron transport chain (at cytochrome bc1). This causes a total collapse of the mitochondrial membrane potential.
    • Proguanil (a Biguanide): A prodrug converted in the liver to Cycloguanil, which potently inhibits plasmodial DHFR.
  • Pharmacokinetics: Atovaquone is highly lipophilic; its absorption is drastically increased if taken with a fatty meal. If the patient vomits within 1 hour of the dose, it will not be effective.
  • Resistance Warning: Resistance to Atovaquone can emerge rapidly via a single point mutation in the cytochrome b gene. It must NEVER be used as monotherapy.

IX. Antibiotics in Malaria Therapy

Certain bacterial antibiotics possess slow-acting blood schizonticidal activity because they target the ribosomes inside the parasite's apicoplast (a unique plant-like organelle).

Tetracycline & Doxycycline
  • MOA: Inhibit protein synthesis by binding to the 30S ribosomal subunit.
  • Uses: Used daily for traveler's chemoprophylaxis. Used as a partner drug with Quinine (7-day course) to treat resistant, uncomplicated malaria.
  • Contraindications: Highly teratogenic. Absolutely contraindicated in pregnancy and in children < 8 years old due to permanent dental staining and bone growth inhibition. Causes severe photosensitivity (sunburns) and esophageal irritation.
Clindamycin
  • MOA: Inhibits protein synthesis by binding to the 50S ribosomal subunit.
  • Uses: The absolute partner drug of choice to pair with Quinine for treating malaria during the 1st Trimester of Pregnancy and in young children (< 8 years old) where Doxycycline is forbidden.
  • Advertisements

Clinical Rule: Because antibiotics are "slow-acting," they are NEVER used alone for acute severe infections. They must always be paired with a fast-acting drug like Quinine.


X. The 8-Aminoquinolines (Radical Cures & Gametocides)

This class contains Primaquine and the newer Tafenoquine. They are unique because they target the liver stages and the sexual stages, but do absolutely nothing to the symptomatic blood stages.

Clinical Indications for 8-Aminoquinolines
  • 1. Radical Cure (Hypnozoiticide): The only drugs capable of hunting down and destroying the dormant liver hypnozoites of P. vivax and P. ovale, ensuring the patient never relapses.
  • 2. Transmission Blocking (Gametocidal): They destroy the sexual gametocytes of P. falciparum circulating in the blood. A single low dose (0.25 mg/kg) is added to ACT therapy in some endemic settings to ensure the patient cannot transmit the disease to a new mosquito.
  • Mechanism of Action: They generate highly reactive oxidative metabolites that target and destroy intrahepatic parasites. The exact molecular target is still not fully defined.
  • Pharmacokinetics:
    • Primaquine: Requires metabolic activation by the liver enzyme CYP2D6. Patients with CYP2D6 genetic polymorphisms (poor metabolizers) will experience treatment failure and relapse! Dosed as 15 mg base daily for 14 days.
    • Tafenoquine: A long-acting analogue that achieves radical cure in a single dose, massively improving patient adherence compared to the 14-day Primaquine regimen.
The G6PD Deficiency Danger

Because these drugs unleash massive oxidative stress, they will absolutely shred the red blood cells of a patient who lacks the protective antioxidant enzyme Glucose-6-Phosphate Dehydrogenase (G6PD).

  • Administering these drugs to a G6PD-deficient patient will cause massive, fatal hemolytic anemia.
  • G6PD testing is strictly mandatory before administering a radical cure of Primaquine or Tafenoquine.
  • They are absolutely contraindicated in pregnancy and breastfeeding because the G6PD status of the fetus/infant is unknown.
  • They also carry a risk of inducing Methemoglobinemia.

XI. Drug Interactions & Pharmacovigilance

When treating malaria, especially with older drugs or combinations, you must be hyper-vigilant regarding drug interactions:

  • QT Prolongation: Drugs like Mefloquine, Lumefantrine, Halofantrine, and Quinine all prolong the QT interval on an ECG. Combining them (e.g., giving Halofantrine to a patient who just failed Mefloquine prophylaxis) can trigger fatal Torsades de Pointes arrhythmias.
  • CYP450 Interactions: Artemether is heavily metabolized by CYP3A4. Enzyme inducers (like Rifampin or Phenytoin) will clear the drug too fast, causing treatment failure. Enzyme inhibitors (like Ritonavir or Ketoconazole) will cause toxic buildup. Primaquine requires CYP2D6 to work.
  • Pharmacovigilance: Always report serious adverse events to national databases. Watch for: SJS with SP, agranulocytosis with amodiaquine, severe hemolysis with primaquine, and delayed hemolysis 4 weeks after IV artesunate.

XII. WHO Clinical Treatment Algorithms

1. The Approach to Fever in an Endemic Area

Assess for Danger Signs (coma, severe anemia, respiratory distress, shock). If severe features are present → treat instantly as Severe Malaria with parenterals. If not severe → Test with RDT or Microscopy. If positive → treat based on species. If negative but suspicion is high → repeat testing or treat empirically.

2. Uncomplicated P. falciparum

  • First-Line: An oral ACT (e.g., Artemether-Lumefantrine for 3 days).
  • If ACT is unavailable/contraindicated: Quinine + Doxycycline (or Clindamycin) for 7 days.

3. Uncomplicated P. vivax / P. ovale

  • Step 1 (Blood Stage): Chloroquine (if the region is strictly chloroquine-sensitive) OR an ACT (if chloroquine-resistant).
  • Step 2 (Radical Cure): Add Primaquine (14 days) or Tafenoquine (single dose) to kill the hypnozoites. Must test for G6PD first!

4. Severe Malaria (Medical Emergency)

  • First-Line: IV Artesunate is the undisputed drug of choice (superior to quinine in survival rates).
    Dosing: 2.4 mg/kg IV or IM at 0, 12, and 24 hours, then daily.
  • Step-down: Continue IV for at least 24 hours. Once the patient is conscious and can tolerate oral fluids, you MUST switch to a full 3-day course of an oral ACT to finish the job.
  • Second-Line: If Artesunate is completely unavailable, use IV Quinine (with a careful loading dose, watching for hypoglycemia and QT prolongation).

5. Special Populations (Pregnancy & Children)

PopulationUncomplicated MalariaSevere Malaria
1st Trimester PregnancyQuinine + Clindamycin for 7 days (ACTs are generally avoided due to theoretical teratogenicity, though WHO is updating this as more safety data emerges).IV Artesunate (the risk of maternal death far outweighs theoretical fetal risks).
2nd & 3rd TrimesterStandard ACTs.IV Artesunate.
Children (< 8 years)Standard ACTs (weight-based dosing).IV Artesunate. Strictly avoid Tetracyclines/Doxycycline.

XIII. Public Health, Prophylaxis & Prevention

1. Chemoprophylaxis for Travelers

Drugs used to prevent malaria must be started before entering the endemic zone, taken during the stay, and continued after returning to ensure any late-emerging liver parasites are killed.

  • Atovaquone-Proguanil (Malarone): Taken daily. Start 1-2 days before travel. Because it acts causally on the liver stage, you only need to continue it for 7 days after return.
  • Doxycycline: Taken daily. Cheap and effective. Start 1-2 days before. Must continue for 4 weeks after return. (Watch for sun sensitivity).
  • Mefloquine: Taken weekly. Start 1-2 weeks before travel to build up blood levels and test for neuropsychiatric side effects. Continue for 4 weeks after return.
  • Chloroquine: Taken weekly. Only useful in the very rare regions where P. falciparum is still sensitive (e.g., parts of Central America/Caribbean).

2. Vector Control & Preventive Chemotherapies

  • Vector Control: The bedrock of prevention relies on Insecticide-Treated Nets (ITNs), Indoor Residual Spraying (IRS), and breeding site larval control.
  • IPTp: Intermittent Preventive Treatment in Pregnancy. Giving pregnant women full treatment doses of SP (Sulfadoxine-Pyrimethamine) at routine antenatal visits (starting in the 2nd trimester) clears asymptomatic placental malaria and saves fetal lives.
  • SMC: Seasonal Malaria Chemoprevention. Administering monthly courses of amodiaquine + SP to children during the rainy season in the Sahel sub-region of Africa.
  • Vaccines: The RTS,S/AS01 (Mosquirix) and the newer R21/Matrix-M vaccines are currently being rolled out in selected African countries. They target the pre-erythrocytic sporozoite stage to protect young children from severe disease.

Quick Quiz

Antimalarial Agents Quiz

Pharmacology

Privacy: Your details are used only for quiz tracking and certificates.

Advertisements

Pharmacology of Antimalarial Agents Read More »

Pharmacology of Antifungal Agents

Pharmacology of Antifungal Agents

Pharmacology of Antifungal Agents

I. Foundational Concepts: Understanding the Enemy

Before memorizing any antifungal drugs, you must understand the target. Why can't we just use normal antibiotics like Penicillin to kill fungi? Because bacteria are prokaryotes, while fungi are eukaryotes (just like human cells). This structural similarity makes finding drugs with "selective toxicity" (killing the fungus without killing the human) incredibly difficult.

The 3 Major Differences (Antifungal Targets)

To selectively kill fungi, our drugs exploit three unique features of the fungal cell:

  1. The Cell Membrane (Ergosterol): Human cell membranes use Cholesterol for stability. Fungal cell membranes use Ergosterol. Most antifungal drugs target the synthesis or the structure of Ergosterol.
  2. The Cell Wall (Beta-Glucan): Humans do not have cell walls. Fungi have a rigid cell wall composed of chitin and β-glucan. Destroying this causes the fungal cell to burst (lysis).
  3. Fungal Enzymes: Fungi possess unique enzymes (like cytosine deaminase) that human cells lack, which can be exploited to turn harmless prodrugs into toxic fungal killers.

1. Classification of Fungi (Morphology)

Fungi are classified based on how they grow and look under a microscope:

1. Yeasts (Unicellular)

They grow as single round cells and divide by budding. Examples include:

  • Candida albicans (Causes thrush/vaginal candidiasis).
  • Cryptococcus neoformans (Has a thick capsule; causes severe meningitis).
  • Trichosporon & Rhodotorula.
2. Moulds (Multicellular Hyphae)

They grow in long, branching thread-like structures called hyphae.

  • Septate Hyphae (Have cross-walls dividing cells): Aspergillus, Scedosporium, Fusarium (Opportunists) and Trichophyton, Microsporum (Dermatophytes).
  • Aseptate/Coenocytic Hyphae (Lack cross-walls/membranes between cells): Zygomycetes like Rhizopus and Mucor.
3. Dimorphic Fungi

These shape-shifters act like Moulds in the cold (25°C environment) and Yeasts in the heat (37°C human body).

  • Histoplasma capsulatum
  • Blastomyces dermatitidis
  • Coccidioides immitis
  • Paracoccidioides brasiliensis

2. Clinical Classification of Fungal Infections (Mycoses)

  • Superficial: Surface of hair/skin (e.g., Tinea versicolor, Tinea nigra, Piedra).
  • Cutaneous (Dermatophytosis): Deep epidermis, hair, nails (e.g., Tinea pedis [athlete's foot], Tinea cruris [jock itch], Tinea unguium/Onychomycosis [nails], Tinea capitis [scalp], Tinea barbae [beard]).
  • Subcutaneous: Muscle/fascia via puncture wounds (e.g., Sporotrichosis, Chromoblastomycosis, Mycetoma).
  • Systemic: Deep organ infections, often fatal (e.g., Cryptococcosis, Histoplasmosis, Coccidioidomycosis, Blastomycosis, and systemic Candidiasis).

II. Mechanism of Action Overview: The 6 Classes of Antifungals

Antifungal drugs are divided into six distinct classes based on their structure and exactly where they attack the fungal cell.

Drug ClassKey ExamplesTarget Mechanism
1. PolyenesAmphotericin B, NystatinPhysically bind to Ergosterol in the membrane, tearing open pores.
2. AntimetabolitesFlucytosine (5-FC)Inhibits fungal DNA/RNA synthesis from the inside.
3. AzolesFluconazole, Ketoconazole, ItraconazoleInhibits 14-α-demethylase, stopping the synthesis of Ergosterol.
4. EchinocandinsCaspofungin, MicafunginInhibits β-glucan synthase, destroying the fungal cell wall.
5. AllylaminesTerbinafine, NaftifineInhibits squalene epoxidase, causing toxic squalene buildup.
6. Mitotic InhibitorsGriseofulvinBinds to keratin and disrupts fungal microtubule formation.

III. The Polyene Antibiotics (Amphotericin B & Nystatin)

Polyenes are naturally occurring antifungal antibiotics isolated from Streptomyces soil bacteria. Chemically, they are "macrolides" (containing a large lactone ring) with "polyene" characteristics (containing many double bonds). Amphotericin A exists but is not used clinically. We exclusively use Amphotericin B (Amp B).

1. Amphotericin B (The "Heavy Artillery")

  • Mechanism of Action (MOA): Amphotericin B is an amphoteric compound (meaning it has both highly polar and nonpolar structural components). It inserts itself directly into the fungal cell membrane and physically binds to Ergosterol. Multiple Amp B molecules group together to form artificial "pores" or channels. This disrupts membrane permeability, causing vital intracellular ions (like Potassium) to leak out, resulting in rapid fungal cell death (Fungicidal).
  • Spectrum of Activity: It has an extremely broad spectrum. It remains the Drug of Choice (DOC) or co-DOC for severe, life-threatening systemic infections caused by:
    • Most Candida spp. and Cryptococcus.
    • Most Aspergillus spp. and Mucorales (Mucor, Rhizopus).
    • Endemic Dimorphic fungi (Histoplasma, Blastomyces, Coccidioides).
  • Mechanisms of Resistance: Fungi become resistant to Amp B by preventing the drug from binding to the membrane. They do this by either:
    1. Decreasing the total concentration of ergosterol in their membrane.
    2. Modifying the chemical structure of the sterol target molecule so the drug cannot attach.
    Clinically notable resistant species: Candida lusitaniae, Aspergillus terreus, Scedosporium spp., and Fusarium spp.
Pharmacokinetics & Routes of Administration

Amphotericin B is a massive, bulky molecule. Understanding its PK is vital for exams:

  • Poor Oral Absorption: It is not absorbed from the GI tract. Oral forms are only effective for localized GI fungal infections.
  • Systemic Route: MUST be given as a Slow I.V. Infusion.
  • Distribution: Highly bound to plasma proteins. It has a massive half-life of 15 days. It crosses the Blood-Brain Barrier (BBB) very poorly.
  • Special Routes:
    • Intrathecal: Injected directly into the spinal canal for severe CNS fungal infections.
    • Topical drops/Subconjunctival: For mycotic corneal ulcers/keratitis.
    • Local injection: Directly into joints for fungal arthritis.
    • Bladder irrigation: For severe Candiduria.
    • Advertisements

  • Clearance: Slowly metabolized by the liver and excreted unchanged in the urine over several days.

The Notorious Toxicity of Amphotericin B ("Ampho-Terrible")

Because human cholesterol is somewhat structurally similar to fungal ergosterol, Amp B causes significant collateral damage to human cell membranes, limiting its use to severe, life-threatening infections.

1. Immediate Infusion-Related Toxicity

Upon IV administration, the drug triggers massive histamine release from mast cells.

  • Symptoms: Severe fever, chills, muscle rigors/spasms, vomiting, headache, and hypotension.
  • Prevention/Management:
    1. Give a small "Test Dose" first.
    2. Slow down the IV infusion.
    3. Pre-medicate the patient with antipyretics (acetaminophen), NSAIDs, antihistamines, meperidine (for rigors), or adrenal corticosteroids.
2. Dose-Dependent Nephrotoxicity

Amp B is directly toxic to the renal tubules and aggressively constricts renal arteries.

  • Symptoms: Drastically decreased GFR, renal tubular acidosis, and severe loss of electrolytes (↓ K+ and ↓ Mg 2+).
  • Anemia: Kidney damage reduces the production of erythropoietin (EPO), leading to a reversible normocytic anemia.
  • Prevention: Protect the kidneys with aggressive Na+ (Saline) loading/hydration prior to infusion.

The Solution: Liposomal Amphotericin B. To reduce toxicity, scientists packaged the drug inside a lipid delivery system (a microscopic fat bubble). This formulation preferentially binds to the fungal cell membrane rather than the human kidney cell membrane. It vastly reduces nephrotoxicity and infusion reactions, and is highly effective, but it is much more expensive.


2. Nystatin (The Topical Cousin)

  • Structure & MOA: A polyene macrolide structurally and mechanistically identical to Amphotericin B.
  • Toxicity: It is far too toxic for systemic IV use. It would destroy human kidneys.
  • Clinical Uses: Because it is not significantly absorbed from the skin, mucous membranes, or the GIT, it is used exclusively topically.
    • Formulated as creams, ointments, oral suspensions ("swish and swallow"), and vaginal suppositories.
    • Used to prevent or treat superficial candidiasis of the mouth (oral thrush), esophagus, intestinal tract, and vaginal candidiasis.
    • Can be safely combined with antibacterial agents and corticosteroids.

IV. The Antimetabolites: Flucytosine (5-FC)

Flucytosine is a synthetic pyrimidine antimetabolite. It is essentially a chemotherapeutic (cytotoxic) drug that has been weaponized specifically against fungi. It acts as a systemic fungistatic agent.

  • Mechanism of Action (The Trojan Horse): Flucytosine (5-FC) enters the fungal cell via an enzyme called cytosine permease. Once inside, a uniquely fungal enzyme called Cytosine Deaminase converts 5-FC into 5-Fluorouracil (5-FU), a highly toxic anticancer drug. Human cells lack cytosine deaminase, so they do not convert the drug themselves.
    • The 5-FU is triphosphorylated and incorporated into fungal RNA, causing faulty protein synthesis.
    • 5-FU is also converted to 5-fluorodeoxyuridine monophosphate (5-Fd-UMP), which powerfully inhibits Thymidylate Synthase. This halts the production of thymine, shutting down fungal DNA synthesis.
  • The Synergy Rule: Flucytosine is almost never used alone because resistance emerges extremely rapidly. It is used in combination with Amphotericin B. Amphotericin B tears holes in the fungal membrane, which massively increases cell permeability, allowing vast amounts of 5-FC to flood into the cell. They are highly synergistic.
  • Pharmacokinetics: Unlike Ampho B, Flucytosine is rapidly and well absorbed orally. It is widely distributed throughout the body and has excellent penetration into the CSF. It is excreted mainly unchanged through the kidneys with a half-life of 3-6 hours.
  • Clinical Uses: Severe, deep fungal infections. The most highly tested use is in combination with Amphotericin B for the treatment of Cryptococcal meningitis in AIDS patients (due to its excellent CSF penetration).
Adverse Effects of Flucytosine

If human cells can't convert 5-FC to the toxic 5-FU, why is this drug toxic? Because intestinal bacteria (gut flora) DO possess cytosine deaminase! They convert the drug to toxic 5-FU right inside the gut, which is then absorbed into the human bloodstream.

  • Gastrointestinal Toxicity: Nausea, vomiting, diarrhea, and potentially severe, life-threatening enterocolitis.
  • Bone Marrow Depression: The 5-FU damages rapidly dividing cells in the bone marrow, causing reversible neutropenia and thrombocytopenia.
  • Other: Reversible alopecia (hair loss) and elevated hepatic enzymes.

V. The Azoles (Synthetic Fungistatic Agents)

The Azoles are a massive group of synthetic, broad-spectrum antifungal agents. Fascinatingly, they also possess mild antibacterial, antiprotozoal, and anthelminthic (anti-worm) properties. They are broadly divided into two chemical groups: the older, less selective Imidazoles and the newer, highly selective Triazoles.

Mechanism of Action (MOA) of All Azoles

Azoles act primarily by starving the fungal cell of its vital membrane component, ergosterol, while simultaneously poisoning it from within:

Advertisements

  1. Inhibition of 14-α-demethylase: This is a specific fungal cytochrome P450 enzyme. It is responsible for converting lanosterol to ergosterol. By blocking this enzyme, the fungal cell membrane loses its structural integrity.
  2. Mitochondrial Cytochrome Oxidase Inhibition: This blockade leads to a massive accumulation of toxic peroxides inside the cell, causing autodigestion of the fungus.
  3. Nucleic Acid Alteration: Imidazoles specifically may also alter fungal RNA and DNA metabolism.

Mechanism of Resistance: Fungi become resistant primarily via efflux pumps, leading to decreased intracellular accumulation of the azole.

1. The Imidazoles: Ketoconazole, Miconazole, Clotrimazole

The Imidazoles were the first breakthrough oral antifungals, but they share a massive pharmacological flaw: They lack selectivity. Not only do they inhibit the fungal cytochrome P450 enzyme, but they also severely inhibit Human P450 hepatic enzymes.

Ketoconazole & Endocrine Toxicity

Because Ketoconazole strongly inhibits human P450 enzymes involved in gonadal and adrenal steroid synthesis, it drastically decreases the production of Testosterone and Cortisol. This leads to highly testable side effects:

  • In Males: Gynaecomastia (breast development), loss of libido, and impotence.
  • In Females: Menstrual irregularities.
  • Clinical Hack: While a terrible side effect for a fungal infection, this exact mechanism makes Ketoconazole occasionally useful as an off-label treatment for Prostate Cancer (which relies on testosterone to grow).

Ketoconazole: Pharmacokinetics & Uses

  • Absorption Rules: Ketoconazole is well-absorbed orally, but it requires a highly acidic stomach environment to dissolve. Its bioavailability is severely decreased if the patient takes antacids, H 2 blockers, or Proton Pump Inhibitors (PPIs). Exam tip: Giving patients acidic Cola drinks dramatically improves absorption, especially in patients with achlorhydria (lack of stomach acid).
  • Metabolism & Distribution: Inactivated in the liver and excreted in bile (feces) and urine. It does not cross the blood-brain barrier (BBB). Its half-life increases with the dose (typically 7-8 hours).
  • Clinical Uses: Used for oral/vaginal candidiasis, dermatophytosis, and mucocutaneous candidiasis. It is the Co-DOC for Paracoccidioides and acts as a backup for Blastomyces and Histoplasma. Systemic use is now uncommon due to liver toxicity.
  • Contraindications: Absolutely contraindicated in pregnancy (highly teratogenic), lactation, and hepatic dysfunction.

2. The Triazoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole

Triazoles were developed to fix the problems of Imidazoles. They are highly selective for fungal enzymes, resistant to degradation, and cause far less endocrine disturbance.

Fluconazole

The most commonly used, versatile azole.

  • PK: Highly water-soluble. Excellent oral bioavailability that is NOT affected by food or gastric pH. The plasma concentration is identical whether given orally or IV. Excreted mainly unchanged through the kidneys (Half-life 25-30 hrs). Has the least effect on human hepatic microsomal enzymes.
  • Distribution: Penetrates the BBB beautifully.
  • Uses: The absolute Drug of Choice (DOC) for Cryptococcal meningitis (treatment, prophylaxis, and suppression). DOC for esophageal and invasive candidiasis. Safely used to reduce fungal infections in bone marrow transplant patients.
  • Limitations: Not effective against Aspergillosis.
  • Unique Side Effect: Reversible alopecia (hair loss).
Itraconazole

The lipophilic alternative.

  • PK: Given orally & IV. Unlike Fluconazole, food significantly INCREASES its absorption. It is highly lipid-soluble, distributing well into bone, sputum, and adipose tissue, but it cannot cross the BBB. Metabolized in the liver. Half-life 30-40 hours.
  • Uses: DOC for blastomycosis, sporotrichosis, and non-CNS histoplasmosis (including AIDS-associated). Very effective for dermatophytosis and onychomycoses.
  • Toxicity & Warnings: Causes nausea, hypokalemia, hypertension, and edema. It strongly inhibits the metabolism of oral anticoagulants. Strictly contraindicated in patients with ventricular dysfunction (heart failure). Hepatic function must be evaluated.
Voriconazole

The Aspergillus killer.

  • PK: High oral bioavailability, given oral/IV. Penetrates tissues incredibly well, including the CSF.
  • Uses: The undisputed DOC for invasive Aspergillosis and severe infections.
  • Unique Side Effects: Neurotoxicity and reversible visual disturbances (flashes of light, color vision changes), alongside severe photosensitivity.
Posaconazole

The niche saver.

  • Use: It is the only azole with clinical activity against Mucorales (Mucormycosis / "Black Fungus" infections, which cause severe rhinocerebral and pulmonary necrosis).
Class-Wide Azole Toxicities & Interactions
  • Hepatotoxicity: Elevated LFTs are common to all azoles.
  • Teratogenicity: Highly teratogenic; strictly avoid in pregnancy.
  • Massive Drug-Drug Interactions: Because they inhibit human CYP450 to varying degrees, they violently interact with and increase the blood levels of Warfarin, Rifampin, and Anti-seizure medications.

VI. The Echinocandins (The "Penicillins" of Antifungals)

Examples: Caspofungin, Micafungin, Anidulafungin.

Echinocandins are large, complex cyclic hexapeptides. Because they target the fungal cell wall (a structure humans do not possess), they are highly selective and generally well-tolerated.

  • Mechanism of Action: They specifically inhibit β(1,3)-D-glucan synthase. This halts the production of beta-glucan, a critical structural component of the fungal cell wall. The weakened wall ruptures, leading to cell lysis and death.
    • They are Fungicidal against Candida spp.
    • They are Fungistatic against Aspergillus.
    • Advertisements

  • Pharmacokinetics: Due to their large peptide structure, they have poor oral bioavailability and must be given exclusively via IV route. They are highly bound to plasma proteins with a half-life of 9-11 hours. They are slowly metabolized by hydrolysis and N-acetylation, and elimination is split equally between urine and feces.
  • Clinical Uses: Second-line "salvage" therapy for invasive Aspergillus and severe Candida infections in patients who have failed or cannot tolerate Amphotericin B or Itraconazole.
  • Adverse Effects: Very expensive. Causes nausea, vomiting, and characteristic Flushing (due to rapid histamine release from mast cells during infusion). Liver function must be monitored.

VII. Mitotic Inhibitors: Griseofulvin

Griseofulvin is an old, narrow-spectrum, fungistatic drug derived from Penicillium griseofulvum.

  • Mechanism of Action: It enters the fungal cell and binds to tubulin, inhibiting fungal mitosis by disrupting microtubule assembly and function.
  • Pharmacokinetics & Tissue Targeting: Given orally. Its absorption is heavily increased if taken with a high-fat meal. It has a unique distribution: it is taken up selectively by newly formed skin cells and concentrates heavily in keratin.
  • Clinical Uses: Active only against dermatophytes (ringworm of the skin, hair, and nails, including severe athlete's foot). It is ineffective topically and completely useless against subcutaneous/deep systemic mycoses or Candida.
  • The Time Factor: Because it binds only to new keratin, the patient must take it for 2 to 6 weeks (or months for nails) to allow the infected, old keratin to grow out and be physically replaced by the new, resistant keratin structure.
  • Adverse Effects: Peripheral neuritis, mental confusion, fatigue, vertigo, blurred vision, and GIT upset.
  • Drug Interactions: It is a strong Cytochrome P450 enzyme inducer (will speed up the breakdown of other drugs). It also increases alcohol intoxication, causing a severe Disulfiram-like reaction if the patient drinks alcohol.

VIII. The Allylamine Derivatives

Examples: Terbinafine, Naftifine, Butenafine.

The Allylamines are a powerful, modern class of drugs used primarily to eradicate superficial dermatophyte infections, particularly in the nails.

Mechanism of Action

They act one step earlier in the ergosterol pathway than the Azoles. They inhibit the fungal enzyme Squalene Epoxidase. This has a dual lethal effect:

  1. It decreases the synthesis of ergosterol (starving the membrane).
  2. It causes a massive intracellular accumulation of squalene, which is highly toxic to the organism, causing rapid fungal cell death. Therefore, these drugs are Fungicidal.

1. Terbinafine (The Nail Champion)

  • Uses: The absolute Drug of Choice (DOC) for treating severe dermatophytes (Onychomycoses/nail infections). Its fungicidal activity is limited to Candida albicans and dermatophytes. It is much better tolerated than Griseofulvin and requires a shorter duration of therapy: 6 weeks for fingernail infections, and 12 weeks for toenail infections.
  • Pharmacokinetics: Well absorbed orally, but bioavailability decreases due to heavy first-pass metabolism in the liver. Highly protein-bound. It accumulates massively in the skin, nails, and fat tissue.
  • Severe Toxicities: Severely Hepatotoxic. Can cause acute liver failure and even death. Liver enzymes must be checked before and during therapy. It accumulates in breast milk and should not be given to nursing mothers. Also causes severe GIT upset (diarrhea, dyspepsia), and uniquely alters taste and visual disturbances.

2. Naftifine

A topical broad-spectrum fungicidal agent available as a cream or gel. Uniquely, it possesses additional antibacterial and anti-inflammatory properties. Highly effective for the treatment of Tinea cruris (jock itch).


IX. Topical Antifungal Agents

Topical therapy is used exclusively for superficial fungal infections (Dermatophytosis/ringworm, cutaneous candidiasis, and fungal keratitis). They are completely ineffective against mycoses of the nails, hair, or deep subcutaneous tissues because the drug cannot penetrate deep enough. The preferred formulation is a cream or solution.

AgentClass / CharacteristicsClinical Uses & Side Effects
Clotrimazole & MiconazoleTopical Azoles: Available as vaginal creams, suppositories, and tablets (given once daily). Systemic absorption is very low (<0.5% from intact skin, 3-10% from the vagina). Vaginal activity remarkably persists for up to 3 days post-application.Used for dermatophytes, cutaneous candidiasis, and vulvovaginal candidiasis.
SE: Local erythema (redness), edema, urticaria, and a mild vaginal burning sensation.
Nystatin & AmphotericinPolyenes: Discussed extensively in Part 1. Highly toxic systemically, so restricted entirely to topical/oral-swish use.Oral thrush, superficial mucocutaneous candidiasis.
TolnaftateThiocarbamate: MOA is likely identical to Allylamines (inhibits squalene epoxidase). Applied twice daily as a cream, gel, powder, or solution.Highly effective for most cutaneous mycoses (achieves an 80% cure rate in Tinea pedis/athlete's foot).
High Yield Note: It is completely ineffective against Candida.
Terbinafine & NaftifineTopical Allylamines: Highly fungicidal topically against dermatophytes.Tinea corporis, tinea cruris, tinea pedis.

Quick Quiz

Antifungal Agents BNS Quiz

Pharmacology

Privacy: Your details are used only for quiz tracking and certificates.

Advertisements

Pharmacology of Antifungal Agents Read More »

Pharmacology of Lipid-Lowering Drugs & Cardiovascular Prevention

Pharmacology of Lipid-Lowering Drugs & Cardiovascular Prevention

Pharmacology of Lipid-Lowering Drugs & Cardiovascular Prevention

I. Introduction: The Burden of Atheromatous Disease

Atheromatous disease (atherosclerosis) is common globally. It is the underlying pathology responsible for the most common causes of death, primarily Myocardial Infarction (Heart Attacks), and severe disability, such as Ischemic Strokes. Atheroma is a focal disease of the intima (the innermost lining) of large and medium-sized arteries.

While we cannot change our genetics, Hypertension and Dyslipidemia are two of the most critical, modifiable risk factors that are highly amenable to pharmacological therapy. To understand how lipid-lowering drugs save lives, we must first understand how lipids destroy blood vessels.


II. The Pathophysiology of Atherosclerosis

Atherosclerosis is not just "fat clogging a pipe." It is a highly active, chronic inflammatory response triggered by damage to the blood vessel lining.

1. The Healthy Endothelium (The Protector)

A healthy, intact endothelium actively maintains an anti-coagulant and anti-thrombotic surface to keep blood flowing smoothly. It produces two vital protective molecules:

  • Prostacyclin (PGI 2): A potent vasodilator that actively prevents platelet adhesion and aggregation.
  • Nitric Oxide (NO): A powerful vasodilator that prevents platelets and White Blood Cells (monocytes) from sticking to the vessel wall.

2. Endothelial Dysfunction (The Trigger)

This is the earliest visible change in cardiovascular disease. Mechanical, chemical, or inflammatory mediators damage the endothelium, causing it to lose its protective PGI 2 and NO. Triggers include:

  • High Blood Pressure: Mechanical shearing stress tears the delicate lining.
  • Smoking: Introduces free radicals that oxidatively damage the endothelium.
  • Hyperlipidemia: Excess toxic lipids circulating in the blood.
  • Elevated homocysteine and other inflammatory stimuli.
The Inflammatory Shift

When damaged, the endothelium stops producing protective NO and PGI 2 and instead shifts to a pro-coagulant, pro-thrombotic surface. It begins overexpressing Pro-Inflammatory Molecules to call for help:

  • Chemokines: Monocyte Chemoattractant Protein 1 (MCP-1) calls immune cells to the area.
  • Inflammatory Cytokines: Tumor Necrosis Factor alpha (TNF-α).
  • Adhesion Molecules: ICAM-1 and VCAM-1 act like "velcro," forcing passing white blood cells to stick to the damaged artery wall.

3. The Stages of Atherogenesis (Plaque Formation)

Once endothelial dysfunction occurs, a deadly cascade begins:

  1. Monocyte Attachment & Migration: White blood cells (monocytes) stick to the VCAM-1 "velcro" on the damaged endothelium and undergo transmigration, squeezing into the subendothelial space (inside the artery wall) where they transform into Macrophages.
  2. LDL Infiltration & Oxidation: Excess Low-Density Lipoprotein (LDL) in the blood leaks into this damaged artery wall. Here, free radicals attack the lipids and the apoB 100 protein on the LDL, creating highly toxic Oxidized LDL (oxLDL).
  3. Foam Cell Formation: The macrophages attempt to clean up the toxic oxLDL by engulfing it. However, they eat so much fat that they die, turning into fat-bloated corpses called Foam Cells.
  4. Plaque Growth: The accumulation of dead foam cells creates a necrotic core of fat. Smooth muscle cells migrate to the area, proliferating and creating a fibrous cap over the fat to wall it off. Calcium deposits (calcification) harden the artery.
  5. Plaque Rupture: Eventually, the inflammatory cells thin out the fibrous cap. The plaque ruptures, spilling highly thrombogenic fat into the bloodstream. A massive blood clot forms instantly, causing a heart attack or stroke.

III. Lipid Transport: The Lipoproteins

Lipids (Cholesterol [CHO] and Triglycerides [TG]) are fats. Because blood is mostly water, fats cannot dissolve in it. To travel through the blood, they must be packaged inside protein submarines called Lipoproteins.

Advertisements

1. Chylomicrons

The "cargo ships" of the gut. They transport dietary (exogenous) Triglycerides and Cholesterol from the intestines to the tissues.

2. VLDL (Very Low-Density Lipoprotein)

The liver's delivery trucks. They transport newly synthesized (endogenous) Triglycerides and Cholesterol from the liver to the body's tissues.

3. LDL (Low-Density Lipoprotein)

The "Bad Cholesterol." Once VLDL drops off its triglycerides, it shrinks into LDL. LDL is packed with heavy Cholesterol. This is the highly atherogenic particle that gets stuck in artery walls.

4. HDL (High-Density Lipoprotein)

The "Good Cholesterol" or the "Garbage Trucks." HDL absorbs excess cholesterol from tissue breakdown and brings it back to the liver for excretion.

The Two Pathways of Lipid Metabolism

  • The Exogenous Pathway (From Food): Dietary CHO and TG are absorbed from the GI tract and enter the lymphatic system, eventually reaching the plasma as Chylomicrons. In the capillaries of muscle and adipose tissue, an enzyme called Lipoprotein Lipase hydrolyzes the core triglycerides, allowing tissues to take up Free Fatty Acids for energy. The leftover "chylomicron remnants" are taken up and destroyed by the liver.
  • The Endogenous Pathway (From the Liver): The liver liberates CHO. It can store it, oxidize it into bile acids, or package it into VLDL to send to the body. As VLDL travels, it drops off fatty acids to muscles and slowly shrinks, ultimately becoming LDL. Cells throughout the body take up this LDL via specific LDL Receptors to use the cholesterol for cell membranes and steroid synthesis.

IV. Dyslipidemia: Clinical Application & Case Study

Dyslipidemia is an abnormal amount of lipids in the blood. It can be Primary (genetically determined, like familial hypercholesterolemia) or Secondary (acquired due to diabetes, alcoholism, nephrotic syndrome, chronic renal failure, or certain drugs).

Clinical Case Study: Mulago Outpatient Clinic

Patient: 52-year-old male.
Complaint: Occasional chest discomfort when walking quickly uphill that settles with rest (Classic presentation of Stable Angina, indicating partial atherosclerotic blockage of coronary arteries).
History: Poorly controlled hypertension (6 years), sedentary lifestyle, high-fat diet (fried foods/processed meat). Father died suddenly of a heart issue at 58 (strong family history of premature CVD).
Vitals: BP 156/94 mmHg (Hypertensive), BMI 29 kg/m² (Overweight).

Laboratory Findings & Interpretation:

  • Total Cholesterol: 7.1 mmol/L (Normal is < 5.2 mmol/L) → Severely Elevated.
  • LDL-C: 4.8 mmol/L (Normal is < 3.4 mmol/L) → Dangerously Elevated. This is the primary target for therapy.
  • HDL-C: 0.9 mmol/L (Normal for men > 1.0 mmol/L) → Abnormally Low. Lacking cardiovascular protection.
  • Triglycerides: 2.6 mmol/L (Normal < 1.7 mmol/L) → Elevated.
  • Glucose, ALT (Liver), Creatinine (Kidney): All normal. This is crucial because lipid-lowering drugs require healthy liver and kidney function to be safely administered.

Conclusion: This patient has severe mixed dyslipidemia, hypertension, and symptomatic atherosclerotic disease (stable angina) placing him at massive risk for a fatal myocardial infarction. He urgently requires aggressive lipid-lowering pharmacotherapy alongside dietary management and blood pressure correction.

Target "Ideal" Fasting Lipid Profile (mg/dL reference)

Lipid ParameterIdeal, Healthy Level
Total Cholesterol< 200 mg/dL
LDL-Cholesterol (The Target)< 100 mg/dL
HDL-Cholesterol (The Protector)≥ 60 mg/dL
Triglycerides< 150 mg/dL

V. Pharmacotherapy: Lipid-Lowering Drugs

Drug therapy is always used in addition to dietary management and the correction of other modifiable risk factors (like stopping smoking and treating hypertension). There are 4 major classes of lipid-lowering drugs.

Advertisements

1. Statins (The Cornerstone of Therapy)

Examples: Simvastatin, Pravastatin, Atorvastatin, Rosuvastatin.

Statins are the absolute first-line treatment for lowering LDL cholesterol and preventing cardiovascular events.

  • Mechanism of Action (MOA): They are competitive HMG-CoA Reductase Inhibitors. This enzyme normally catalyzes the conversion of HMG-CoA to mevalonic acid, which is the rate-limiting step of cholesterol synthesis in the liver.
  • The Real Pharmacodynamic Effect: By decreasing hepatic cholesterol synthesis, the liver panics because it needs cholesterol. To get it, the liver upregulates (creates more) LDL receptors on its cell surface. These receptors grab circulating LDL out of the plasma and pull it into the liver cells, drastically increasing LDL clearance from the blood.
  • Pharmacokinetics (PK): They are well absorbed orally. Because they target the liver, they undergo extensive pre-systemic biotransformation (First-Pass Effect) to reach their target tissue. Note: Simvastatin is administered as an inactive pro-drug and must be activated by the liver. Atorvastatin and Rosuvastatin are highly potent, long-lasting inhibitors.
Clinical Uses
  • Secondary Prevention: Mandatory for patients who already have symptomatic atherosclerotic disease (like our case study patient with angina, or post-MI/stroke patients) to prevent a second attack.
  • Primary Prevention: Used in patients at high risk due to elevated CHO or other risk factors, before a heart attack ever happens.
  • Atorvastatin is potent enough to lower CHO even in patients with severe homozygous familial hypercholesterolemia.
Pleiotropic Effects (Beyond Lipids)

Statins don't just lower fat; they actively heal the blood vessels:

  • Improve endothelial function (restore NO).
  • Reduce vascular inflammation & platelet aggregability (antithrombotic).
  • Stabilize atherosclerotic plaques (prevents them from rupturing).
  • Increase neovascularization of ischemic tissue.
  • Enhance fibrinolysis (clot-busting).
Adverse Drug Reactions (ADRs) & Monitoring
  • Mild: Gastrointestinal disturbances.
  • Hepatotoxicity: Raised concentrations of liver enzymes (ALT/AST) in plasma. Liver function tests must be monitored.
  • Myopathy: Can cause severe muscle pain and muscle breakdown known as Severe Myositis or Rhabdomyolysis, which can lead to kidney failure.
  • Rare: Angio-oedema.

2. Fibrates

Examples: Fenofibrate, Clofibrate, Gemfibrozil, Ciprofibrate.

Fibrates are the drugs of choice for severely elevated Triglycerides.

  • Mechanism of Action: They stimulate the beta-oxidative degradation of fatty acids. More importantly, they increase the activity of Lipoprotein Lipase (LPL) in the tissues. This drastically increases the hydrolysis and breakdown of triglycerides inside Chylomicrons and VLDL particles. They liberate free fatty acids for storage in fat or metabolism in striated muscle.
  • Pharmacodynamic Result: They severely reduce hepatic VLDL production, lower triglycerides, and increase hepatic LDL uptake.
  • Other Effects: They improve glucose tolerance and inhibit vascular smooth muscle inflammation.
  • Clinical Uses: Used for Mixed Dyslipidemia (raised TG and CHO) and in patients with low HDL and high CV risk (often Type 2 Diabetics). Can be combined with other drugs in severe, treatment-resistant dyslipidemia.
  • Adverse Effects: Mild GIT symptoms. Severe Risk: In patients with renal impairment, they can cause massive Myositis (Rhabdomyolysis) leading to myoglobinuria and acute renal failure. Fibrates should be strictly avoided in patients with severe renal impairment, and caution is required if combined with statins.

3. Bile Acid Binding Resins

Examples: Colestyramine, Colestipol.

These are unique because they never actually enter the bloodstream; they stay entirely within the gut.

  • Mechanism of Action: Normally, the liver uses cholesterol to make bile acids, which are secreted into the gut to digest fat, and then reabsorbed back into the liver (enterohepatic recirculation). Resins physically bind to (sequester) these bile acids in the GI tract, forcing them to be excreted in the stool.
  • The Result: Because bile is lost, the liver is forced to metabolize its endogenous cholesterol stores to make new bile acids. To get more cholesterol, the liver increases the expression of LDL receptors, aggressively pulling LDL out of the blood, reducing plasma LDL concentrations. Note: This can sometimes cause an unwanted compensatory increase in Triglycerides.
  • Clinical Uses: Used as an add-on to statins if the response is inadequate, or for hypercholesterolemia when statins are contraindicated. Unrelated uses: Treats Pruritus (severe itching) in patients with partial biliary obstruction, and treats bile acid diarrhea (seen in diabetic neuropathy).
  • Adverse Effects: Because they stay in the gut, they cause severe GIT symptoms (nausea, abdominal bloating, massive constipation, or diarrhea). The resins are highly unappetizing (like drinking sand), though mixing with fruit juice helps.
  • Crucial Drug Interactions: Resins are sticky. They will interfere with the absorption of fat-soluble vitamins (A, D, E, K) and critical drugs (Chlorothiazide, Digoxin, Warfarin). Rule: Other drugs must be given at least 1 hour BEFORE or 4-6 hours AFTER taking a resin.
  • Advertisements

4. Other Lipid-Lowering Agents


Nicotinic Acid (Niacin / Vitamin B3)

  • Mechanism & Effects: Powerfully inhibits hepatic TG production and the subsequent secretion of VLDL. It provides a modest reduction in LDL but is the most effective drug for increasing HDL.
  • Adverse Effects: Notoriously causes severe Flushing (prostaglandin-mediated red, hot skin) and palpitations, alongside GIT disturbances. Compliance is often poor due to the flushing.

Fish Oil (Omega-3 Marine Triglycerides)

  • Rich in highly unsaturated fatty acids.
  • Effects: Excellent at reducing plasma Triglycerides. However, they can paradoxically increase LDL-Cholesterol (which is strongly associated with coronary artery disease).
  • Clinical Note: While epidemiological evidence suggests that eating fish regularly reduces ischemic heart disease, the specific mortality/morbidity benefits of purified fish oil supplements remain clinically unproven.

VI. Summary & Key Take-Home Points

  • Dyslipidemia is a major, highly modifiable risk factor for atherosclerotic cardiovascular disease. Left untreated, it drives endothelial dysfunction, foam cell formation, and ultimately plaque rupture (heart attacks/strokes).
  • Lipid-lowering drugs work through different molecular targets (enzymes in the liver, receptors in the gut, lipid metabolism in muscle) to systematically reduce atherogenic lipoproteins, particularly LDL-C.
  • Understanding the flow of MOA → Pharmacodynamics → Pharmacokinetics → Adverse Reactions is the only way to guide the rational selection and safe use of lipid-lowering therapy.
  • Statins are the undisputed cornerstone of LDL-lowering therapy. Other agents (Fibrates, Resins, Niacin) are used when additional lipid-lowering is required, for isolated high triglycerides, or when statins are clinically unsuitable.
  • Treatment must always be highly individualized. You must consider the patient's overall cardiovascular risk, expected therapeutic benefits, adverse side effects (like checking liver and kidney function), drug interactions, and specific lifestyle factors.

References & Further Reading

  • Katzung, B. G. (2020). Basic & Clinical Pharmacology (15th ed.). McGraw-Hill Education. (Chapter on Agents Used in Dyslipidemia).
  • Ross, R. (1999). Atherosclerosis—an inflammatory disease. New England Journal of Medicine, 340(2), 115-126. (Source of the atherogenesis visual models).
  • Brunton, L. L., et al. (2017). Goodman and Gilman's The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill. (In-depth mechanisms of HMG-CoA reductase inhibitors and Fibrates).
  • Mach, F., et al. (2020). ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal.

Quick Quiz

Lipid Lowering Drugs Quiz

Pharmacology

Privacy: Your details are used only for quiz tracking and certificates.

Advertisements

Pharmacology of Lipid-Lowering Drugs & Cardiovascular Prevention Read More »

Pharmacology of Antiviral Agents

Pharmacology of Antiviral Agents

Pharmacology of Antiviral Agents

Pharmacology of Antiviral Agents: Complete Clinical Guide

I. Introduction to Virology (The Enemy)

Before we can understand how to kill a virus, we must understand what it is. Viruses are incredibly difficult to treat pharmacologically because of their nature. They are Obligate Intracellular Parasites. This means they cannot live, metabolize, or divide on their own outside of a host cell.

Why are Antivirals so difficult to make?

Unlike bacteria, viruses lack a cell wall, a cell membrane, and most metabolic enzymes. Because they rely entirely on the human host cell machinery to decode their genetic instructions and replicate, any drug designed to kill the virus often ends up severely damaging the human host cell as well. Finding drugs with "selective toxicity" is the biggest challenge in antiviral pharmacology.

1. The Basic Structure of a Virus

A virus is essentially just a package of genetic instructions waiting to be delivered. It consists of three essential parts:

  • Central Core: Contains the genetic instructions, which can be either DNA or RNA (never both).
  • Capsid: A protective protein shell made of subunits called capsomeres. Human viruses are classified into 4 types depending on the exact geometrical shape of this capsid.
  • Envelope: A lipid membrane surrounding the capsid. Note: Not all viruses have an envelope. Those that do, steal it (acquire it) from the human host cell membrane as they exit the cell.

2. Types of Viral Infections & Risk Factors

Viral infections manifest in different ways:

  • Asymptomatic: Infection occurs, but the patient shows no disease symptoms.
  • Acute: Rapid onset of active disease symptoms (e.g., the common cold).
  • Persistent (Long-term):
    • Chronic: The infectious virus is continuously present and replicating (e.g., Hepatitis B).
    • Latent: The virus stops replicating and hides in the body, waiting to reactivate later (e.g., Herpes Zoster / Shingles).
  • Transformation: The virus alters host cell regulation, leading to tumor production/cancer. The viral DNA is completely or partially integrated into the host DNA.
Risk Factors for Severe Infection

A competent, well-functioning immune system is the absolute best defense; it will eliminate or effectively destroy viral replication. However, an Incompetent Immune System leads to severe, life-threatening viral infections. High-risk populations include:

  • Cancer Patients: Especially those with leukemia or lymphoma.
  • Transplant Patients: Due to lifelong pharmacological immunosuppressive therapy to prevent organ rejection.
  • AIDS Patients: Because the HIV disease specifically attacks and destroys the immune system (CD4 T-cells).

3. Common and Harmful Human Viruses

DNA VirusesRNA Viruses
Poxvirus (Smallpox)Paramyxovirus (Measles, Mumps)
Herpesviruses (HSV, VZV, CMV)Rubella virus (German measles)
Adenovirus (Eye infections, Gastro)Rhabdovirus (Rabies)
Papillomavirus (HPV Warts)Picornavirus (Cold, Poliomyelitis)

The "RICHH" Acronym for highly harmful viruses: R espiratory syncytial virus (RSV), I nfluenza A (the flu), C ytomegalovirus (CMV), H erpes simplex virus (HSV), H IV, and H epatitis B & C (HBV/HCV).


II. The Viral Lifecycle & Antiviral Sites of Action

To stop a virus, pharmacologists have designed drugs that interrupt specific steps of the viral replication cycle. An effective antiviral must be able to enter the infected cell, interfere with viral nucleic acid synthesis/regulation, or prevent the virus from binding in the first place.

1. Recognition & Attachment

The virus finds the host cell and attaches to its surface receptors.

Drug Targets: Receptor antagonists (e.g., Maraviroc for HIV), Neutralizing Antibodies (Human Serum Immunoglobulin).

2. Penetration & Uncoating

The virus enters the cell and sheds its protein coat to release its genetic material.

Drug Targets: Uncoating inhibitors (e.g., Amantadine for Influenza A), Fusion inhibitors (e.g., Enfuvirtide for HIV).

3. Transcription & Translation

The viral genetic material forces the host to make viral RNA and viral proteins.

Drug Targets: Interferons, Antisense DNA (e.g., Fomivirsen), siRNA, Ribozymes.

4. Replication (Synthesis)

The virus copies its DNA/RNA massively.

Drug Targets: Nucleoside/Nucleotide Analogues (e.g., Acyclovir, Zidovudine), Reverse Transcriptase Inhibitors.

5. Assembly & Maturation

The newly minted viral parts are put together into a mature infectious particle.

Drug Targets: Protease Inhibitors (e.g., Ritonavir).

6. Release

The new viruses break free (via lysis or exocytosis/budding) to infect other cells.

Drug Targets: Neuraminidase Inhibitors (e.g., Oseltamivir for Influenza).


III. The Foundation of Antivirals: Nucleosides vs. Nucleotides

To understand the majority of antiviral drugs, you absolutely must master the concept of Analogues (Base Mimics). Viral DNA and RNA are built using a sugar attached to specific nitrogenous bases (Purines and Pyrimidines).

  • Purines (Double-ring structure): Adenine (A) and Guanine (G).
  • Pyrimidines (Single-ring structure): Cytosine (C), Thymine (T) (found only in DNA), and Uracil (U) (found only in RNA).
  • The Sugar: Ribose is used for RNA (Ribonucleosides). Deoxyribose is used for DNA (Deoxyribonucleosides).
  • The Glycosidic Bond: This is the chemical bond linking the base to the sugar (between N9 of purines or N1 of pyrimidines to the C1' carbon of the sugar).
The "Trojan Horse" Mechanism (Chain Termination)

Most antivirals are Nucleoside or Nucleotide Analogues. They are structurally designed to look exactly like the normal A, G, C, or T bases. The viral DNA polymerase enzyme gets tricked. It picks up the fake drug (the analogue) and inserts it into the growing viral DNA chain. However, because the drug is chemically defective (it lacks a specific 3'-OH group), the next base cannot be attached. This halts DNA polymerase activity and causes Viral Chain Termination.

The Crucial Difference: Activation (Phosphorylation)

  • Nucleo S ide Analogues: These drugs enter the cell without any phosphate groups. To become active and trick the DNA polymerase, they must be phosphorylated THREE times (converted to a triphosphate form). Often, the first phosphate is added by a specific viral kinase, and the next two by host cellular kinases.
  • Nucleo T ide Analogues: These drugs (like Tenofovir, Adefovir, Cidofovir) are already monophosphates (they already contain one phosphate group). They do NOT require a viral kinase to be activated. They are directly phosphorylated by host enzymes to their active diphosphate/triphosphate form. This is huge clinically because they remain active even against mutated, kinase-deficient resistant viral strains!

Categorizing the Analogues

Advertisements

Analogue Class (Base Mimic)Drug ExamplesPrimary Clinical Use
Guanine (Purine) AnaloguesAcyclovir, Ganciclovir, Ribavirin, AbacavirHerpes, CMV, RSV/HCV, HIV
Adenosine (Purine) AnaloguesDidanosine, Vidarabine, Tenofovir (Nucleotide), Adefovir (Nucleotide)HIV, Herpes (rare), Hep B
Cytidine (Pyrimidine) AnaloguesLamivudine (3TC), Zalcitabine, Emtricitabine, Cidofovir (Nucleotide), Cytarabine (Ara-C)HIV, Hep B, CMV retinitis, Leukemia
Thymidine (Pyrimidine) AnaloguesZidovudine (AZT), Stavudine, Trifluridine, IdoxuridineHIV, HSV keratitis
Uracil (Pyrimidine) AnaloguesFluorouracil (5-FU), Sofosbuvir (Nucleotide)Cancers, Hep C

III. Class 1: Fusion Inhibitors

Fusion inhibitors work at the very first step of the viral lifecycle. Their primary goal is to prevent the attachment of the virus to the host cell membrane.

  • Neutralizing Antibodies:
    • Passive Immunization and Adoptive T-cell therapy.
    • Human Serum Immunoglobulin (HSG): Contains various antibodies extracted from a pool of adults who were initially infected. It is given IV and is used primarily for Hepatitis A & B, and Measles.
    • Human Virus Specific Immunoglobulin (HVSG): Extracted from the plasma of patients with known, specific antibodies. Used for Hepatitis B, Rabies, and Varicella-Zoster infections.
  • Receptor Antagonists:
    • Enfurvitide: A peptide analogue that blocks cell receptors.
    • Maraviroc: A specific Chemokine receptor inhibitor.
    • Sugar/peptide analogues of the cell receptor itself can be used to trick the virus into binding the drug instead of the cell.
  • Other Fusion Inhibitors:
    • Sulfated galactomannans: Investigated for use against Dengue and Yellow fever.

IV. Class 2: Uncoating Inhibitors

These drugs prevent the release of the viral RNA complex from its protective nucleoprotein complex (the capsid). If the virus cannot uncoat, it cannot replicate.

1. The Adamantane Derivatives (M2 Inhibitors)

Examples: Amantadine, Rimantadine.

  • Mechanism of Action: They interfere with the membrane coating protein M2. The M2 protein functions as a proton ion channel that allows acidification inside the virus, which is required for it to disassemble. By blocking M2, these drugs prevent viral uncoating.
  • Potency: Rimantadine is 4 to 10 times more potent than Amantadine.

2. Neuraminidase Inhibitors (H5N1)

Examples: Zanamivir, Oseltamivir (Tamiflu).

While often classed under release inhibitors, they are functionally grouped here as they target surface viral proteins.

  • Mechanism of Action: Neuraminidase exists on the surface of the virus and catalyzes the cleavage of sialic acid from the host cell, which facilitates the release of the viral particle.
  • Sialic Acid Analogues: Zanamivir and Oseltamivir are potent inhibitors of neuraminidase. They are used specifically to treat Influenza A & B (given intranasally or orally).

V. Class 3: Nucleoside & Nucleotide Analogues

This is the largest and most important class of antiviral drugs. They achieve selective inhibition of virus DNA replication.

Mechanism of Action

These drugs act as "fake building blocks" (base mimics). They work by:

  1. Acting as a competitive inhibitor of viral DNA polymerase.
  2. Causing Viral chain termination. Because the drug lacks the proper chemical structure to attach the next DNA base, once it is incorporated into the growing viral DNA chain, the chain cannot be extended.
  3. Leading to the complete inactivation of DNA polymerase.

Understanding the Chemical Structure

Nucleosides consist of a base and a sugar linked by a Glycosidic Bond (between the N1/N9 atom of the base and the C1' carbon of the sugar).

  • The Sugar: Ribose is used for ribonucleosides (RNA). Deoxyribose is used for deoxyribonucleosides (DNA).
  • Purine Bases: Adenine (A) or Guanine (G).
  • Pyrimidine Bases: Cytosine (C), Uracil (U - in RNA), or Thymine (T - in DNA).

Comprehensive Master Table of Analogues

Drug NameTypeClass (Base Mimic)Clinical Use
Zidovudine (AZT)NucleosideThymidine analogHIV (antiretroviral)
Lamivudine (3TC)NucleosideCytidine analogHIV, Hepatitis B
AbacavirNucleosideGuanosine analogHIV
Emtricitabine (FTC)NucleosideCytidine analogHIV
Didanosine (ddI)NucleosideAdenosine analogHIV
AcyclovirNucleosideGuanosine analogHerpes simplex virus (HSV), VZV
GanciclovirNucleosideGuanosine analogCytomegalovirus (CMV retinitis & systemic)
Cytarabine (Ara-C)NucleosideCytidine analogLeukemia (AML)
GemcitabineNucleosideDeoxycytidine analogPancreatic, breast, lung cancer
Vidarabine (Ara-A)NucleosideAdenosine analogHerpes viruses (rarely used now)
Tenofovir (TDF, TAF)NucleotideAdenosine monophosphate analogHIV, Hepatitis B
Adefovir dipivoxilNucleotideAdenosine monophosphate analogHepatitis B
CidofovirNucleotideCytidine monophosphate analogCMV retinitis (HIV patients)
SofosbuvirNucleotideUridine monophosphate analogHepatitis C
Fluorouracil (5-FU)Nucleoside prodrugUracil analogColorectal, breast, GI cancers
Ribavirin (RTCD)NucleosideGuanosine analogInfluenza A/B, RSV, LV, HV
Zalcitabine (ddC)NucleosideCytosine analogHIV
Idoxuridine (IDU)NucleosideThymine analogHSV
Stavudine (d4T)NucleosideThymine analogHIV
TrifluridineNucleosideThymine analogHSV

Classic Examples Explained in Detail

Nucleoside Analogs
  • Zidovudine (AZT): A Thymidine analog used for HIV treatment. MOA: Must be phosphorylated by host enzymes to AZT-triphosphate → inhibits HIV reverse transcriptase → chain termination.
  • Cytarabine (Ara-C): A Cytidine analog used for Leukemia (AML). MOA: Incorporated into human DNA → halts DNA polymerase activity (anticancer effect).
  • Gemcitabine: A Deoxycytidine analog used for Pancreatic, breast, and non-small cell lung cancer. MOA: Inhibits ribonucleotide reductase and DNA synthesis.
Nucleotide Analogues

These already contain a monophosphate group.

  • Tenofovir disoproxil fumarate (TDF): An Adenosine monophosphate analogue used for HIV and Hepatitis B. MOA: Converted to tenofovir diphosphate → inhibits reverse transcriptase → chain termination.
  • Adefovir dipivoxil: An Adenosine monophosphate analogue used for Hepatitis B. MOA: Converted to adefovir diphosphate → DNA polymerase inhibition.
  • Cidofovir: A Cytidine monophosphate analogue used for CMV retinitis in AIDS patients. MOA: Because it is already a monophosphate, it skips the need for viral activation and inhibits viral DNA polymerase directly.

Pharmacology of Antiviral Agents: Part 2 (Specific Viral Therapies)

Following our mastery of viral structure and analogue mechanisms, we will now meticulously break down the specific drug classes used to combat the most dangerous viral infections: Herpes, Hepatitis, Influenza, and HIV.

IV. Anti-Herpesvirus Agents

The Human Herpesvirus (HHV) family is notorious for establishing latent infections—they hide in the body's nerve ganglia and reactivate when the immune system dips.

  • HHV-1: Primary herpetic gingivostomatitis (oral cold sores).
  • HHV-2: Genital lesions (clinically similar to HHV-1).
  • HHV-3: Varicella-Zoster Virus (VZV), which causes Chickenpox initially and Shingles upon reactivation.
  • CMV (Cytomegalovirus): A severe opportunistic infection.
  • Advertisements

1. The Prototype: Acyclovir & Valacyclovir

Acyclovir is a Guanine analogue exclusively active against the Herpes group (HSV-1, HSV-2, and VZV). Valacyclovir is simply its prodrug, designed for much better oral bioavailability.

The Genius of Acyclovir's Mechanism

Acyclovir is an acyclic guanosine derivative. To become active, it must be phosphorylated three times (converted to AcycloGTP).

  1. The very first phosphate can ONLY be added by a specific viral enzyme: Viral Thymidine Kinase.
  2. Because human cells lack this specific kinase, the drug remains completely inactive (and harmless) in healthy cells. It has a 200x higher affinity for viral enzymes than mammalian enzymes!
  3. Once monophosphorylated by the virus, host cellular kinases add the next two phosphates.
  4. Active AcycloGTP then selectively inhibits viral DNA polymerase by competing with endogenous dGTP, and incorporates into the viral DNA, causing immediate chain termination.
  • Clinical Uses: Oral, IV, and Topical formulations for HSV and VZV. It is NOT effective for CMV because CMV lacks the thymidine kinase enzyme!
  • Resistance Mechanism: The virus outsmarts the drug by mutating its viral thymidine kinase (so the drug never gets activated) or mutating its DNA polymerase. This creates cross-resistance to valacyclovir, famciclovir, and ganciclovir.
  • Toxicity: Generally safe (nausea, diarrhea, headache). However, because it is cleared by glomerular filtration and tubular secretion, high IV doses can cause Renal Insufficiency (crystal nephropathy) and Encephalopathy (tremors, delirium).

2. Anti-Cytomegalovirus (CMV) Agents

CMV is an extremely dangerous opportunistic infection. It is a major cause of death and multi-organ disease (pneumonia, hepatitis, gastroenteritis, retinitis leading to blindness, and encephalitis) in people with AIDS, bone marrow/stem cell transplant (HCT) recipients, and those undergoing chemotherapy.

Ganciclovir & Valganciclovir

Acyclic guanosine analogs (Valganciclovir is the high-bioavailability oral prodrug suitable for chronic outpatient management).

  • MOA: Similar to Acyclovir, but in CMV, the first phosphorylation is catalyzed by a specific CMV phosphotransferase enzyme called UL97.
  • Uses: The Drug of Choice (DOC) for CMV retinitis, pneumonia, colitis. Also active against HSV, VZV, and EBV.
  • Severe Toxicity: Highly toxic! Causes profound Bone Marrow Suppression (Leukopenia in 40%, Thrombocytopenia in 20%) and CNS effects (psychosis, coma, convulsions). 1/3 of patients must stop therapy due to toxicity.
Cidofovir

A Cytidine monophosphate (Nucleo T ide) analog given IV only.

  • MOA: Because it already has one phosphate group, it skips viral kinase activation entirely. It is directly phosphorylated to its active diphosphate form to inhibit viral DNA polymerase.
  • Uses: CMV retinitis, especially in ganciclovir-resistant strains. Investigational for HPV, adenovirus, and BK virus.
  • Toxicity: Severe, dose-limiting Nephrotoxicity. Must be co-administered with oral probenecid to reduce renal toxicity.
High Yield Exception: Foscarnet

Foscarnet is entirely unique. It is NOT a nucleoside or nucleotide. It is an inorganic pyrophosphate analog.

  • Mechanism: It does NOT require any activation by phosphorylation. It binds directly to the pyrophosphate binding site of viral DNA polymerase (and HIV Reverse Transcriptase) and inhibits DNA chain elongation directly.
  • Uses: Used IV for CMV retinitis and HSV/VZV infections that are heavily resistant to Acyclovir and Ganciclovir.
  • Severe Side Effects: Nephrotoxicity (most common ADR, 25% of patients) and profound Electrolyte Disturbances. It chelates divalent cations causing massive Hypocalcemia, hypomagnesemia, hypokalemia, which can lead to seizures.

Highly Specialized Agents

  • Fomivirsen: An Antisense Oligonucleotide (synthetic antisense RNA). It binds perfectly to CMV immediate-early mRNA, physically blocking its translation into viral protein. Used via direct intravitreal injection into the eye for CMV retinitis. It was the first antisense drug approved for humans, though rarely used now.
  • Trifluridine: A thymidine nucleoside analog. Because it lacks selectivity (it is phosphorylated by host kinases and inhibits both viral AND human host DNA polymerases), it is highly toxic systemically. Therefore, it is only used topically (1% ophthalmic drops) for acyclovir-resistant ocular HSV keratoconjunctivitis/keratitis. Side effects include eye irritation and lid edema.

V. Anti-Hepatitis Agents (HBV & HCV)

Nucleosides/Nucleotides
  • Lamivudine (3TC): A Cytidine analog (NRTI). Phosphorylated intracellularly to inhibit both HIV reverse transcriptase and HBV DNA polymerase. Uses: HIV and Hepatitis B. Resistance: Can occur via HBV YMDD motif mutation.
  • Adefovir Dipivoxil: An Adenosine monophosphate analog (Nucleotide). Competitively inhibits HBV DNA polymerase → chain termination. Uses: Chronic Hep B. Side effect: Nephrotoxicity.
  • Tenofovir (TDF/TAF): Adenosine monophosphate analog (Nucleotide). Inhibits HBV DNA pol and HIV RT. Uses: Backbone of HIV ART and first-line monotherapy for Hep B.
Ribavirin

A broad-spectrum Guanosine analog.

  • MOA: Highly complex. Phosphorylated by host enzymes → inhibits capping of viral mRNA, inhibits viral RNA-dependent RNA polymerase, induces lethal mutagenesis, and depletes GTP pools via IMP dehydrogenase inhibition.
  • Uses: Chronic HCV (with interferon) and RSV.
  • Toxicity: Hemolytic anemia. Highly Teratogenic (strictly avoid in pregnancy!).

Interferons (Alfa & Pegylated)

Interferons are natural immunomodulators (cytokines) with antiviral and anticancer properties. Recombinant Type I interferon binds to cell surface receptors and induces host enzymes to inhibit viral RNA translation, degrade viral mRNA/tRNA, and halt virion assembly.

  • Clinical Uses: Hepatitis B and C, HPV warts, Kaposi's sarcoma, Hairy cell leukemia, and melanoma.
  • Pegylation Concept: Pegylated Interferon Alpha has a linear or branched Polyethylene Glycol (PEG) moiety attached to it. This vastly increases the drug's half-life and provides steady drug concentrations, meaning less frequent dosing and sustained antiviral activity.
  • Toxicity: Severe "Flu-like syndrome", Bone Marrow suppression, and profound CNS effects.

VI. Anti-Influenza Agents

Used to prevent and treat Influenza A and B, including H5N1 (avian flu) and the novel 2009 H1N1 (swine flu).

Advertisements

FeatureAmantadine & Rimantadine (Uncoating Inhibitors)Oseltamivir & Zanamivir (Neuraminidase Inhibitors)
Mechanism of ActionAdamantane derivatives. They bind to the M2 proton ion channel protein, preventing the acidification of the virus. This physically blocks viral uncoating (disassembling).Analogues of sialic acid. They competitively inhibit the surface enzyme Neuraminidase. Neuraminidase normally cleaves sialic acid residues to allow newly formed viruses to break free. Inhibiting it causes virions to clump to the host cell, preventing viral release and spread.
Effective AgainstInfluenza A ONLY. (Due to high resistance in circulating strains, clinical use is now heavily limited).Both Influenza A and B. Active against current H3N2 and H1N1 strains.
PharmacokineticsOral. Rimantadine is 4-10x more potent than Amantadine.Oseltamivir (Tamiflu): Oral Prodrug activated by hepatic esterases (Age ≥2 weeks).
Zanamivir: Active drug given via Inhalation (Diskhaler) (Age ≥7 years).
Specific Side EffectsAmantadine: High CNS penetration (confusion, dizziness, insomnia, Livedo reticularis). Also treats Parkinson's disease.
Rimantadine: Lower CNS penetration, mostly GI upset.
Oseltamivir: Nausea, vomiting.
Zanamivir: Severe bronchospasm and cough (Contraindicated in Asthma/COPD patients!).

VII. HIV and Antiretroviral Therapy (ART)

To treat HIV/AIDS, we use a cocktail of drugs that attack different stages of the HIV replication cycle.

The 9 Stages of HIV Replication
  1. Attachment: HIV binds to CD4 receptors and co-receptors (CCR5/CXCR4).
  2. Fusion/Entry: Viral envelope fuses with the host-cell membrane.
  3. Reverse Transcription: Viral RNA is converted into DNA by reverse transcriptase.
  4. Integration: Viral DNA enters the nucleus and is spliced into the host-cell DNA by integrase.
  5. Transcription: Integrated DNA directs production of viral RNA.
  6. Translation: Viral RNA produces viral proteins.
  7. Assembly: RNA and proteins assemble into immature particles.
  8. Budding: New particles bud from the membrane.
  9. Maturation: Viral protease cleaves viral proteins, creating a mature, infectious HIV particle.

1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

Examples: Zidovudine (AZT), Lamivudine (3TC), Abacavir (ABC), Emtricitabine (FTC), Tenofovir (TDF/TAF), Didanosine, Zalcitabine, Stavudine.

  • Mechanism: They are fake building blocks. They enter via passive diffusion, are phosphorylated to the triphosphate form, and competitively inhibit the viral Reverse Transcriptase enzyme, causing chain termination.
  • Zidovudine (AZT) Specifics: A deoxythymidine analog. Highly effective in preventing mother-to-newborn transmission. Major Toxicity: Severe Myelosuppression (anemia, neutropenia), GI intolerance, headaches, and insomnia.
  • Other Specific NRTI Toxicities (Highly Testable):
    • Didanosine: Can cause severe, fatal Pancreatitis.
    • Zalcitabine & Stavudine: High risk of painful Peripheral Neuropathy.
    • Abacavir: Very effective, but can cause a fatal, genetically-linked Hypersensitivity Reaction.

2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Examples: Nevirapine, Delavirdine, Efavirenz.

  • Mechanism: These drugs do NOT compete with nucleosides and do NOT require phosphorylation. They bind directly to an allosteric site on the viral reverse transcriptase enzyme, causing a blockade of RNA/DNA-dependent DNA polymerase activity.
  • Clinical Rules: They are substrates and inhibitors of CYP3A4 (many drug interactions). They can never be given alone.
  • Specific Drugs:
    • Nevirapine: Excellent for preventing mother-to-newborn transmission when given at the onset of labor and to the neonate at delivery.
    • Delavirdine & Efavirenz: Teratogenic. Absolutely contraindicated during pregnancy.

3. Protease Inhibitors (PIs)

Examples: Indinavir, Ritonavir, Saquinavir, Nelfinavir, Amprenavir, Atazanavir, Lopinavir, Darunavir (All end in -navir).

  • Mechanism: They inhibit HIV protease. This prevents the cleavage of viral polyproteins, meaning the cell produces immature, completely non-infectious virions.
  • Class-Wide Toxicity: PIs cause a highly specific syndrome of metabolic derangement: Altered body fat distribution, Insulin resistance, and Hyperlipidemia.
  • Drug-Specific Key Differences:
    • Atazanavir: Causes Hyperbilirubinemia → jaundice.
    • Indinavir: Crystalluria and Kidney Stones (requires extremely good hydration).
    • Ritonavir: A massive CYP3A4 Inhibitor / Pharmacokinetic Booster. It increases concentrations of other HIV drugs by inhibiting their metabolism. Contraindication: Never give with antifungal azoles.
    • Amprenavir: Can cause Stevens-Johnson Syndrome.
    • Saquinavir: Cardiac conduction/QT prolongation concerns.
    • Darunavir: High resistance barrier.
    • Lopinavir: Severe GI + metabolic effects.

4. Other Advanced HIV Drug Classes

Integrase Strand Transfer Inhibitors (INSTIs)

Examples: Dolutegravir, Raltegravir, Bictegravir (End in -tegravir).

Mechanism: They inhibit HIV integrase, preventing the integration of viral DNA into the host-cell genome.

Entry / Fusion Inhibitors

Examples: Maraviroc, Enfuvirtide (T-20).

Enfuvirtide (Fuzeon): Binds to the gp41 subunit of the viral envelope glycoprotein. This prevents the conformational changes required for the viral membrane to fuse with the cellular membrane.
Maraviroc: CCR5 antagonist.
Fostemsavir: Attachment inhibitor.
Ibalizumab: Post-attachment inhibitor.


VIII. Clinical Nursing Implications for Antivirals

Antiviral therapies require stringent clinical oversight and intensive patient education to prevent resistance and manage severe toxicities.

  • Pre-Therapy Assessment: Thoroughly assess underlying disease, medical history, allergies, baseline vital signs, and nutritional status. Assess for contraindications and vast potential for drug-drug interactions (especially with PIs and NNRTIs metabolized by CYP3A4).
  • Infection Control & Application: Teach proper application techniques for topical ointments and aerosol powders. Emphasize strict hand washing before and after administration to prevent site contamination. Patients must wear a glove or finger cot when applying topical antiviral ointments to affected areas to prevent self-inoculation.
  • Patient Education (Crucial!):
    • Inform patients that antiviral agents are not cures. They only help manage symptoms.
    • Instruct patients to strictly consult their physician before taking ANY other medication, including OTC medications.
    • The medication must be taken exactly as prescribed and for the full course of treatment to prevent viral resistance.
    • Specific AZT warning: Inform patients that hair loss MAY occur (rare, but requires preparation), and the medication should be taken on an empty stomach.
  • Monitoring:
    • Side Effects: Effects are extremely varied and specific to each individual agent (monitor kidneys, liver, bone marrow, and CNS).
    • Therapeutic Effects: Effects vary depending on the virus. Look for delayed progression of AIDS and AIDS-Related Complex (ARC), a decrease in flu-like symptoms, decreased frequency of herpes-like flare-ups, or crusting over of herpetic lesions.

References & Further Reading

  • Katzung, B. G. (2020). Basic & Clinical Pharmacology (15th ed.). McGraw-Hill Education. (Detailed mechanisms of NRTIs vs. Nucleotides and Protease Inhibitor metabolic syndromes).
  • Brunton, L. L., et al. (2017). Goodman and Gilman's The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill. (In-depth analysis of anti-herpesvirus and anti-influenza pharmacokinetics).
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. (2022). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services.

Quick Quiz

Antiviral Agents Quiz

Pharmacology

Privacy: Your details are used only for quiz tracking and certificates.

Advertisements

Pharmacology of Antiviral Agents Read More »

Pharmacology of the Renal System: Diuretics

Pharmacology of the Renal System: Diuretics

Pharmacology of the Renal System: Diuretics

I. Introduction: The Kidneys and the Nephron

Pharmacology can seem intimidating, but it becomes beautiful once you understand the underlying physiology. Before we memorize drugs, we must understand the organ they target: The Kidneys.

Physiological Foundation

The main function of the kidneys is to maintain the constancy of the body's "interior environment." They do this by:

  • Eliminating metabolic waste products.
  • Strictly regulating fluid volume, electrolyte content, and blood pH, regardless of dietary intake or environmental demands.
  • Acting as the primary organ by which drugs and their metabolites are eliminated from the body. Because of this, if a patient has renal failure, the dosing regimens of many drugs must be drastically adapted to prevent toxic buildup.

The functional unit of the kidney is the Nephron. Its job is to filter the blood and form a protein-free plasma filtrate (Ultrafiltration). The nephron is a tubular structure consisting of specific segments, each with unique transport mechanisms:

  1. Renal Corpuscle (Glomerulus + Bowman's Capsule): Where filtration begins.
  2. Proximal Convoluted Tubule (PCT): The heavy worker, reabsorbing the bulk of water and solutes.
  3. Loop of Henle (Descending and Ascending limbs): Creates the concentration gradient.
  4. Distal Convoluted Tubule (DCT): Fine-tunes the filtrate.
  5. Collecting Duct: The final arbiter of water and potassium balance.

II. Clinical Case Study: The Presentation of Fluid Overload

Let us anchor our pharmacological knowledge to a real patient presentation.

Emergency Department Case

Patient: A 65-year-old man comes to the ER with severe shortness of breath. His wife reports he has long-standing hypertension but refused medications because he "felt fine."

Presentation: Over the last month, he noted increasing ankle edema, reduced exercise tolerance, and difficulty sleeping while lying flat (orthopnea). He now has pitting edema up to his knees and is acutely uncomfortable lying down. He denies chest pain.

Vitals & Exam: Blood pressure is 190/140 mm Hg, pulse 120 bpm, respiratory rate 20/min. Chest auscultation reveals loud rhonchi (fluid in the lungs). ECG shows Left Ventricular Hypertrophy (LVH).


1. What is the diagnosis?
Acute Pulmonary Edema secondary to Congestive Heart Failure (CHF). His untreated chronic hypertension severely increased the heart's workload (afterload), causing LVH and eventual left ventricular failure. Fluid has backed up into his lungs and systemic circulation.

2. What diuretic is most appropriate?
A Loop Diuretic (like Furosemide). He requires rapid, massive mobilization of fluid from his lungs and systemic circulation to save his life.

3. What are the possible toxicities?
Hypokalemia, severe dehydration, hypotension, ototoxicity (deafness), and hyperuricemia.


III. Diuretics: General Principles & Cardiovascular Effects

Diuretics are crucial for the management of Cardiovascular (CVS) diseases. By definition, diuretics are drugs that block renal ionic transport (specifically the reabsorption of Na+ and Cl-). This blockade causes diuresis (an increase in urine volume), which is almost always associated with natriuresis (an increase in Na+ excretion).

  • The 1% Rule: The increase in urine flow is directly related to the amount of Na+/Cl- reabsorption blocked. If a drug blocks just 1% of normal solute reabsorption, urine output will increase by a massive 1.8 Liters per day!

How Diuretics Help the Heart (CVS Effects)

You might wonder, why do we use kidney drugs for heart problems? Here is the physiological chain reaction:

  1. Diuretics decrease Na+ and water balance, leading to a decrease in total blood volume and venous pressure.
  2. This directly decreases the preload (the volume of blood filling the heart), which drops ventricular stroke volume and cardiac output, safely lowering arterial blood pressure.
  3. The decrease in venous pressure reduces capillary hydrostatic pressure. This stops fluid from leaking out of the vessels and promotes fluid reabsorption back into the blood, effectively reducing edema (swelling).
  4. Long-term Effect: Prolonged use of diuretics results in a fall in systemic vascular resistance (by mechanisms still somewhat unknown), which helps sustain long-term reductions in blood pressure.

Mechanisms of Action

Diuretics force the body to lose water through four main pathways:

1. Blocking Transport Proteins

Directly plugging the channels that reabsorb ions. Includes Loop Diuretics and Thiazides.

2. Hormonal Antagonism

Blocking the receptors for hormones that tell the kidney to save water. Includes Potassium-Sparing Diuretics (Aldosterone antagonists).

3. Osmotic Effects

Creating a heavy, sugary pull inside the urine tube that traps water and prevents it from leaving. Includes Osmotic Diuretics.

4. Enzyme Inhibition

Blocking the chemical reactions needed to reabsorb bicarbonate. Includes Carbonic Anhydrase Inhibitors.


IV. Loop Diuretics (High-Ceiling Diuretics)

Examples: Furosemide (Lasix - Prototype), Bumetanide, Torsemide, Ethacrynic acid.

These are the most powerful and effective diuretics available. They produce a greater loss of fluids and electrolytes than any other class.

Advertisements

  • Site of Action: They act specifically on the Thick Ascending Limb (TAL) of Henle's loop.
  • Mechanism of Action: They directly block the Na+/K+/2Cl- co-transporter on the luminal membrane. Normally, this massive pump reabsorbs 25% of all filtered NaCl. By blocking it, a massive amount of sodium (and therefore water) stays in the urine. They also induce the renal synthesis of prostaglandins, which vasodilates renal blood vessels.

1. Pharmacokinetics

  • Oral Administration: Diuresis begins in 60 minutes and persists for about 8 hours.
  • Intravenous (IV) Admin: Diuresis begins in 2 minutes and persists for 2 hours (perfect for the emergency room).
  • Undergoes hepatic metabolism and active renal excretion (secreted into the proximal tubule).

2. Therapeutic Uses

Used strictly for patients requiring rapid or massive mobilization of fluids:

  • Acute Pulmonary Edema: This is their major use.
  • Congestive Heart Failure (CHF): When severe diminution of Extracellular Fluid (ECF) volume is required to minimize venous and pulmonary congestion.
  • Cirrhosis of the liver complicated by ascites (fluid in the abdomen).
  • Severe edema of Nephrotic Syndrome or Renal Failure.
  • Severe Hypertension: Used when BP is uncontrolled by other diuretics. (Note: their short half-life makes them less useful than thiazides for standard, mild hypertension).
  • Hypercalcemia: Because they force calcium out in the urine.

3. Adverse Drug Reactions (ADRs)

Because they are so powerful, their side effects are severe derivations of electrolyte loss:

The "Hypo" State
  • Hyponatremia (low sodium) and Hypochloremia (low chloride).
  • Hypocalcemia (low calcium) and Hypomagnesemia (low magnesium).
  • Hypokalemia (Low Potassium): By blocking Na+ in the loop, a massive wave of unabsorbed Na+ reaches the distal tubule. The distal tubule frantically tries to save this Na+, but to do so, it must trade and throw away K+ and H+. This massive loss of K+ is highly dangerous and causes arrhythmias. The loss of H+ leads to Metabolic Alkalosis.
Advanced Physiology: Hypokalemia and Insulin

Loop diuretics can strangely cause Hyperglycemia (high blood sugar) in diabetic patients. Why? It all connects to cell membrane potentials.

  1. As the diuretic forces Potassium (K+) out of the body, extracellular fluid K+ drops.
  2. This increases the concentration gradient across cell membranes, causing K+ to aggressively diffuse out of cells, removing positive charges from the inside.
  3. The Resting Membrane Potential (RMP) becomes excessively negative (Hyperpolarized).
  4. Now, it is much harder for the cell to reach the threshold voltage required to open Voltage-Gated Calcium (Ca 2+) channels.
  5. In the Pancreatic β-cells, calcium influx is what triggers the release of insulin. Because the channels won't open, insulin secretion is drastically reduced, leading to high blood sugar!
  • Dehydration (Hypovolemia): Leading to severe hypotension and fainting.
  • Uric Acid Effects:
    • Acute Admin: Hypouricemia (increases uric acid excretion).
    • Chronic Admin: Hyperuricemia and Gout. Dehydration causes the proximal tubule to hyper-absorb. Also, the diuretic competes with uric acid for the organic secretory pump in the proximal tubule. The diuretic wins, leaving uric acid trapped in the blood, settling into joints to cause painful Gout.
  • Metabolic: Hypercholesterolemia, hypertriglyceridemia, increased LDL.
  • Ototoxicity: Dose-related tinnitus (ringing), hearing impairment, deafness, vertigo, and a sense of fullness in the ears. The inner ear uses similar electrolyte transport mechanisms, which the drug accidentally blocks.
  • Others: Rashes, photosensitivity, paresthesias, bone marrow depression, and GI disturbances.

4. Drug Interactions

  • Digitalis: Hypokalemia vastly potentiates digitalis toxicity (fatal arrhythmias).
  • NSAIDs (Ibuprofen): Reduces the diuretic efficacy! NSAIDs block prostaglandin (PGE2) synthesis. Without PGE2, Na+ reabsorption is favored, fighting the diuretic.
  • Aminoglycosides & Cisplatin: Highly enhances the risk of permanent ototoxicity and nephrotoxicity.
  • Antiarrhythmics (Quinidine): A potentially lethal interaction. Quinidine prolongs the QT interval. Loop-induced hypokalemia wildly increases the risk of Torsades de pointes (a fatal polymorphic ventricular tachycardia) triggered by early after-depolarizations.
  • Lithium: Causes Lithium toxicity due to decreased renal elimination.
  • Thiazides: Synergism! Combining them leads to profound, dangerous diuresis.
  • Corticosteroids / Amphotericin B: Intensify the dangerous loss of potassium.

Examples: Hydrochlorothiazide (Prototype), Bendroflumethiazide, Chlorothiazide. Related: Metolazone, Chlorthalidone, Indapamide.

These are the most commonly used diuretics globally. They are weak diuretics but also possess mild intrinsic vasodilator properties, making them exceptional for blood pressure control.

  • Site & Mechanism of Action: They act on the Distal Convoluted Tubule (DCT). They physically block the Na+/Cl- co-transporter, preventing sodium and chloride reabsorption, forcing water to follow it into the urine.
  • Kidney Dependency: They are significantly less powerful than loop diuretics. Crucially, their action heavily depends on adequate kidney function; they are ineffective when GFR is low (unlike loop diuretics, which still work in renal failure).
  • Advertisements

The Calcium Paradox

While Loop diuretics force calcium out of the body, Thiazides force the body to retain calcium.

  1. Blocking the Na+/Cl- pump drops intracellular sodium levels in the DCT.
  2. This creates a strong gradient, pulling Na+ into the cell from the basolateral (blood) side via the Na+/Ca 2+ exchanger.
  3. As Na+ rushes in, Calcium is rapidly pumped out into the blood.
  4. This drops intracellular Calcium, which pulls more Calcium out of the urine filtrate. Thus, Thiazides elevate serum Ca 2+ (Hypercalcemia) and decrease urine calcium.

1. Pharmacokinetics

  • Taken orally, usually once a day.
  • Onset is 2 hours after administration. Peaks at 4-6 hours and persists for up to 12 hours.

2. Therapeutic Uses

  • Hypertension: The absolute preferred first-line agent in uncomplicated hypertension. They are better tolerated than loops and clinical trials prove they reduce the risk of stroke and heart attacks.
  • Mild/Moderate Edema: Used in mild CHF (though loops are preferred for severe cases).
  • Severe Resistant Edema: Metolazone is famous for being used synergistically with loop diuretics to break stubborn edema.
  • Idiopathic Hypercalciuria: Because they pull calcium out of the urine, they are given to prevent recurrent calcium kidney stone formation.
  • Nephrogenic Diabetes Insipidus: Paradoxically, they reduce urine volume by up to 50% in this disease, though the exact mechanism remains mysterious.

3. Adverse Drug Reactions (ADRs)

Many ADRs are identical to Loop diuretics, but with a few key differences:

  • Electrolytes: Hypokalemia, Hyponatremia, Hypochloremia, Hypomagnesemia. Metabolic alkalosis. Unlike Loops, they cause Hypercalcemia.
  • Metabolic: Hyperuricemia (chronic use = Gout), Hyperglycemia (in diabetics), Hypercholesterolemia, hypertriglyceridemia, increased LDL.
  • Azotemia: Toxic buildup of nitrogenous waste in patients with pre-existing renal disease.
  • Male Impotence: The reduced blood volume and arterial pressure cause massive activation of the RAAS system. This leads to systemic vasoconstriction, severely impacting erectile function.
  • Idiosyncratic: Rashes, and blood dyscrasias like thrombocytopenia (low platelets).

4. Interactions

Similar to Loops: Hypokalemia potentiates Digitalis toxicity and quinidine-induced Torsades de pointes. NSAIDs reduce their efficacy. Bile acid sequestrants reduce their absorption from the gut. Corticosteroids worsen hypokalemia. They diminish the effect of insulin/sulfonylureas. They induce Lithium toxicity.


VI. Potassium-Sparing Diuretics

These are very weak diuretics. They are rarely used alone. Their entire purpose is to be used in conjunction with loop and thiazide diuretics. They provide two useful responses: a modest increase in urine, and a substantial decrease in K+ excretion, acting as a shield against the fatal hypokalemia caused by the stronger drugs.

They are divided into two subcategories based on exactly how they work in the collecting duct.

Category 1: Aldosterone Antagonists

Spironolactone (Aldactone) & Eplerenone

Aldosterone is a hormone released by the adrenal cortex (stimulated by Angiotensin II). It acts on the genetics of the kidney cell to express apical Na+ channels, causing the body to retain Na+ and throw away K+ and H+.

  • Mechanism: Spironolactone is a steroid hormone analogue. It competitively binds and blocks the aldosterone receptor in the distal nephron. This prevents the expression of those channels, causing the exact opposite effect: Retention of K+ and excretion of Na+.
  • Kinetics: Well absorbed from the gut. Because it works on cellular genetics (making/destroying proteins), its onset is very slow (taking 48 hours to work). Spironolactone's active metabolite is Canrenone (t½ 16 hrs). Eplerenone has a shorter half-life and no active metabolites. Taken orally once daily.
Category 2: Non-Aldosterone Antagonists

Triamterene & Amiloride

These drugs do not care about the aldosterone receptor or genetics.

  • Mechanism: They physically bind to and block the apical Na+ channel (ENaC) in the distal tubule and collecting duct. By plugging the hole, they stop the Na+/K+ exchange entirely, immediately inhibiting K+ loss.
  • They produce only a very modest diuresis.

Uses & Adverse Effects of Potassium-Sparing Diuretics

  • Uses (Spironolactone): Added to K+-losing diuretics to prevent dangerous hypokalemia (especially in patients on digoxin or amiodarone). It is the diuretic of choice for hepatic cirrhosis and nephrotic syndrome. Added to heart failure therapy to prevent fibrotic remodeling of the heart. Used to treat Primary (Conn's Syndrome) and Secondary hyperaldosteronism.
  • Dangerous ADR: Hyperkalemia. Retaining too much potassium is just as fatal as losing it. This can stop the heart.
  • Endocrine ADRs (Spironolactone only): Because spironolactone is a steroid, it accidentally acts on progesterone and androgen receptors throughout the body. This results in Gynecomastia (male breast tissue growth), menstrual disorders, and testicular atrophy.
  • Contraindications: Absolutely contraindicated in patients who already have hyperkalemia, or patients at high risk (renal failure, patients on ACE inhibitors, or taking K+ supplements).
  • Advertisements


VII. Osmotic Diuretics

Examples: Mannitol (Osmitrol, mostly IV), Urea (IV), Glycerin (oral), Isosorbide (oral).

These drugs act completely differently from the others. Mannitol is simply a sugar molecule. It acts like a molecular "sponge" moving through the blood and kidneys.

  • Mechanism of Action: Mannitol is freely filtered in the glomerulus. It undergoes minimal reabsorption, is not metabolized, and is pharmacologically inert. Once inside the lumen of the nephron, it creates a massive osmotic force. It literally holds onto water, inhibiting passive reabsorption, thereby wildly increasing urine flow. It has no significant direct effect on the excretion of K+ or other electrolytes.
  • Kinetics: Very poorly absorbed by the GIT. If you drink it, it stays in the gut and pulls water into the intestines, causing osmotic diarrhea. Therefore, for systemic effects on the kidneys or brain, it must be given IV. Distributes entirely into extracellular water. Diuresis begins in 30-60 mins and lasts 6 hours.

Therapeutic Uses & Severe Warnings

  • Uses: Prophylaxis of acute renal failure (to forcefully maintain urine flow and wash out debris).
    Brain & Eye: In the brain, its hyperosmotic presence in the blood draws water out of the swollen brain tissue, reducing Intracranial Pressure (ICP). It works the exact same way in the eye, pulling out intraocular fluid to reduce Intraocular Pressure (IOP).
  • Adverse Effects: Transient expansion of ECF volume. Before mannitol gets filtered by the kidneys, it sits in the blood and pulls water out of the body's tissues into the vascular system. This suddenly expands blood volume, carrying a massive risk of causing Left Ventricular Failure (Pulmonary Edema) in a weak heart.
  • Also causes dilutional hyponatremia, leading to headache, nausea, and vomiting.

VIII. Carbonic Anhydrase Inhibitors (CAIs)

Examples: Acetazolamide (Diamox, Glaumox), Dichlorphenamide (Daranide), Methazolamide (Glauctabs).

These are very weak diuretics and are rarely used to mobilize fluid. Their value lies in their ability to manipulate body pH and specific fluid pressures.

Mechanism: The Bicarbonate Cycle

In the Proximal Tubule, the body wants to save Bicarbonate (HCO 3-) to keep the blood alkaline. However, bicarbonate cannot cross the cell membrane directly.

  1. In the urine, HCO 3- binds with H+ to form H 2 CO 3.
  2. The enzyme Carbonic Anhydrase breaks this into H 2 O and CO 2.
  3. These gases easily diffuse into the cell. Inside the cell, Carbonic Anhydrase stitches them back together into HCO 3-, which is then pumped back into the blood.

The Drugs: CAIs block this enzyme. Bicarbonate is trapped in the urine. Therefore, they increase the excretion of Bicarbonate, along with accompanying Na+, K+, and water. This results in the flow of a highly alkaline urine, while the blood becomes acidic.

Therapeutic Uses

  • Glaucoma: Carbonic anhydrase is present in extrarenal tissues. In the ciliary processes of the eye, it mediates the formation of large amounts of bicarbonate into aqueous humor. Inhibiting it drops the formation of eye fluid, reducing IOP. Used in Open-angle and secondary/pre-operative acute angle-closure glaucoma.
  • Acute Altitude Sickness: In the erythrocytes, CAIs interfere with CO 2 transport. This effectively increases CO 2 in peripheral tissues and drops it in expired gas. This mild induced acidosis stimulates the brain to breathe deeper and faster, treating altitude sickness. (More effective if given prophylactically).
  • Infantile Epilepsy: Acetazolamide creates a mild metabolic acidosis which has a direct anticonvulsant action in the CNS (though rapid tolerance limits usefulness).
  • Correcting Alkalosis: Specifically metabolic alkalosis caused by severe diuretic-induced H+ excretion.
Adverse Drug Reactions & Contraindications
  • Sulfonamide Allergy: They are sulfa-derivatives. They can cause bone marrow depression, severe skin toxicity, renal lesions, and allergic reactions.
  • CNS: Large doses cause drowsiness, paresthesias (tingling), and somnolence.
  • Hepatic Encephalopathy Risk: Because the urine becomes alkaline, ammonia (NH 3) from the kidney is not trapped as ammonium in the urine. It is diverted back into the systemic circulation. This can travel to the brain and worsen hepatic encephalopathy. Absolutely contraindicated in hepatic cirrhosis!
  • Kidney Stones: Precipitation of calcium phosphate salts in the alkaline urine causes calculus formation and ureteral colic.
  • Acidosis Risk: Worsens metabolic/respiratory acidosis. Contraindicated in hyperchloremic acidosis or severe COPD.
  • Reduces the urinary excretion of weak organic bases.

IX. Summary: General Indications for Diuretics

1. Edema

Urinary output will increase, flushing excess, pooled fluid out of the body tissues (Loop diuretics primarily).

2. Congestive Heart Failure (CHF)

The aggressive sodium loss in the kidney is directly associated with water loss, reducing the preload crushing the failing heart.

3. Hypertension

Diuretics (Thiazides primarily) decrease total blood volume, serum sodium, and eventually systemic vascular resistance.

4. Glaucoma & High ICP

Osmotic diuretics provide a physical osmotic pull to remove fluid, while CAIs stop the chemical formation of aqueous humor to decrease IOP.

Quick Quiz

Diuretics Pharmacology Quiz

Pharmacology

Privacy: Your details are used only for quiz tracking and certificates.

Advertisements

Pharmacology of the Renal System: Diuretics Read More »

Thyroid and Antithyroid Drugs

Thyroid and Antithyroid Drugs

Thyroid and Antithyroid Drugs

Pharmacology of the Thyroid and Antithyroid Drugs

I. Introduction and Clinical Case Study

Pharmacology is best understood when applied to real clinical scenarios. Let us examine a comprehensive case study to introduce thyroid pathology.

Clinical Case Study: Case 537

Patient Presentation: An 11-year-old female with no significant past medical history presented with symptoms of weight loss and heat intolerance. She has also experienced a decline in grades at school. Her family history is significant for thyroid disease in both grandmothers (both are currently on thyroid replacement therapies).

Laboratory Investigations & Results: The clinician ordered comprehensive thyroid function tests:

  • Free Thyroxine (FT4): 2.87 ng/dL (High; Prepubertal ref: 0.73-1.77 / Pubertal-Adult ref: 0.73-1.84)
  • Total Triiodothyronine (T3): 374.00 ng/dL (High; Pediatric ref: 123-211)
  • Thyroid-Stimulating Hormone (TSH): <0.018 uU/ml (Suppressed)
  • Thyroxine (T4): 18.2 ug/dL (High; Ref: 5.0-12.0)
  • Antithyroglobulin antibodies: >3000 IU/ml (Strongly Positive; Negative is <60, Equivocal 60-100, Positive >100 IU/mL)
  • Antithyroid peroxidase (Anti-TPO) antibodies: 2667 IU/mL (Positive; Ref: <60)
  • Anti-TSH receptor antibodies: 69.6% Inhibition (Positive; Ref: <=16.0%)

Questions & Clinical Reasoning:

  1. What is the diagnosis? Hyperthyroidism secondary to Graves' disease. The elevated T3/T4 and suppressed TSH indicate primary hyperthyroidism. The presence of Anti-TSH receptor antibodies confirms the autoimmune etiology (Graves' disease).
  2. How should this patient be managed? Medical management with Antithyroid drugs (Thioamides like Methimazole) and Beta-blockers for symptomatic control, as radioiodine or surgery is generally reserved or delayed in young children.

II. Basic Thyroid Gland Physiology & Functions

The thyroid is a bilobed gland located in the neck, sitting below the thyroid cartilage and in front of the cricoid cartilage and trachea. It contains large stores of thyroid hormone bound in the form of thyroglobulin. These massive stores maintain systemic concentrations of thyroid hormone despite daily variations in dietary iodine availability and nutritional intake.

1. The Hormones Produced

The thyroid gland is the source of two fundamentally different types of hormones:

  • Thyroid Follicles: Produce the iodothyronine hormones: Tetraiodothyronine / Thyroxine (T4) and 3,5,3-triiodothyronine (T3).
  • Parafollicular Cells (C-cells): Produce Calcitonin, a hormone directly involved in the control of plasma Calcium (Ca 2+) and bone health.

2. Systemic Functions of Thyroid Hormones

Thyroid hormones are essential for normal growth, development, and maintaining metabolic homeostasis. They influence the function of virtually all organ systems:

Neurological & Brain Development

Essential for normal development of the Central Nervous System (CNS). In a healthy brain, it promotes neurogenesis, glucose metabolism, synaptic transmission, structural spine formation, and cell migration/proliferation.

Neurological Disorders linked to dysfunction: Alzheimer's disease, Depression, and Autism spectrum disorder.

Metabolism & Organ Function
  • Metabolism: Mitochondrial biogenesis, increased basal metabolism, and metabolism of proteins, carbohydrates, and lipids.
  • Cardiovascular: Regulates heart function and contractions.
  • Other systems: Regulates digestion, bone formation and health, and kidney clearance rates.

3. The Hypothalamic-Pituitary-Thyroid Axis

The secretion of thyroid hormones is controlled by a delicate negative feedback loop:

  • Hypothalamus: Releases Thyrotrophin-releasing hormone (TRH) in response to stimuli. Note: Acute psychosis, severe stress, or circadian/pulsatile rhythms (prolonged exposure to cold) activate this axis.
  • Anterior Pituitary: TRH stimulates the release of Thyroid-stimulating hormone (TSH). Note: Somatostatin, Corticoids, and Dopamine directly inhibit TSH release.
  • Thyroid Gland: TSH stimulates T4 and T3 synthesis and release.
  • Negative Feedback: Circulating T3 and T4 in turn inhibit both TRH and TSH synthesis and release to maintain balance.

III. Synthesis, Storage, Release & Metabolism of T3 and T4

Small amounts of iodide are absolutely necessary for hormone production, but interestingly, large amounts of endogenous or exogenous iodide actively inhibit T3 and T4 production and release. The synthesis involves five highly specific main steps:

The 5 Steps of Synthesis & Pharmacological Targets
  1. Trapping (Uptake): Uptake of plasma iodide (I-) by the follicle cells via the Sodium-Iodide Symporter (NIS). Pharmacology: Ionic inhibitors block this step 1.
  2. Oxidation: Oxidation of iodide to iodine by the enzyme Thyroidal Peroxidase (TPO). Pharmacology: Thioamides (Propylthiouracil and Carbimazole) inhibit step 2.
  3. Organification: Iodination of tyrosine residues on the thyroglobulin molecule. Pendrin assists in moving iodine into the colloid. This forms Monoiodotyrosine (MIT) and Diiodotyrosine (DIT).
  4. Coupling: MIT + DIT = T3. DIT + DIT = T4.
  5. Secretion (Proteolysis): Endocytosis of the colloid back into the cell, where lysosomes cause proteolysis of thyroglobulin, releasing free T3 and T4 into the blood. Pharmacology: Excess Iodine interferes with steps 1, 2, 3, and 5. Propylthiouracil (PTU) also blocks peripheral conversion (step 6).

Peripheral Metabolism of Thyroxine

T4 is released into the peripheral blood where it undergoes metabolism inside cells:

  • Activation: Deiodination of T4 yields 3,5,3'-Triiodothyronine (Active T3).
  • Inactivation: Deiodination can also yield 3,3',5'-Triiodothyronine (Reverse T3), which is inactive. Further inactivation occurs via Deamination, Decarboxylation, and Conjugation (glucuronide or sulfate) in the liver.

Summary of Thyroid Hormone Kinetics

Advertisements

VariableThyroxine (T4)Triiodothyronine (T3)
Volume of Distribution10 L40 L
Extrathyroidal Pool800 mcg54 mcg
Daily Production75 mcg25 mcg
Fractional Turnover per day10%60%
Metabolic Clearance per day1.1 L24 L
Half-life (Biologic)7 Days1 Day
Serum Levels (Total)4.8 - 10.4 mcg/dL60 - 181 ng/dL
Serum Levels (Free)0.8 - 2.7 ng/dL230 - 420 pg/dL
Amount Bound to Protein99.96%99.6%
Biologic Potency14 (Four times more potent)
Oral Absorption80%95%

IV. Disorders of the Thyroid Gland

Thyroid problems are very common and consist of two general presentations:

  1. Changes in size or shape of the gland: Nodules and Goiter. A Simple non-toxic goitre is usually caused by dietary iodine deficiency and typically presents with normal thyroid function.
  2. Changes in the secretion of hormones: Overt hyperthyroidism or hypothyroidism. These present the clinician with dramatic clinical manifestations. Note: If the thyroid can no longer produce T3 and T4, there is no negative feedback to the hypothalamus and anterior pituitary, causing TSH to skyrocket.

V. Hypothyroidism

Hyposecretion of T3 and T4 leads to a massive reduction in the body's metabolic rate.

1. Clinical Presentations

  • Cretinism (Infants): The most prevalent endocrine disorder in the newborn. Caused by congenital absence or incomplete development of the thyroid. Characterized by gross retardation of physical growth and profound mental deficiency.
  • Myxoedema (Adults): Severe cases in adults. Manifestations include a low metabolic rate, slow speech, deep hoarse voice, lethargy, bradycardia, sensitivity to cold, and mental impairment. Patients develop a characteristic thickening of the skin (puffy appearance, non-pitting edema), which gives myxoedema its name.

2. Causes of Hypothyroidism

  • Hashimoto's Thyroiditis: A chronic autoimmune disease where an immune reaction destroys thyroglobulin or other components of thyroid tissue.
  • Iatrogenic: Therapy of thyroid tumors with surgery or radioiodine.
  • Hypopituitarism: Lack of TSH from the pituitary gland.

3. Pharmacological Management: Thyroid Hormones

Used to treat myxoedema, diffuse non-toxic goitre, Hashimoto's thyroiditis, thyroid carcinoma, and neonatal hypothyroidism (which requires prompt treatment for normal development).

A. Levothyroxine Sodium (Synthetic T4)

  • Why it is the Treatment of Choice: Used for maintenance therapy because of its stability, content uniformity, low cost, lack of allergenic foreign protein, easy laboratory measurement of serum levels, and a long half-life (7 days) which permits convenient once-daily administration.
  • Mechanism: It acts as a pro-hormone. T4 is naturally converted to T3 intracellularly; thus, giving T4 effectively produces both hormones in the body.
  • Administration Rules:
    • Orally administered once daily on an empty stomach, 30 minutes to 1 hour before breakfast.
    • Avoid taking with other medications.
    • Always check the patient's pulse before administration.
  • Dosing & Onset: Daily dose is 50-200 mcg/day. It takes 4-6 weeks to reach steady-state concentration (SSC).
  • Note: Used to treat an underactive thyroid (occurring naturally, injured by radiation, or removed by surgery). It is also used to treat certain goiters and thyroid cancer. It should not be used to treat infertility unless the infertility is specifically caused by low thyroid hormone levels.
  • Contraindication: Thyrotoxicosis.

B. Liothyronine Sodium (Synthetic T3)

  • Pharmacokinetics: Taken by mouth (with or without food, usually once daily at the same time each day to keep levels constant). It is 3 to 4 times more potent, more rapidly metabolized, and has a much more rapid effect than levothyroxine. Peak activity is reached within 24 hours. The biologic half-life is 24 hours (two days or less).
  • Disadvantages for Routine Use: It is NOT recommended for routine replacement therapy because its shorter half-life requires multiple daily doses, it has a higher cost, and there is a greater difficulty in monitoring the adequacy of replacement using conventional lab tests.
  • Cardiotoxicity Risk: Because of its greater hormone activity and consequent greater risk of cardiotoxicity, it should be strictly avoided in patients with cardiac disease.
  • Specific Indications: Best used for short-term suppression of TSH, or in severe hypothyroid states where a rapid response is desired. Its rapid action makes it highly useful given intramuscularly (IM) for treating Myxoedema Coma while simultaneously starting maintenance therapy with oral thyroxine.
  • Drug Interactions: Certain medications drastically decrease the absorption of liothyronine. These include: products containing aluminum or magnesium, antacids, sucralfate, calcium supplements, iron, bile acid-binding resins (such as cholestyramine, colestipol, colesevelam), simethicone, sevelamer, and sodium polystyrene sulfonate, among others.
  • Contraindication: Thyrotoxicosis.

C. Other Formulations

  • Liotrix: A synthetic combination of T4 and T3 in a specific 4:1 ratio.
  • Thyroid desiccated: Natural preparations derived from animal thyroids. (Largely replaced by synthetics).
Crucial Warning: Addison's Disease Co-existence

Hypothyroidism sometimes coexists with Addison's disease (both share an autoimmune aetiology). When treating a patient for myxoedema coma (especially if hypopituitarism is suspected), Glucocorticosteroid (hydrocortisone) replacement MUST be started first empirically. If you administer thyroid hormones and rapidly increase the metabolic rate without providing corticosteroids, an Acute Adrenal Insufficiency will be precipitated, which can be fatal.


VI. Hyperthyroidism (Thyrotoxicosis)

In thyrotoxicosis, there is excessive, uncontrolled activity of the thyroid hormones, leading to a hypermetabolic state that affects nearly every organ system.

1. Clinical Presentation

Symptoms include a remarkably high basal metabolic rate, an increase in skin temperature, warm moist skin, sweating, marked intolerance to heat, nervousness, irritability, insomnia, depression, tremor (shaking hands), tachycardia, arrhythmias (specifically atrial fibrillation), high blood pressure, muscle cramps, muscle weakness (proximal myopathy), and increased appetite strangely associated with a loss of weight and a strong feeling of hunger. Other signs include frequent diarrhea, fragile fingernails (Plummer's nails), broken hair/hair loss, menstrual cycle disorders (amenorrhea or oligomenorrhea), and finger clubbing (thyroid acropachy).

Advertisements

2. Types and Causes

There are several types, but only two are extremely common:

  • Graves' Disease (Diffuse Toxic Goitre / Exophthalmic Goitre): The most common cause. An autoimmune disorder where thyroid-stimulating immunoglobulins (TSI) act as antibodies that stimulate the TSH receptor, causing the thyroid to overproduce hormones. Frequently accompanied by exophthalmos (bulging eyes) and pretibial myxedema.
  • Toxic Nodular Goitre (Plummer's Disease): One or more adenomatous nodules grow on the thyroid and independently increase hormone production, escaping the normal pituitary feedback loop.
  • Thyroiditis: Inflammation of the thyroid which causes a "leak" of stored hormones into the blood. Arrives in three different ways: subacute (De Quervain's), postpartum, and silent.
  • Increased Thyroid Hormone Medicine: Iatrogenic hyperthyroidism occurring in patients being treated to correct hypothyroidism or those taking suppressive therapy for thyroid cancer.
  • Secondary Hyperthyroidism: A rare condition caused by a TSH-secreting pituitary adenoma, where the pituitary drives the thyroid to overwork despite high hormone levels.

VII. Pharmacological Management: Antithyroid Drugs

1. Thioamides (Thioureylenes)

Includes Carbimazole, Methimazole, and Propylthiouracil (PTU). Given orally, they are quickly absorbed, widely distributed in the body, enter breast milk, and cross the placenta. They are metabolized in the liver and excreted in the urine primarily as metabolites. All are concentrated in the thyroid (intrathyroid t½ is longer, so the effect of a single dose lasts longer than the plasma t½ would suggest).

  • Mechanism of Action: They prevent hormone synthesis by inhibiting the thyroid peroxidase-catalyzed reactions. This blocks iodine organification (reducing iodination of tyrosine residues on thyroglobulin) and blocks the coupling of the iodotyrosines (MIT and DIT).
  • Uses: Used for hyperthyroidism either to medically prepare patients for a thyroidectomy (surgery) to achieve a euthyroid state, as an adjunct to radioactive iodine, or for long-term clinical management (remission therapy).
  • Carbimazole: This is a prodrug that is converted to the active metabolite methimazole in vivo. It is widely used in the UK. It is longer acting than propylthiouracil.
FeaturePropylthiouracil (PTU)Carbimazole / Methimazole
PotencyLess potent (Methimazole is about 10x more potent).About 5x more potent than PTU (Carbimazole). Methimazole is 10x more.
DosingMultiple (2-3) daily doses needed.Mostly single daily dose.
Plasma Protein BindingHighly plasma protein bound (~75%).Less bound (virtually unbound).
Placenta & Milk TransferLess transferred across the placenta and in milk (because of high protein binding).Larger amounts cross to the fetus and appear in breast milk.
KineticsPlasma t½ 1-2 hours. Single dose acts for 4-8 hours. No active metabolite.Single dose acts for 12-24 hours. Produces active metabolite (methimazole).
Peripheral ActionInhibits peripheral conversion of T4 to T3. (via 5'-deiodinase inhibition).Does NOT inhibit T4 to T3 conversion.
HepatotoxicityHigher risk of severe liver failure (Black Box Warning).Lower risk, but can cause cholestatic jaundice.
Clinical Notes on Thioamides:
  • Cross-Sensitivity: About 50% of patients show cross-sensitivity; however, Propylthiouracil may be cautiously used in patients who suffer mild sensitivity reactions to carbimazole.
  • Pregnancy Caution: PTU is generally preferred in the first trimester (due to methimazole-associated embryopathy like aplasia cutis). Carbimazole/Methimazole is preferred in the 2nd and 3rd trimesters to reduce PTU-induced liver risk.
  • Agranulocytosis: This is the most serious ADR. Patients must be warned to report a sore throat, fever, or mouth ulcers immediately for a White Blood Cell (WBC) count.
  • Adverse Drug Reactions (ADRs): Nausea, mild GI disturbances, headache, rashes and pruritus, arthralgia. Rarely causes myopathy, alopecia, bone marrow suppression (including pancytopenia and agranulocytosis), and jaundice.

Advantages vs. Disadvantages of Antithyroid Drugs (Over Surgery/131I)

  • Advantages: No surgical risk, no scar, no chances of injury to parathyroid glands or the recurrent laryngeal nerve. If hypothyroidism is induced, it is completely reversible by dose adjustment. Can be safely used even in children, young adults, and during pregnancy.
  • Disadvantages: Prolonged (often 12-18 months) treatment is needed because the relapse rate is high (approx. 50% after cessation). Not practicable in uncooperative or unintelligent patients. High risk of drug toxicity requiring frequent blood monitoring.

2. Radioactive Iodine (131 I)

Radioiodine is a first-line treatment for hyperthyroidism, particularly in the USA and for recurrent Graves' disease. 131 I is the treatment of choice after 25 years of age and if Congestive Heart Failure (CHF), angina, or any other absolute contraindication to surgery is present.

  • Mechanism of Action: The only isotope used is 131 I (usually given orally as the sodium salt). It is taken up and processed by the thyroid in the exact same way as stable iodide, eventually becoming incorporated into thyroglobulin.
  • Cytotoxic Action: The isotope emits both β radiation (short range: 0.5–2 mm) and γ rays. The γ rays pass through the tissue and are used for scanning, but the β particles are absorbed locally. They exert a powerful, precise cytotoxic action affecting only the thyroid follicle cells, resulting in pyknosis and necrosis of the tissue without damaging neighboring structures like the parathyroids.
  • Kinetics: It has a physical T1/2 of 8 days. Given as one single dose, its cytotoxic effect on the gland is delayed for 1-2 months and does not reach its maximum for a further 2-4 months.
  • Advantages: Treatment is simple, inexpensive, and conveniently given on an outpatient basis. There is no surgical risk, scar, or injury to parathyroid glands or recurrent laryngeal nerves. Once hyperthyroidism is controlled, the cure is permanent.
  • Disadvantages & Contraindications: Hypothyroidism is the most common outcome (seen in 5-10% of patients in the first year and 3% per year thereafter). There is a long latent period of response requiring thioamides in the interim. It may worsen Graves' ophthalmopathy.

    Absolute Contraindication: Pregnant women or nursing mothers, since it freely crosses the placenta to completely destroy the fetal thyroid gland and is excreted in breast milk.
  • Advertisements

3. Ionic Inhibitors (Iodine/Iodide)

Iodine is converted in vivo to iodide (I-). It is given orally in high doses in a solution with potassium iodide (known as 'Lugol's iodine') or as Potassium Iodide (SSKI).

  • Mechanism of Action: High doses transiently inhibit the release of thyroid hormones (the Wolff-Chaikoff effect) and powerfully decrease the size and vascularity of the gland.
  • Indications: Used for Thyrotoxicosis strictly pre-operatively (to shrink the gland to make surgery safer/less bloody) and as part of the emergency treatment of severe thyrotoxic crisis (thyroid storm). Also used to protect the thyroid from accidental radiation exposure.
  • Limit of Use: The effect is transient; the thyroid "escapes" from the inhibitory effect after 10–14 days, leading to a rebound of symptoms if used alone.
  • Allergic Reactions (Iodism): Can cause angio-oedema, rashes, drug fever, lacrimation, conjunctivitis, pain in the salivary glands, and a characteristic metallic taste or "cold-like" syndrome.

4. Adrenoceptor Blockers (Beta-Blockers)

Beta-blockers like Propranolol, Atenolol, or Metoprolol are used as adjuvant therapy.

  • Role: They do not affect the thyroid gland directly but rapidly control the "sympathetic" symptoms of hyperthyroidism: tachycardia, palpitations, tremor, and anxiety.
  • Peripheral Effect: High-dose Propranolol also helps by slightly inhibiting the peripheral conversion of T4 to T3.
  • Use Case: Essential for rapid symptom relief while waiting for thioamides or radioiodine to take effect.

4. Other Drugs Used (Adjuvants)

  • β-blockers (e.g., Propranolol): Extremely useful for rapidly decreasing many of the signs and symptoms of hyperthyroidism (tachycardia, dysrhythmias, tremor, and agitation). They are used during the preparation of thyrotoxic patients for surgery, in most patients during the initial treatment period while thioamides or radioiodine take effect, and as part of the treatment for an acute hyperthyroid crisis.
  • Guanethidine: A noradrenergic-blocking agent used in eye drops to ameliorate the exophthalmos of hyperthyroidism.
  • Glucocorticoids (e.g., Prednisolone): May be needed to mitigate severe, vision-threatening exophthalmia in Graves' disease.

VIII. Comprehensive Systemic Manifestations: Thyrotoxicosis vs. Hypothyroidism

To accurately diagnose and monitor treatment, one must master the systemic differences between hormone excess and deficiency.

SystemThyrotoxicosis (Excess T3/T4)Hypothyroidism (Deficient T3/T4)
Skin and appendagesWarm, moist skin; sweating; heat intolerance; fine, thin hair; Plummer's nails; pretibial dermopathy (Graves' disease).Pale, cool, puffy skin; dry and brittle hair; brittle nails.
Eyes, faceRetraction of upper lid with wide stare; periorbital edema; exophthalmos; diplopia (Graves' disease).Drooping of eyelids; periorbital edema; loss of temporal aspects of eyebrows; puffy, nonpitting facies; large tongue.
Cardiovascular systemDecreased peripheral vascular resistance; increased heart rate, stroke volume, cardiac output, pulse pressure; high-output heart failure; increased inotropic and chronotropic effects; arrhythmias; angina.Increased peripheral vascular resistance; decreased heart rate, stroke volume, cardiac output, pulse pressure; low-output heart failure; ECG: bradycardia, prolonged PR interval, flat T wave, low voltage; pericardial effusion.
Respiratory systemDyspnea; decreased vital capacity.Pleural effusions; hypoventilation and CO 2 retention.
Gastrointestinal systemIncreased appetite; increased frequency of bowel movements; hypoproteinemia.Decreased appetite; decreased frequency of bowel movements; ascites.
Central nervous systemNervousness; hyperkinesia; emotional lability.Lethargy; general slowing of mental processes; neuropathies.
Musculoskeletal systemWeakness and muscle fatigue; increased deep tendon reflexes; hypercalcemia; osteoporosis.Stiffness and muscle fatigue; decreased deep tendon reflexes; increased alkaline phosphatase, LDH, AST.
Renal systemMild polyuria; increased renal blood flow; increased glomerular filtration rate.Impaired water excretion; decreased renal blood flow; decreased glomerular filtration rate.
Hematopoietic systemIncreased erythropoiesis; anemia (usually normochromic and caused by increased red blood cell turnover).Decreased erythropoiesis; anemia (can be normochromic, hyperchromic, or hypochromic due to decreased production rate, decreased iron/folic acid absorption, or autoimmune pernicious anemia).
Reproductive systemMenstrual irregularities; decreased fertility; increased gonadal steroid metabolism.Hypermenorrhea; infertility; decreased libido; impotence; oligospermia; decreased gonadal steroid metabolism.
Metabolic systemIncreased basal metabolic rate; negative nitrogen balance; hyperglycemia; increased free fatty acids; decreased cholesterol and triglycerides; increased hormone degradation; increased requirements for fat- and water-soluble vitamins; increased drug metabolism; decreased warfarin requirement.Decreased basal metabolic rate; slight positive nitrogen balance; delayed degradation of insulin with increased sensitivity; increased cholesterol and triglycerides; decreased hormone degradation; decreased requirements for fat- and water-soluble vitamins; decreased drug metabolism; increased warfarin requirement.

*Note on Hematopoiesis/Enzymes: LDH = lactic dehydrogenase; AST = aspartate aminotransferase.


IX. Bibliography / Iodine Food Sources

  • Goodman and Gilman’s. The Pharmacological Basis of Therapeutics (12th edition).
  • Katzung, Bertram G. Basic and Clinical Pharmacology.
  • Rang and Dale’s. Pharmacology (6th edition).
  • Lippincott’s. Pharmacology (9th edition).
  • Dietary Notes: Iodine rich foods include garlic, salt, seafish, cheese, and onions. National iodized refined salt is used to prevent endemic goitre in regions where the diet is inherently iodine-deficient.

Quick Quiz

Thyroid and Antithyroid Drugs Quiz

Pharmacology

Privacy: Your details are used only for quiz tracking and certificates.

Advertisements

Thyroid and Antithyroid Drugs Read More »

Want notes in PDF? Join our classes!!

Send us a message on WhatsApp
0726113908

Scroll to Top
Enable Notifications OK No thanks